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Introduction and outline of the thesis
Lung cancer is the leading cause of cancer mortality in the United States and Europe (1). 
Approximately 85% of the patients with lung cancer have non–small cell lung cancer 
(NSCLC), which can be classified into squamous, adeno, large cell and not otherwise 
specified (NOS) histologies. The most common histologies are: adenocarcinoma (  50%), 
squamous cell (  20%), and large cell (  10%) (2). More than two third of the patients 
have locally advanced or metastatic disease at the time of diagnosis (3,4).
LOCALLy AdVANCEd NSCLC
Approximately one third of patients with non-small cell lung cancer are diagnosed with 
locally advanced (stage III) disease. Stage III includes a fairly heterogeneous group of 
tumours, including resectable and unresectable tumours, ranging from T3N1 to T4 N3 
cancers. In stage IIIA, 5 subgroups are defined. (Table 1) A first subgroup of stage IIIA 
patients consists of tumours with locoregional extension without mediastinal lymph 
node involvement (IIIA-0). Due to the novel definitions for T3 and T4 and the inclusion of 
T4N0-1 tumours in stage IIIA in the 7th edition of the new TNM classification (Table 2 and 
3), it is likely that this subgroup will numerically increase in the near future.
A second subgroup contains patients with so-called unexpected N2-involvement in the 
pathology specimen (pIIIA-1) or at thoracotomy (pIIIA2), found in 14-24% of the patients.
The largest subgroup of stage IIIA consists of patients with clinical ipsilateral lymph 
node invasion at presentation, either demonstrated by non-invasive imaging or (mini-
mally) invasive techniques (IIIA-3) or ‘bulky’ at imaging (IIIA-4). Patients from the IIIA-3 
subgroup are variously considered ‘resectable’ or ‘marginally resectable’, depending on 
the number and location of the lymph node(s) involved, whereas patients from the IIIA-4 
subcategory are considered ‘primary unresectable’.
Table 1 Subclassification of stage IIIA (5)
Subgroup Definition Frequency
IIIA-0 T3N1 or T4N0-1 without N2 involvement 6% of NSCLC at presentation, 32% of stage IIIA 
IIIA-1 Incidental nodal metastases found on final 
pathology examination of the resection specimen
Up to 14% of thoracotomies 
IIIA-2 Nodal (single station) metastases recognized 
intraoperatively
IIIA-3 Nodal metastases (single or multiple station) 
recognized by prethoracotomy staging 
(mediastinoscopy, other nodal biopsy, or PET scan)
10% of NSCLC at presentation, 67% of clinical 
and pathological stage IIIA
IIIA-4 Bulky or fixed multistation N2 disease
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Table 2. Definitions for T, N, and M descriptors according to the seventh edition of the TNM classification.
T (Primary Tumour)
TX Primary tumour cannot be assessed, or tumour proven by the presence of malignant cells in sputum or 
bronchial washings but not visualized by imaging or bronchoscopy
T0 No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour 3 cm in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence 
of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus)a
 T1a Tumour ≤2 cm in greatest dimension
 T1b Tumour > 2 cm but ≤3 cm in greatest dimension
T2 Tumour > 3 cm but <7 cm or tumour with any of the following features 
Involves main bronchus, >2 cm distal to the carina
Invades visceral pleura
Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve 
the entire lung
 T2a Tumour > 3 cm but ≤5 cm in greatest dimension
 T2b Tumour > 5 cm but ≤7 cm in greatest dimension
T3 Tumour > 7 cm or one that directly invades any of the following: chest wall (including superior sulcus 
tumours), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumour in the main 
bronchus (< 2 cm distal to the carinaa but without involvement of the carina; or associated atelectasis or 
obstructive pneumonitis of the entire lung or separate tumour nodule(s) in the same lobe
T4 Tumour of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent 
laryngeal nerve, esophagus, vertebral body, carina, separate tumour nodule(s) in a different ipsilateral lobe
N (Regional Lymph Nodes)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, 
including involvement by direct extension
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)
N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or 
supraclavicular lymph node(s)
M (Distant Metastasis)
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
 M1a Separate tumour nodule(s) in a contralateral lobe; tumour with pleural nodules or malignant pleural (or 
pericardial) effusion b
 M1b Distant metastasis
a The uncommon superficial spreading tumour of any size with its invasive component limited to the bronchial wall, which 
may extend proximally to the main bronchus, is also classified as T1a.
b Most pleural (and pericardial) effusions with lung cancer are due to tumour. In a few patients, however, multiple 
cytopathologic examinations of pleural (pericardial) fluid are negative for tumour, and the fluid is nonbloody and is not an 
exudate. Where these elements and clinical judgement dictate that the effusion is not related to the tumour, the effusion 
should be excluded as a staging element and the patient should be classified as T1, T2, T3 or T4.
From Goldstraw et al. 
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Stage III patients are quite a heterogeneous group of patients with diffferent prognostic 
and therapeutic subsets.
Resectable stage pIIIA with incidental N2 disease should be treated with adjuvant 
platinum-based chemotherapy (6), whereas stage IIIB with pathologically confirmed in-
volvement of the pleura (T4, pleural effusion) is synonymous with advanced disease and 
is preferably treated with palliative chemotherapy. For the remainder of the patients, 
who have potentially curable disease, treatment goals include local tumour control and 
eradication of distant micrometastases, while minimizing adverse events. For both stage 
IIIA and IIIB disease, combined modality therapy including chemotherapy, radiation 
and/or surgery is the treatment of choice. The evolving approaches for resectable and 
unresectable stage III NSCLC are described below.
Unresectable stage III non-small cell lung cancer
Stage III unresectable patients, candidate to radical treatment, include T4 without pleu-
ral effusions and/or bulky N2 or N3 tumours, although selected T4 patients may benefit 
from surgery. 
Radiotherapy alone was initially considered the standard of care for these patients, but 
the disappointing 5-year survival of no more than 5%, mostly due to distant metastatic 
relapse, raised the need for systemic disease control. This observation led to further 
evaluations aimed at investigating the role of chemotherapy regimens in patients with 
unresectable disease, in order to eradicate the micrometastatic disease and improve 
patients outcome.
The first combination studies explored a sequential approach, with chemotherapy fol-
lowed by radiotherapy. The role of induction chemotherapy has been investigated in 
Table 3 Stage Grouping
6th edition T/M 7th edition T/M N0 N1 N2 N3
T1 (≤ 2cm) T1a IA IIA IIIA IIIB
T1 (> 2-≤ 3cm) T1b IA IIA IIIA IIIB
T2 (> 3-≤ 5cm) T2a IB IIB→IIA IIIA IIIB
T2 (> 5-7cm) T2b IB→IIA IIB IIIA IIIB
T2 (≥ 7cm) T3 IB→IIB IIB→IIIA IIIA IIIB
T3 (invasion) T3 IIB IIIA IIIA IIIB
T4 (same lobe nodules) T3 IIIB→IIB IIIB→IIIA IIIB→IIIA IIIB
T4 (extension) T4 IIIB→IIIA IIIB→IIIA IIIB IIIB
M1 (ipsilateral lung) T4 IV→IIIA IV→IIIA IV→IIIB IV→IIIB
T4 (pleural effusion) M1a IIIB→IV IIIB→IV IIIB→IV IIIB→IV
M1 (contralateral lung) M1a IV IV IV IV
M1 (distant) M1b IV IV IV IV
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three randomized trials including more than 900 patients with NSCLC which randomly 
assigned patients with unresectable locally advanced disease to radiotherapy alone or 
versus sequential chemo-radiotherapy (7-9, Table 4). All trials included platinum-based 
regimens and demonstrated a significant survival advantage favouring the addition of 
chemotherapy to radiation treatment, with median survival up to almost 14 months, 
mostly due to lower distant failure rates rather than improved local disease control. The 
meta-analysis performed in 1995 by the NSCLC Collaborative Group showed an advan-
tage in survival favouring the addition of chemotherapy prior to radical radiation with a 
hazard ratio of 0.9 and a 5-year survival advantage of 5% (10).
A few years later different studies claimed concurrent chemo-radiation to be superior 
to sequential therapy with higher response rates and improved survival (11-17). The 
concomitant approach is compared to the sequential approach in several randomized 
trials. (14-17, Table 5). The first of these studies was performed by the West Japan Lung 
Tabel 4. Outcomes of sequential and concurrent chemoradiotherapy compared with radiotherapy alone. 
Study
Randomized 
patients
Treatment
Median 
survival 
(mos)
5-year 
survival rate 
(%) 
P value Reference
CALGB 8433 155
Radiotherapy 10 6 
0.01
Dillman, 1996 (7)
Sequential 
Chemoradiotherapy 
14 17
Intergroup 458
Radiotherapy 11.4-12 5-6
0.04
Sause, 2000 (8)
Sequential 
Chemoradiotherapy
13.2 8
French 353
Radiotherapy 10 3
0.02
Le Chevalier, 
1994 (9)Sequential 
Chemoradiotherapy
12 6
Table 5 Outcomes of sequential vs. concurrent chemoradiotherapy.
Study Randomized 
patients
Chemoradiotherapy 
treatment
Median 
survival 
(mos) 
Survival 
rate (%) 
P 
value
Reference
West Japan Lung 
Cancer Group 
320 Concurrent 17 16 (5-yr) 0.039 Furuse,1999  (14)
Sequential 13 9  (5-yr)
RTOG 9410 610 Concurrent 17 21 (4-yr) 0.046 Curran,2003 (16)
Sequential 14.6 12 (4-yr)
Fournel NPC 
95-01
200 Concurrent
Sequential
16.3
14.5
21 (4-yr)
14 (4 yr)
0.24 Fournel, 2005 (15)
Czech, phase II 102 Concurrent
Sequential
16.6
12.9
18.6 (3y)
9.5 (3y)
0.023 Zatloukal,2004 (17)
Veerle BW 2.indd   15 19-11-09   15:56
Chapter 1
16
Cancer Group and showed that patients treated with cisplatin/vindesine/mitomycine 
concurrently with radiotherapy gained prolonged survival compared with those who 
received sequential treatment (17 versus 13 months, p< 0.04) (14). Similar results have 
emerged from the 3-arm phase 3 RTOG 9410 trial, in which concurrent chemoradiation 
was compared with sequential chemoradiation. This study showed an improved overall 
survival for the concurrent standard radiotherapy arm compared with the sequential 
approach (17 versus 14.6 months, p=0.046), without benefit for patients who received 
hyperfractionated radiation with chemotherapy (16). A Czech phase II trial, with cispla-
tin and vinorelbine concurrent with radiotherapy, showed improved survival compared 
with the sequential arm (17). Overall available data indicate that concurrent chemora-
diation is superior in terms of survival compared to the sequential approach, although 
higher toxicity, especially esophageal toxicity, limits the use to fit patients (Table 6).
In a meta-analysis and in the National Institute of Health and Clinical Excellence (NICE) 
guidelines, the use of concurrent chemo-radiotherapy is recommended only in selected 
patients, which means: patients with low co-morbidity, good performance status and 
pulmonary function and patients who are adequately staged (11,18). As a result the 
sequential approach is still widely used in Europe and a doublet of platinum combined 
with a third-generation chemotherapeutic agent is considered to be the most active 
induction regimen.
In the combined modality approach, the definitive dose thoracic radiotherapy should be 
no less than the biologic equivalent of 60 Gy, in 1.8-Gy to 2.0-Gy fractions to the planning 
target volume (PTV). Ideally, this requires 3-dimensional (3D) conformal radiotherapy, a 
technique characterized by beam outlines that match the shape of the PTV. Mapping 
of the PTV is improved when using information from FDG-PET/CT-scan and-whenever 
available- from the (minimally) invasive mediastinal staging techniques, to match the 
closest possible the actual ‘involved field’ (IF).
A major drawback in the treatment of locally advanced NSCLC is the high, 70% relapse 
rate, which occurs approximately one third locally, one third distantly and one third both 
locally and distantly (8-14). The challenge today is to reduce this high relapse rate by 
identifying the optimal radiation dose in combination with the most effective systemic 
Table 6 Grade 3 or greater acute toxicities comparing sequential chemoradiotherapy with concurrent chemoradiotherapy in RTOG 9410 
(Curran et al, 2003).
Toxicity (grade) Sequential chemoradiotherapy (%) Concurrent chemoradiotherapy (%)
Esophagitis (3-4) 4 25-47
Pneumonitis (3-5) 7 3-4
Neutropenia (4-5) 56 48-58
Thrombocytopenia (4-5) 2 4-8
Any Grade 5 3 2-3
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therapy. So far, neither the best drug combination nor the optimum radiation dose 
has been defined. Therefore, new chemo-radiotherapy combinations are needed and 
further research is warranted. 
Potentially resectable stage III NSCLC
As mentioned before, this remains the most controversial area: some recommend che-
motherapy with concurrent radiotherapy, others induction chemotherapy followed by 
surgery in downstaged patients (mediastinal clearance, pN0 after induction treatment) 
as the treatment of choice. 
The potential role of a surgical resection following induction chemotherapy (with or 
without radiation) in stage IIIA and IIIB NSCLC remains controversial. 
Preoperative chemotherapy and preoperative chemoradiotherapy.
Several small phase 2 studies have been published on the outcome of patients with 
stage IIIA NSCLC treated with neoadjuvant chemotherapy (19). A systematic review 
from six prospective phase II trials reported tumour response to preoperative (primary) 
chemotherapy in patients with stage IIIA or IIIB NSCLC (20). The review reported a non-
weighted average effect size for radiological response rate of 64%, a disease progression 
of 4% and for histological complete response of 24% of patients. Survival was improved 
as compared with historical controls and was influenced by patients age, complete 
resection, pathologic stage, nodal downstaging and extent of resection, but not by the 
type of induction regimen, i.e. chemo-or chemoradiotherapy (21-23). Three randomized 
trials have compared chemotherapy and chemoradiotherapy as induction regimen in 
stage III NSCLC (24-26). These trials suggest that induction chemoradiotherapy results 
in better rates of resectability, pathological downstaging and pathological complete 
remissions than chemotherapy alone, but without significant benefit for overall or 
progression-free survival. This issue is currently being addressed by the Swiss Group 
for Clincal Cancer Research, conducting a phase III randomized trial of preoperative 
cisplatin and docetaxel chemotherapy versus chemoradiotherapy with the same agents 
followed by surgical resection (27).
Twelve randomized trials have compared neoadjuvant chemotherapy followed by 
surgery vs surgery alone in patients with stage IIIA NSCLC with variable numbers of N2-
involvement (20,28,29). It can be concluded from the meta-analysis (29) that a significant 
benefit in favour of neoadjuvant chemotherapy is present ranging at 5 years from 6-14%, 
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albeit weakened by confounding factors as the inhomogeneity of the patients included, 
the inadequate sample size and the variable addition of postoperative treatments. 
Surgical resection following neoadjuvant therapy versus radiotherapy following 
neoadjuvant therapy.
The role of surgical resection, in comparison to RT, following induction therapy in pa-
tients with stage IIIA disease is unclear. Two large randomized phase III trials have not 
found a survival benefit for surgery in comparison to RT following chemotherapy or for 
surgery following concurrent chemoradiotherapy (Table 7).
The European Organization for Research and Treatment of Cancer (EORTC) study 08941 
examined the issue of radiotherapy versus surgical resection following induction che-
motherapy in patients with clinical stage IIIA-N2 NSCLC (30). In this study, 579 patients 
received induction chemotherapy with three cycles of platinum-based chemotherapy. 
Following chemotherapy, 332 patients with at least stable disease were randomized to 
receive definitive RT 60-62.5 Gy to the primary tumour and involved mediastinum, with 
40-46 Gy to the uninvolved mediastinum versus surgical resection. Surgical resection did 
not improve overall survival or progression free survival compared with RT. In a posthoc 
unplanned univariate subgroup analysis of the surgical arm, 5 year survival was longer if 
radical resection was performed, nodal downstaging was present or if a lobectomy was 
performed. 
The Intergroup 0139 trial evaluated 429 patients with stage IIIA NSCLC that were treated 
initially with concurrent RT (45 Gy) plus chemotherapy with cisplatin 50 mg/m2 on days 
1, 8, 29, and 35 plus etoposide 50 mg/m2 on days 1 to 5, and 29 to 33; 396 patients with 
at least stable disease were then randomized to surgical resection or a continuation of 
RT to 61 Gy (31). Two additional cycles of chemotherapy were given to both groups. 
Median overall survival was 23.6 moths in the surgical group versus 22.2 months in the 
radiotherapy group.(p=0.24). In an unplanned exploratory analysis, overall survival was 
improved for patients who underwent lobectomy, but not pneumonectomy compared 
to matched irradiated patients.
As many controversies exist in locally advanced NSCLC, there is vast room for improv-
ing outcomes for these patients. A multidisciplinary approach to managing this diverse 
group of patients is strongly recommended.
Table  7. OS at 5 years comparing surgery with radiotherapy after induction therapy.
Study Randomized 
patients
Surgical 
resection
Radiotherapy P value Reference 
EORTC 08941 332 15.7% 14% 0.60 van Meerbeeck, 2007 (30)
Intergroup 0139 396 27% 20% 0.10 Albain, 2009 (31)
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METASTATIC NON-SMALL CELL LUNg CANCER
Patients with malignant pleural and pericardial effusions are classified as stage IIIB under 
the current staging system, but their prognosis and treatment is similar as for patients 
with metastatic disease. Therefore, in the new staging system they will be classified as 
stage IV disease. Depending on the primary tumour size, 30-40% of the patients with 
early-stage disease will subsequently relapse with metastatic disease (32). Thus, the 
vast majority of patients with NSCLC will potentially be candidate for chemotherapy for 
metastatic disease. 
In patients with advanced stage NSCLC, the patient’s performance status (PS) is used to 
estimate a patient’s prognosis, as well as their tolerance of and potential benefit from 
chemotherapy. The Eastern Cooperative Oncology Group (ECOG) or Zubrod and Karnof-
sky (33,34) scales are commonly used to assess the PS. Standard of care for patients with 
a good PS, defined as asymptomatic or ambulatory but restricted from strenuous ac-
tivities, is platinum-based doublet chemotherapy (35,36). Treatment with chemotherapy 
has been shown to extend survival, reduce disease-related symptoms and improve qual-
ity of life (Qol) in comparison to best supportive care (BSC) in this patient population 
(37,38). Patients with performance status 2, defined as ambulatory and active more than 
50% of the time but unable to carry out work activities, have a worse prognosis, and the 
role of chemotherapy in this patient population is less certain. For patients who are only 
capable of limited self care and confined to a bed or chair more than 50% of the time or 
incapable of self care, BSC is the standard of care. Thus, a detailed history of the patient’s 
daily activities and a careful assessment of his or her PS are critical to selection of the 
appropriate therapy. 
Trials comparing different platinum-based combinations have, in general, revealed 
equal efficacy but different toxicity profiles (37). This led by some investigators to the 
defaitistic view that we might have reached a “therapeutic plateau” with standard 
cytotoxic chemotherapy (38). Recent trials have explored the addition of a so called 
“targeted agent” to platinum-based chemotherapy. These agents are active against a 
specific pathway involved in the pathogenesis and metastases of NSCLC. Currently two 
types of therapeutic targets are developed successfully: anti-angiogenesic agents and 
epidermal growth factor receptor (EGFR) inhibitors. There was initial enthusiasm for the 
integration of targeted agents into the treatment of advanced NSCLC; however, after 
the sobering results of several phase III trials, it became apparent that the integration 
of targeted agents would be more difficult than anticipated. For example, the EGFR 
tyrosine kinase inhibitors (TKI), gefitinib and erlotinib, have shown promising activity in 
phase II trials (39,40) and four phase III trials of chemotherapy with and without EGFR TKI 
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therapy were performed (41-44). Unfortunately, none of these trials revealed a survival 
benefit with the addition of EGFR TKI therapies to the standard chemotherapy. In North 
America bevacizumab, a monoclonal antibody that targets vascular endothelial growth 
factor (VEGF), is approved in advanced NSCLC for patients with non-squamous histology 
based on the result of the ECOG 4599 and is in combination with chemotherapy ac-
cepted as standard care (45). The AVAIL trial performed in Europe has raised issues about 
the clinical benefit of bevacizumab in combination with cisplatin-gemcitabine; in this 
trial progression free survival was improved in patients receiving chemotherapy plus 
bevacizumab, overall survival was not improved (46). The FLEX trial, a randomized phase 
III trial comparing cisplatin, vinorelbine versus cisplatin, vinorelbine and the monoclonal 
antibody cetuximab, showed improved overall survival in favour of the cetuximab arm 
(47). Today there is strong evidence from the IPASS study that patients harbouring EGFR 
mutations, should be treated with EGFR-TKI’s in first line and that the conclusions of this 
study are not geographical but biological determined (48). This thesis will not further 
deal with targeted agents in the treatment of NSCLC. 
First-line therapy 
The benefit of first-line chemotherapy in patients with a good PS is well established. In 
the past decades the optimal number of agents, selection of agents and the duration 
of chemotherapy has been evaluated in different trials and meta-analyses. The optimal 
number of agents was assessed in a meta-analysis performed by Delbaldo and colleagues 
(49). 13601 patients were included from 65 trials; platinum-based doublets yielded a 
superior response and survival rates compared with non-platinum based single-agent 
chemotherapy (50). The addition of a third cytotoxic agent did not improve survival and 
resulted in greater toxicity in comparison to two chemotherapeutic agents (51). Thus, 
most trials currently consist of platinum compound (cis- or carboplatinum) with a 3rd 
generation non-platinum agent, usually paclitaxel, gemcitabine, vinorelbine or docetax-
el and more recently pemetrexed in patients with non-squamous histology (35–37,50). 
However, there is a continuing debate on the type of the platinum compound used. In 
two meta-analyses cisplatin has been compared with carboplatin. Both meta-analyses 
showed a superior response for cisplatin compared with carboplatin-based therapies, 
but similar overall survival (51,52). In the meta-analysis by Ardizzoni and coworkers, 
carboplatin treatment was associated with a non–statistically significant increase in 
the HR for mortality relative to treatment with cisplatin (hazard ratio [HR], 1.07; 95% 
confidence interval [CI], 0.99–1.15; P = 0.10) (52). In a subgroup analysis, patients with 
non-squamous histology and those treated with a third-generation chemotherapy, 
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carboplatin-based chemotherapy was associated with a statistically significant increase 
in mortality (HR, 1.12; 95% CI, 1.01–1.23 and HR, 1.11; 95% CI, 1.01–1.21, respectively). 
In the meta-analysis by Hotta et al., cisplatin-based chemotherapy was associated with 
a non-significant survival advantage (HR, 1.050; 95% CI, 0.907–1.216; P = 0.515), but 
in a subset analysis a superior survival was found for cisplatin in combination with 3rd 
generation chemotherapy than for carboplatin in combination with a 3rd generation 
drug (HR, 1.106; 95% CI, 1.005–1.218; P = 0.039) (51). These meta-analyses indicate that 
cisplatin is the more active agent when combined with new chemotherapy agents. Both 
meta-analyses revealed an increase in nausea, vomiting and renal toxicity for cisplatin-
based therapy. Carboplatin-based therapy was associated with an increased rate of 
thrombocytopenia. At this time, both therapies are considered acceptable. Those in 
favour of cisplatin base their arguments on the improved efficacy, while those in favour 
of carboplatin refer to the lower toxicity of carboplatin. 
Another issue in advanced stage NSCLC is the optimal duration of chemotherapy and 
this has been an area of investigation as well. Five trials have compared a shorter dura-
tion of platinum-based therapy (three or four cycles) with a longer duration of therapy 
(six cycles or until disease progression) (53–57). Four trials (51-53, 57) showed that a 
short course of therapy was not associated with impaired survival, while prolonged 
therapy had equivalent or greater toxicity compared with a short course (54,55). The 
quality of life has been equivalent (54,56) or better with a shorter duration of therapy 
(54,57). Recently four cycles of carboplatin-based therapy have been compared with 
six cycles. Preliminary results revealed a significant improvement in overall survival for 
the long course therapy (56). The cumulative data of the currently available phase III 
trials favour a short course of platinum-based chemotherapy because a short course of 
chemotherapy does not compromise overall survival while there is an increased risk of 
toxicity and loss in quality of life with a longer duration of therapy. The sequential use of 
non-cross resistant chemotherapy might be an approach to overcome these problems. 
Sequential chemotherapy administration offers the possibility to increase drug diversity 
while maintaining dose intensity, potentially leading to less dose reductions, an optimal 
dose intensity and prolonged treatment duration and disease control. 
Second-line therapy 
Second-line therapy is generally defined as therapy given after disease progression after 
first-line therapy. Approximately 40 to 50% of patients enrolled in first-line trials have 
subsequently received second-line therapy (53). Patients with a good PS, non-squamous 
histology and female gender appear to be more likely to receive second-line therapy 
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(58). There are currently three agents approved by the FDA for second-line therapy; two 
cytotoxic agents, docetaxel and pemetrexed, and an EGFR TKI, erlotinib. 
Docetaxel was the first agent approved based on two phase III trials. In the TAX 317 trial, 
in which docetaxel was compared with BSC the initial docetaxel dose was 100 mg/m2 
every 3 weeks, but because of excessive toxicity the trial was amended and the dose 
was reduced to 75 mg/m2 every 3 weeks. Patients receiving docetaxel at 75 mg/m2 expe-
rienced a significantly longer time to tumour progression, median survival time, and a 
higher 1-year survival rate (59). The second phase III trial, TAX 320, compared docetaxel 
at two different doses, 100 mg/m2 and 75 mg/m2 every 3 weeks with the control arm 
of older chemotherapy agents of vinorelbine or ifosfamide (60). While the overall sur-
vival was not different among the three treatment groups, the 1-year survival rate was 
significantly higher for the treatment arm of docetaxel 75 mg/m2. These trials led to 
FDA approval of docetaxel and established docetaxel at 75 mg/m2 every 3 weeks as the 
standard of care. Subsequent trials have investigated docetaxel on a weekly schedule 
in comparison to the every-three-week schedule. A recent meta-analysis compared 
the two schedules and found equivalent efficacy and a similar rate haematological and 
non-hematological toxicities (61). The rate of febrile neutropenia was significantly lower 
on the weekly schedule and this schedule may be an option for patients who are at 
increased risk of infectious complications. 
Pemetrexed was subsequently approved in the second-line setting on the basis of a 
phase III non-inferiority trial comparing pemetrexed versus docetaxel 75 mg/m2 every 
3 weeks (62). This trial differed from other second-line trials in that patients were only 
allowed to have received one previous line of therapy for advanced disease. Peme-
trexed had a statistically significant lower rate of haematological toxicity and a similar 
rate of grade 3 or 4 non-hematologic toxicities. Based on the similar clinical activity 
of pemetrexed compared with docetaxel and the lower rate of myelosuppression, the 
FDA approved pemetrexed for treatment in the second-line setting (63). A retrospec-
tive analysis revealed that in patients with squamous histology treatment with peme-
trexed led to an inferior overall survival compared with docetaxel (HR, 1.563; 95% CI, 
1.079–2.264; median survival time of 6.2 and 7.4 mo, respectively) (64). In contrast, in 
patients with non-squamous histology pemetrexed yielded superior survival compared 
with docetaxel (HR, 0.778; 95% CI, 0.607–0.997; median survival time of 9.3 and 8.0 mo, 
respectively). The treatment by histology interaction test was statistically significant (P 
= 0.001). These data, in combination with prospective data from another trial (50), are 
suggestive that pemetrexed is more active in patients with non-squamous histology. 
Therefore, the FDA has recently changed the indication of pemetrexed to patients with 
non-squamous histology. 
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Erlotinib was approved by the FDA on the basis of the National Cancer Institute of 
Canada BR.21 trial, which compared erlotinib versus BSC in patients who had progressed 
on one line of therapy and were considered not candidates for further chemotherapy, 
and/or had progressed on two lines of therapy (65). This trial revealed a statistically 
significant improvement in progression free survival and overall survival with erlotinib 
in comparison to best supportive care. Erlotinib was well tolerated, with the principal 
toxicities being rash and diarrhea, and a low rate of myelosuppression and nausea and 
vomiting was observed. Erlotinib is approved in second- as well as third-line treatment 
settings and the fact that it is an oral agent may be more convenient for some patients. 
Early experience with the EGFR TKI therapies erlotinib and gefitinib revealed that some 
patients experienced a rapid and tremendous response to therapy, and that these re-
sponses were associated with a history of never-smoking, female sex, Asian ethnicity 
and adenocarcinoma histology (66). The clinical subgroups were subsequently found 
to have a higher prevalence of activating EGFR mutations in the tyrosine kinase domain 
that was associated with a high response rate to this EGFR TKI therapy (67–69). A separate 
analysis of the BR.21 revealed that smoking status appeared to be the most powerful 
predictor of survival benefit of erlotinib: never-smokers (defined as < 100 cigarettes in 
the entire lifetime) had a significantly higher survival rate (HR, 0.4; P < 0.01) (70). Current 
investigations are trying to determine the combination of clinical and molecular factors 
that will predict a survival benefit for EGFR TKI therapy. 
Maintenance chemotherapy
In order to improve patients’ outcomes, there has been a renewed interest in evaluating 
the role of maintenance or consolidation chemotherapy or both. In a recent randomized 
phase III trial of maintenance pemetrexed plus best supportive care versus placebo plus 
best supportive care, progression free survival was 4 months in the pemetrexed arm 
versus 2 months in the placebo arm with an hazard ratio (HR) of 0.6 (p< 0.00001) and the 
overall survival was 13.4 months versus 10.6 months, respectively (HR 0.79, p=0.012) (71). 
The phase III trial of immediate versus delayed docetaxel after first line chemotherapy 
in advanced NSCLC showed also a superior progression free survival (5.7m versus 2.7m, 
p=0.0001) and a superior median overall survival (12.3m versus 9.7m), although not 
statistically significant for the arm with immediate docetaxel (72). In the Saturn trial the 
earlier initiation of erlotinib resulted in statistically significant  improved PFS and overall 
survival. (73) These trials support the rationale of using a non-cross-resistant third gen-
eration agent before disease progression has occurred. However, question remains if we 
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could preserve the survival benefits if we delayed the second line treatment and allowed 
a treatment break?
Histology in the treatment of NSCLC
For the first time, randomized clinical trials in NSCLC now suggest that histology subtype 
can also be used as a marker for chemotherapy effectivity (50,74). In the Scagliotti trial, 
comparing pemetrexed/cisplatin versus gemcitabine/cisplatin, survival was superior 
in patients with non-squamous histology receiving the pemetrexed-based regimen 
(50). Conversely, gemcitabine/cisplatin resulted in superior survival in patients with 
squamous histology tumours. These data suggest that the histologic subtype can now 
be used to select individual patients who would benefit more or less from different 
chemotherapy regimens.
Personalized therapy in NSCLC
Some studies suggest evidence for a key role for the increased expression of ribonucleo-
tide reductase subunit 1 (RRM1) in acquired gemcitabine resistance. (75,76) Recent tri-
als report that patients with NSCLC with high excision repair cross-complementing 1 
(ERCC1) expression do not benefit from cisplatin based chemotherapy (77,78). These 
data are sufficient to consider ERCC1 and RRM1 as possible molecular selection factors 
for platinum compounds and gemcitabine, respectively. These findings are important 
keys towards a “patient-specific individualized” therapy in NSCLC. 
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OUTLINE OF THE THESIS
As this introduction has pointed out, the optimal treatment of patients presenting with 
locally advanced and metastatic NSCLC is a moving target, as clinicians are constantly 
challenged with improvements in staging and therapy, resulting in evolving patterns 
of approach and research. In this thesis we describe chemotherapy and chemo-radio-
therapy studies aimed to optimize treatment for patients with locally advanced and 
metastatic NSCLC.
For patients with locally advanced unresectable stage III NSCLC, the sequential chemo-
radiotherapy approach is still widely used in Europe. A doublet of platinum combined 
with a third-generation chemotherapeutic agent is considered to be the most active 
induction regimen. Cisplatin-based chemotherapy regimens are not suitable for all 
patients because of the presence of comorbidity or a poor performance status. Carbo-
platin regimens are usually better tolerated in these circumstances, but the activity and 
toxicity of carboplatin-based induction regimens are yet unknown for this disease stage. 
Therefore, we decided to investigate the activity and toxicity of the combination of 
carboplatin and gemcitabine as an induction regimen for unresectable stage III NSCLC. 
This trial is described in chapter 2.
A major drawback in the treatment of locally advanced unresectable NSCLC is the high, 
70% relapse rate, which occurs approximately one third locally, one third distantly and 
one third both locally and distantly.
A challenge today is to reduce this high relapse rate by identifying the optimal radiation 
dose in combination with the most effective systemic therapy. So far, neither the best 
drug combination nor the optimum radiation dose has been defined. The problem with 
most third generation chemotherapeutic drugs is that they cannot be administered 
in full systemic dose in combination with concurrent radiation therapy. Therefore, we 
decided to investigate if the combination of a new third generation agent, pemetrexed, 
with cisplatin could be administered at full systemic dosages with concurrent thoracic 
radiotherapy in patients with unresectable stage III NSCLC. The primary aim of this phase 
I study was to determine the MTD of pemetrexed and cisplatin in combination with con-
ventional radiotherapy and secondly to determine the MTD of cisplatin and pemetrexed 
with hypofractionated radiotherapy. In chapter 3 we describe the results of this phase 
I study.
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Patients with stage IIIA and IIIB NSCLC who are downstaged after induction therapy 
may potentially benefit from surgery. The series published were usually limited to single 
institutional experiences. Proper and reliable restaging after induction therapy is crucial 
in order to prove downstaging. Therefore, the Lung Cancer Group of the European 
Organisation for Research and Treatment of Cancer (EORTC) decided, to investigate in 
patients with stage IIIB NSCLC, by study 08981, the feasibility of a tri-modality approach 
of chemoradiotherapy followed by restaging by means of the re-mediastinoscopy and 
resection in a multicenter setting. This trial is described and discussed in chapter 4.
The controversial issues in the management of patients with stage IIIA-N2 non-small 
cell lung cancer are being reviewed in chapter 5. It discusses the reasons of and the 
biases inherent to this controversy and discusses the different treatment approaches 
with emphasis on survival, as evidenced by meta-analyses and randomized clinical 
trials. Prospects on novel treatment modalities and future research opportunities are 
presented.
For patients with metastatic NSCLC, many North American physicians and Cooperative 
Groups prefer carboplatin-based therapies and also in Europe this regimen has become 
more popular. In the recommended 3-weekly schedule with gemcitabine (1250 mg/m2) 
and carboplatin (AUC 5), both administered on day 1, patients frequently experience 
grade 3-4 neutropenia and/or grade 3-4 thrombocytopenia which requires special at-
tention, repeated blood count controls and if needed, dose reductions and platelets 
transfusions. Question is whether administration of carboplatin on day 8 instead of on 
day 1 might lead to less toxicity while maintaining efficacy. In chapter 6 we address 
this research question in a randomized phase II trial setting in which two schedules of 
carboplatin and gemcitabine are studied.
Sequential chemotherapy administration offers the possibility to increase drug diversity 
while maintaining dose intensity, potentially leading to less dose reductions, an optimal 
dose intensity and prolonged treatment duration and disease control. Chapter 7 de-
scribes the results of a phase II trial, in which non-cross resistant sequential single agent 
chemotherapy is administered in first line metastatic NSCLC. 
Currently many physicians select the second-line agent on the basis of physician and 
patient preference, patient co-morbidity, the toxicity profiles of the different therapies, 
and treatment convenience. Oral agents with few side effects are appealing in 2nd or 3rd 
line setting when patients are usually in a less favourable condition. In chapter 8 we 
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report on the efficacy and toxicity of Uracil-Tegafur and etoposide in second and third 
line advanced stage, Caucasian NSCLC patients and compare the toxicity profile and 
costs of this regimen with historical series of the 2nd line therapy.
The studies described in this thesis are summarized in chapter 9. Futures perspectives 
towards an optimized and personalized treatment for NSCLC patients are highlighted.
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ABSTRACT
Introduction: The objectives of this trial were to evaluate the activity and safety of gem-
citabine/carboplatin as induction therapy in patients with locally advanced non-small 
cell lung cancer.
Methods: Patients received two cycles of gemcitabine (1250 mg/m2 on day 1 and 8), plus 
carboplatin (area under the curve = 5 on day 1), after which response was established. 
Patients received a third course only in the case of an objective response (OR). Non-
responding patients were directly irradiated. Toxicity was assessed according to the 
NCI-CTC version 2, radiation toxicity was assessed according to RTOG criteria. Response 
evaluation was performed according to RECIST criteria.
Results: We identified 42 patients, of whom 37 were eligible. Of these, 51% (95% CI, 
34%-68%) achieved an OR, all partial responses. No disease progression on therapy was 
established. Toxicity was mostly hematological: 35% trombocytopenia grade 3 and 4, 
and 40% neutropenia grade 3 and 4. No severe bleeding or hospitalization because of 
febrile neutropenia occurred.
Conclusions: Gemcitabine and carboplatin administered according to a 3-week sched-
ule is an active and safe induction regimen. Pending the results of a phase III study, 
we believe that it is a reasonable alternative among patients for whom cisplatin-based 
chemotherapy is contraindicated.
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The combination of platinum-based chemotherapy and thoracic irradiation is consid-
ered standard therapy in patients with unresectable locally advanced non-small cell lung 
cancer (NSCLC). In a number of randomized studies and a meta-analysis, chemotherapy 
added to radiotherapy improved survival compared with radiotherapy alone (1). 
Recent studies claim concurrent chemo-irradiation to be superior to sequential therapy 
as it achieves higher response rates and adds 7% on long-term survival benefit (2,3). 
However, the optimal chemo- and radiotherapy combination is yet unknown, and 
its major drawback is its increase in toxicity, both hematologic and non-hematologic 
(mucositis, pneumonitis, and esophagitis). This is the reason that a recent meta-analysis 
and the NICE guideline restrict the use of concurrent chemo-radiotherapy to selected 
patients (2). Although sequential therapy is not the standard of care in the United States, 
it is still widely used in Europe, mainly because of logistical reasons.
In the sequential treatment setting, response to induction chemotherapy is an impor-
tant variable in qualifying for subsequent radiotherapy (1,4). A doublet of platinum 
combined with a third-generation chemotherapeutic agent is considered to be the 
most active induction regimen. One of these third-generation agents is gemcitabine. In 
a recent meta-analysis, gemcitabine-containing regimens led to a better survival than 
other third-generation drug combinations in patients with advanced NSCLC (5). 
Because of its more favourable toxicity profile, carboplatin is often preferred to cisplatin 
(6,7). The most frequently used regimen in the United States combines carboplatin and 
paclitaxel. In a recent meta-analysis, it was concluded that cisplatin combinations have 
a survival benefit compared with carboplatin combinations in advanced NSCLC (7), but 
in phase III studies in which gemcitabine-cisplatin and gemcitabine-carboplatin were 
compared, no survival benefit for the cisplatin combination could be demonstrated in 
advanced disease (6,8). 
The aim of the present study was to investigate the activity and toxicity of the combina-
tion of carboplatin and gemcitabine as an induction regimen for stage III NSCLC.
PATIENTS ANd METHOdS
The study was conducted in three Dutch hospitals in Rotterdam (Erasmus MC, Sint 
Franciscus Gasthuis, and MCRZ) and was approved by the local ethical committees of 
each participating center.
Eligible chemonaive patients had to have a histological or cytological diagnosis of lo-
cally advanced NSCLC. In the case of presumed stage IIIA disease, tissue confirmation 
of N2 involvement was required. In the case of stage IIIB disease, patients with N3 (ex-
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cluding supraclavicular lymphnodes) or T4 (excluding pleural fluid) were eligible. Other 
criteria were: measurable disease according to RECIST criteria, age older than 18 years, 
World Health Organization performance status 2 or less, adequate bone marrow reserve 
(hemoglobin >10 mg/dL or 6 mmol/L, white blood cell count higher then 4.0 ×109/L, 
absolute neutrophil count >2.0 × 109/L, platelet count >100 × 109/L), and a calculated 
creatinine clearance of at least 60 mL/min. Women of child-bearing age were asked to 
use adequate contraceptive methods.
Exclusion criteria were the presence of other malignancies (previous or current), except 
adequately treated in situ carcinoma of the uterine cervix or basal or squamous cell 
carcinoma of the skin, or a previous malignancy more than 5 years ago without evidence 
of recurrence; pregnancy and/or breast feeding; use of any investigational agent in the 
month before enrolment into the study; uncontrolled infections and signs or symptoms 
of metastases; a weight loss of more than 10% in the preceding 3 months.
Pretreatment evaluation included a complete medical history and physical examination, 
chest radiograph and computed tomographic scanning of thorax and upper abdomen, 
pulmonary function testing with diffusion capacity, routine blood sampling, urine analy-
sis and electrocardiogram. All patients had to give written informed consent.
Treatment
The treatment scheme is presented in Figure 1. Chemotherapy consisted of two courses 
of gemcitabine and carboplatin as a 21-day regimen. Gemcitabine was given at a dosage 
of 1250 mg/m2 intravenously (over 30 minutes on days 1 and 8), carboplatin at an area 
under the curve of 5 (intravenous in 30 minutes on day 1) after gemcitabine. Routine 
anti-emetics were given according to institutional practice. No prophylactic growth fac-
tors were allowed. Dose adjustments were made according to the guidelines described 
in Table 1. In the case of non-hematological toxicity grade 4, a dose reduction with 25% 
of both gemcitabine and carboplatin was performed.
                                                                                    
 
 
                                                                                  OR 1 cycle carbo/gem more  adjuvant therapy 
                                                                                   
 Registration  2 cycles carbo/gem evaluation   
                                                                                   
                                                                                  SD or PD adjuvant therapy 
 
Figure 1. Treatment schedule
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After two cycles, response evaluation was performed according to RECIST criteria. In 
case of a response, one more cycle was administered before the start of thoracic radio-
therapy. In the case of stable disease or progressive disease, patients were immediately 
referred for radiotherapy. Radiotherapy was given with a radical intent. Dose was cal-
culated taking into account lung toxicity (V20) and estimated esophagus toxicity. The 
interval between the start of the last chemotherapy and the start of radiotherapy had 
to be at least 4 weeks and less than 6 weeks. Toxicity was assessed weekly using the 
National Cancer Institute common toxicity criteria (NCI-CTC version 2). Radiation toxicity 
was scored according to RTOG criteria.
Statistics
The study was designed according to the two-step Simon design, with a response rate of 
interest after two cycles of chemotherapy of at least 70% with a type 1 error of 0.05 and 
a power of 80%; 37 patients had to be accrued to observe 26 responses. If less than 12 
responses were seen in the first 24 patients, the study should have been discontinued. 
Response analysis was performed for eligible patients only. Toxicity analysis included all 
patients. Survival data were calculated using the Kaplan-Meier method.
RESULTS
Patient Characteristics
Between January 2002 and December 2004, 42 patients were enrolled (23 male, 19 
female; mean age 61.3 years, range 42-78 years). All patients gave informed consent. 
Five patients were ineligible because of stage IV disease in four patients and stage 
IIIB disease with pleural effusion in one patient. Patient characteristics of the eligible 
patients are presented in Table 2.
Table 1. Redosing schedule related to toxicity
Gemcitabine
Dose (mg/m2)
WBC x 109/L ANC x 109/L
 and/or
Platelets x 109/L
and/or
1250
1000
0
> 2
1-2
<1
> 1
0.5 – 1
<0.5
>100
50-100
<50
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Activity
A total of 102 chemotherapy courses were administered, with a median of three cycles 
per patient (range, one to four). Two patients with a partial response received four cycles 
instead of the planned three because of a delay in the start of radiotherapy because of 
logistical problems.
The overall clinical response rate in the 37 eligible patients was 51% (95% CI, 34%-68%) 
and for stage IIIA and IIIB disease 38% (9 of 16) and 61.9% (13 of 21), respectively, with 
no complete responses. No disease progression was observed.
Toxicity and dose Intensity
Five patients were excluded from the toxicity analysis, one because of erythropoietin 
administration and four because only data from cycle one were available. In the remain-
ing 37 patients, grade 3 to 4 thrombocytopenia was seen in 13 patients (35.1%), with 12 
(32.4%) grade 3 and 1 (2.6%) grade 4 (Table 3). Six patients required platelet transfusions, 
but no overt hemorrhages were observed. Grade 3 to 4 neutropenia was observed in 15 
(40.5%) of patients: 13 (35.1%) grade 3 and 2 (5.2%) grade 4. No febrile neutropenia oc-
curred. In one patient (2.6%) a grade 3 anemia was found, but erythrocyte transfusions 
were given in 10 patients (27%) (Table 3).
Except for dyspnea, which was found in five patients (13.2%), non-hematological toxic-
ity was low. The planned dose intensity was 208 mg/wk for carboplatin and 1542 mg/wk 
Table 2. Patients Characteristics
   Characteristics No. of Patients (%)
Male/female
Age (yr)
PS 0
PS 1
PS 2
Stage IIIA
Stage IIIB 
19/18
 61.8
14
21
2
16
21
(51/49)
(51/49)
(38)
(57)
(5)
(43)
(57)
Values are n(%) or mean (range)
Table 3. Hematological toxicity
Grade 3 Grade 4
Anemia   1  (2.7) 0 (0)
Thrombocytopenia 12 (32.4) 1 (2.7)
Leukopenia   9 (24.3) 0 (0)
Neutropenia 13 (35.1) 2 (5.4)
Values are n(%). n = 37.
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for gemcitabine. Relative dose intensity in the 37 patients equaled 99% for carboplatin 
and 91% for gemcitabine.
Radiation Therapy
Of the patients who received the planned treatment, 89% (33 of 37) underwent radio-
therapeutic treatment. Four patients did not undergo radiotherapy. One patient died af-
ter chemotherapy before the start of radiation therapy because of myocardial infarction 
that was not related to chemotherapy. One patient had a marginal pulmonary function 
but was considered by a radiation oncologist to be fit for involved field radiotherapy. 
However, the patient’s clinical condition deteriorated after chemotherapy, and he was 
subsequently judged to be unfit for radiotherapy. In two otherwise fit patients, the initial 
radiation fields were considered to be excessively large for radical radiotherapy, and 
we planned to irradiate the post-chemotherapy volume. A lack of response to chemo-
therapy led to the decision not to irradiate. These were the only two patients included in 
the study for who we planned to irradiate the post-chemotherapy volume. Mean dose 
was 42.5 Gy (range, 20-66 Gy). During and after radiotherapy, one patient developed 
grade 3 esophagitis. Radiation pneumonitis occurred in four patients (grade 1 in two 
patients and grade 3 in two patients).
Follow-Up
Median survival of all 37 patients was 13 months. The Kaplan-Meier survival curve is pre-
sented in Figure 2. Currently 78% of patients have progressed. Median time to disease 
progression is 9.1 months.
dISCUSSION
In this phase II study designed to investigate the activity and safety of the gemcitabine-
carboplatin combination as an induction regimen in sequential chemo-radiation for 
locally advanced NSCLC, an overall response rate of 51% was achieved. Table 4 sum-
marizes the characteristics of the published data on the combination of gemcitabine 
and platinum in locally advanced NSCLC. Because consolidation treatment is different 
among the studies, no valid information on time to progression can be provided. For the 
cisplatin-based schemes, response rates after chemotherapy differ between 40% and 
70%. In the earlier studies, gemcitabine-cisplatin was given in a 4-week schedule. In 
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Table 4.  Articles about gemcitabine platinum in locally advanced NSCLC
Author Phase Induction scheme q n Stage IIIa/
IIIb (%)
Response rate
(95% CI)
Van Zandwijk et al.4 II Gemcitabine 1000 mg/m2 d1,8,15
Cisplatin 100 mg/m2 d2
4 47 100/0 70 (55-83)
Yang et al.17 II Gemcitabine 1000 mg/m2 d1,8,15
Cisplatin 90 mg/m2 d15
4 52 50/50 64 (50-77)
Van Kooten et al.18 II Gemcitabine 1250 mg/m2 d1,8,15
Cisplatin 100 mg/m2 d2
4 29 59/41 62( 45-79)
De Pas et al.13 II Gemcitabine 1000 mg/m2 d1,8,15
(1250 mg/m2 d1,8)
Cisplatin 100 d1 (80 mg/m2 d1)
4 (3) 10(40) 74/26 74 (60-85)
Santo et al.14 II Gemcitabine 1250 mg/m2 d1,8
Cisplatin 100 mg/m2 d8
3 43 33/67 62 (NR)
Cappuzzo et al.15 II Gemcitabine 1000 mg/m2 d1,8
Cisplatin 70 mg/m2 d2
3 129 44/56 62 (54-70)
Vokes et al.12 III Gemcitabine 1250 mg/m2 d1,8
Cisplatin 80 mg/m2 
3 62 67/33 40 (27-55)
Migliorino et al.16 II Gemcitabine 1250 mg/m2 d1,8
Cisplatin 70 mg/m2 d2
3 69 67/33 57 (45-62)
Argiris et al. 9 I/II Gemcitabine 1000 mg/m2 d1,8
Carboplatin AUC = 5
3 39 56/44 41 (26-56)
Current study II Gemcitabine 1250 mg/m2 d1,8
Carboplatin AUC = 5
3 37 45/55 51 (34-68)
AUC = arca under the curve
 
later studies, this was changed to a 3-week schedule. This was done because of toxicity 
(mostly hematological), because of which the gemcitabine on day 15 was often omitted. 
Only one other study with gemcitabine-carboplatin used as an induction regimen in 
locally advanced NSCLC has been published, with a response rate of 41% (9). Recent 
data were presented in the same patient group showing a response rate of 74% (10). In 
the latter studies, the induction treatment was followed by concomitant treatment with 
chemoradiation.
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In the absence of randomized data, no formal comparison can be made between cispla-
tin- and carboplatin-containing regimens for induction. It is unlikely that such a trial will 
ever be conducted because of the large sample size required to demonstrate a true dif-
ference. In advanced disease, such studies have been performed (6,8). In neither of these 
studies was a significant difference in response rate between gemcitabine cisplatin or 
gemcitabine carboplatin found. In both studies, the response rate in the cisplatin arm 
was higher, but this did not reach statistical significance.
Toxicity was limited in the study. The known dose-limiting toxicity of the gemcitabine-
carboplatin combination is hematologic (6). Although thrombocytopenia grade 3 and 4 
was present in 35% of cases, this was never associated with bleeding. Neutropenia grade 
3 and 4 was present in 41% of patients, but no hospitalization because of febrile neutro-
penia was necessary. Anemia grade 3 was present in only one patient, but 10 patients 
received an erythrocyte transfusion, which may have influenced this number. Almost all 
transfusions were given after the completion of the second cycle. The high number of 
transfusions in relation to the objective toxicity numbers may be related to the fact that, 
in 12% of patients, grade 3 and 4 dyspnea was scored, which may have made physicians 
more prone to give blood transfusions. The toxicities are comparable to the numbers 
found in other studies (6,9,11). Survival of our patients was poor. We believe that this is 
related to the patient population included; most of our patients were stage IIIB. Patients 
 
Fig. 2 Survival curve for all 37 eligible patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Survival curve for all 37 eligible patients.
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with minimal N2 disease were included into other study protocols. The recent publication 
of Fournel et al. (3) also included a large population of patients with stage IIIB disease, 
and survival in the sequential arm was comparable to ours. Similarly, the recent phase III 
CALGB study 39801 evaluating two concurrent chemo-radiotherapy schedules reported 
median survivals of 11.4 months for concurrent chemo-radiotherapy, and 13.7 months 
for induction chemotherapy followed by the same concurrent chemo-radiotherapy 
scheme (12). 
In recent years, more and more data on the survival benefit of concurrent therapy have 
become available. At the time of the design of the study, these data were not published. 
It is therefore also likely that patients with good performance status were enrolled in this 
study. These patients will now preferably be treated with concurrent chemoradiotherapy. 
However, in a large group of patients, with poor performance status or with comorbid 
conditions, because of the toxicity of concurrent therapy, sequential therapy will remain 
standard of care. For these patients, the possibility of a lesser toxic chemotherapeutic 
agent is of importance, and, in these situations, carboplatin is preferred.
In conclusion, gemcitabine carboplatin is an active and safe chemotherapeutic regimen, 
especially for patients in whom cisplatin-based chemotherapy is contraindicated.
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ABSTRACT
Background: The objectives were to determine the maximum tolerated dose (MTD) of 
pemetrexed and cisplatin with concurrent radiotherapy. Secondary objectives include 
incidence and nature of acute and late toxicities, tumour response and overall survival.
Patients and methods: Treatment naïve patients received 1 cycle of cisplatin 80 mg/m2 in 
study I (stage III NSCLC), 75 mg/m2 in study II (LD-SCLC)) and pemetrexed 500 mg/m2 be-
fore the phase I part. In Study I, patients were treated in cohorts with escalating cisplatin 
doses (60-80 mg/m2), pemetrexed doses (400-500 mg/m2) and concurrent escalating 
radiotherapy doses (66 Gy in 33-27 fractions). In study II, patients were treated with 
cisplatin 75 mg/m2 and escalating pemetrexed doses (400-500 mg/m2) with concurrent 
escalating radiotherapy doses (50-62 Gy).
Results: The trials closed prematurely: study I because of poor accrual, study II because 
of sponsor decision. Thirteen patients were treated : 4 with NSCLC, 9 with LD-SCLC. No 
dose-limiting toxicity was observed. There was no grade 4 toxicity, grade 3 hematologi-
cal toxicity was mild. One patient developed grade 3 acute esophagitis, but was able to 
complete radiotherapy without delay. Two patients experienced grade 2 late pulmonary 
toxicity. 1 complete response, 6 partial responses and 1 progressive disease were ob-
served.
Conclusions: Although the studies stopped too early to assess MTD, we have demon-
strated that the combination of full doses of cisplatin (75-80 mg/m2) and pemetrexed 
500 mg/m2 with concurrent radiotherapy up to 50 Gy (25 x 2 Gy) is well tolerated. 
Pemetrexed is the first 3rd generation cytotoxic found to be tolerable at full dose with 
concurrent radiotherapy.
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Cisplatin/pemetrexed with concurrent radiotherapy
INTROdUCTION
Lung cancer is the leading cause of cancer-related death in the United States and Europe 
for both men and women. Non-small cell lung cancer (NSCLC) accounts for 87% of all 
lung cancer cases. One third of them presents with locally advanced disease, of which 
the majority is unresectable. Concomitant chemo-radiotherapy improves survival of 
patients with locally advanced NSCLC by 5.7% at 3 years compared to sequential chemo-
radiotherapy, but at the cost of increased acute esophageal toxicity (1). The 70% relapse, 
occurring approximately one third locally, one third distantly and one third both locally 
and distantly (2-7), is a major drawback. A major challenge today is to reduce this high 
relapse rate by identifying the optimal radiation dose in combination with the most 
effective systemic therapy. So far, neither the best drug combination nor the optimum 
radiation dose has been defined. Therefore, new chemo-radiotherapy combinations are 
needed.
Small cell lung cancer (SCLC) accounts for approximately 13% of all lung cancers 
diagnosed and about one third is limited-stage disease (LS-SCLC). Sequential chemo-
radiotherapy has improved 5-year survival rates by 5 % compared to radiotherapy alone 
(8, 9) and has been further improved by the combination of early thoracic radiotherapy 
(TRT) and concurrent chemotherapy (10-13). Like in NSCLC, major challenge is to reduce 
the high relapse rate and to improve survival. Therefore, also for LS-SCLC new chemo-
radiotherapy combinations are needed.
Pemetrexed is a multitargeted antifolate which has activity in a wide range of cancers. 
It has been approved by the U.S Food and Drug Administration for single agent second-
line therapy in metastatic NSCLC (14-16) and for first-line treatment in malignant pleural 
mesothelioma in combination with cisplatin (17) and recently in first-line metastatic 
NSCLC in combination with cisplatin for non-squamous histology (18).
In preclinical studies, the combination of pemetrexed with radiotherapy appeared to be 
synergistic (19). Seiwert et al. was the first to demonstrate in a phase I study in patients 
with locally advanced NSCLC or esophageal cancer that the combination of pemetrexed 
(500 mg/m2) and carboplatin (area under the curve 5 or 6) with concurrent radiation 
was well tolerated and active (20). However, in patients with NSCLC, cisplatin-based 
regimens are superior to carboplatin-based regimens in terms of response rate and, in 
certain subgroups (patients treated with third-generation platinum-based regimens 
and patients with non-squamous histology) in prolonging survival (21). Cisplatin is also 
a potent radiosensitizer, while the radiosensitizing properties of carboplatin are not as 
well established. Therefore, we decided to investigate the combination of pemetrexed 
and cisplatin with concurrent TRT in patients with LS-SCLC and stage III NSCLC in two 
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separate studies. Primary objective of these studies was to determine the maximum 
tolerated dose (MTD) of pemetrexed and cisplatin with concurrent TRT. Secondary 
objectives were acute and late toxicity, objective tumour response and overall survival.
PATIENTS ANd METHOdS
Study I was approved by the Ethical Committee of the Erasmus University Hospital Rot-
terdam, study II by the Ethical Committee Vrije Universiteit Amsterdam.
Patients and treatment plan
Enrolled were patients with histologically or cytologically proven stage III NSCLC not 
amenable for surgical resection (Study I, investigator initiated, Lilly supported) or his-
tologcially or cytologically proven LS-SCLC (Study II, Lilly study number H3E-EW-S107). 
The in- and exclusion criteria and dose limiting toxicity definitions of these two studies 
are summarized in Table 1. Both the NSCLC and LD-SCLC patients received one cycle 
of cisplatin (80 mg/m2 study I, 75 mg/m2 study II) and pemetrexed 500 mg/m2 before 
start of phase I. Starting with cycle 2, chemotherapy and radiotherapy doses differed 
between the cohorts as summarized in Table 2. Patients gave written informed consent 
before enrolment in the studies. 
Chemotherapy
Patients were treated with cisplatin and pemetrexed on day 1 of a 21-day cycle. Peme-
trexed was administered as a 10-minute and cisplatin as a 120-minute intravenous infu-
sion 30 minutes after the end of the pemetrexed infusion. Folic acid supplementation 
(350-600mg) started 5 to 7 days prior to the first dose of pemetrexed and continued daily 
until 3 weeks after the last dose of pemetrexed. Vitamin B12 (1000mg) was administered 
as an intramuscular injection 1 to 2 weeks prior to the first dose of pemetrexed and 
was repeated every 9 weeks until 3 weeks after the last dose of pemetrexed. Patients 
were treated with dexamethasone the day before, the day of and the day after each 
dose of pemetrexed. For all cohorts, radiotherapy was administered 2 hours after the 
chemotherapy administration.
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Radiation therapy
For study I, the initial radiotherapy dose in cohort one through four was 66 Gy admin-
istered over 45 days with daily fractions of 2 Gy, 5 days/week. For study II, the initial 
radiotherapy dose in cohort 1 and 2 was 50 Gy administered in 25 daily fractions of 2 Gy, 
5 days/week. Patients with LS-SCLC who had a complete response, received prophylactic 
cranial irradiation with a total dose of 20-30 Gy, in fractions of 2-2.5 Gy/day over a period 
of 3 weeks.
Radiotherapy was administered according to the recommendations of the European 
Organisation For Research and Treatment of Cancer (EORTC) Radiotherapy Group, ICRU 
Report 50 and ICRU Report 62 (22). The gross tumor volume (GTV) encompassed all 
known pre-chemotherapy primary tumor and involved lymph node locations. Ad-
ditional margins applied for microscopic tumor extension, mobility and daily setup 
Table 1. Eligibility criteria and definition of dose limiting toxicity for patients with non-small cell lung cancer (study I) and small cell 
lung cancer (study II)
Eligibility
criteria
No prior chemo- or radiotherapy
ECOG 0 or 1
ANC ≥ 1.5 X 109/L, platelets ≥ 100 X 109/L and hemoglobin ≥ 9.6 g/ dl
Measurable disease (RECIST)
Calculated creatinin clearance ≥ 60 ml/min (Cockroft and Gault )
 · FEV1 >30% predicted normal value 
 · Diffusion capacity > 40% predicted normal value
 · V20 ≤ 36% 
Able to drain third space fluids
Exclusion
criteria
Pleural effusion with positive cytology
Stage III NSCLC with supraclavicular lymph node involvement
Uncontrolled vena cava superior syndrome
Serious concomitant systemic disorder
Myocardial infarction <6 months or symptomatic heart disease
Significant weight loss (>10%) over previous 6 weeks before study entry
Inability to take folic acid or vitamin B12 supplementation
Inability to take corticosteroids
DLT definition Grade 4 neutropenia lasting > 5 days, or ANC < 0.5 x 109/L on two occasions 7 days apart
Febrile neutropenia
Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding
RTOG grade 3 pulmonary or esophageal toxicity that prohibits 5 or more consecutive days of radiation 
treatment or any RTOG grade 4 pulmonary or esophageal toxicity 
Any other grade 3 non-hematologic toxicity that prohibits 5 or more consecutive days of radiation 
treatment or grade 4 non-hematologic toxicity (except grade 3/4 alopecia, nausea and vomiting)
Death due to toxicity
Grade 2 to 4 myelosuppression prohibiting retreatment on day 22
Definitions of abbreviations: ANC : absolute neutrophil count; RECIST: Response Evaluation Criteria in Solid Tumors; FEV1: forced 
expiratory volume in one second; V20: lung volume minus the planned target volume receiving ≥20 Gy; DLT= dose limiting toxicity; 
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errors in order to derive a planning target volume (PTV) did generally not exceed 1.5 
cm. Mediastinal or hilar lymph nodes > 1cm in shortest diameter found histologically 
positive at cervical mediastinoscopy or endoscopic ultrasound and those considered 
positron-emission-tomography (PET) positive have been included in the PTV. The mar-
gins around visible, enlarged lymph nodes were 1.5 cm in the transverse and 2 cm in the 
longitudinal direction. The PTV has been irradiated by multiple field arrangement swith 
the use of 3D conformal techniques. Dose volume histograms for the PTV, normal lung, 
esophagus and heart have been calculated in order to gain full knowledge of the 3D 
dose distribution.
The spinal cord did not receive more than the equivalent of 50 Gy in 30 fractions us-
ing standard, biologically effective dose corrections at any point. The esophagus was 
included within the 95% isodose in most patients but the maximal length did not ex-
ceed 15 cm. The heart received a maximum tolerated dose < 30% of its volume and the 
volume of both lungs that received more than 20 Gy (V20) was ≤ 36%.
Tabel 2. Treatment plan for patients with non-small cell lung cancer (study I) and treatment plan for patients with small cell lung 
cancer.(study II)
Study I Pemetrexed (mg/m2) Cisplatin (mg/m2) Radiotherapy
(Gy/fractions/days)
Patients 
Cycle 1
All 500 80 None All
Cycles 2-3
Cohort 1 400 60 66/33/45 3-6 (9)
 2 400 70 66/33/45 3-6 (9)
 3 400 80 66/33/45 3-6 (9)
 4 500 80 66/33/45 3-6 (9)
 5 500 80 66/30/40 3-6 (9)
 6 500 80 66/27/37 3-6 (9)
Study II Pemetrexed (mg/m2) Cisplatin (mg/m2) Radiotherapy (Gy/fractions/
days)
Patients
Cycle 1
All 500 75 None All
Cycles 2-3
Cohort 1 400 75 50/25/25 3-6
 2 500 75 50/25/25 3-6
 3 500 75 56/28/28 3-6
 4 500 75 62/31/31 3-6
Cycle 4
All 500 75 None all
Definitions of abbreviations: Gy= gray
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Dose escalations and dose-limiting toxicity
The definitions of the dose-limiting toxicities for the two studies (DLT) are summarized 
in Table 1. They apply to the complete chemo-radiation period up to 6 weeks after the 
last fraction of radiotherapy administration. If none of the patients experienced a DLT, 
the next dose level was explored and if 1 of the first 3 patients had DLT, 3 additional 
patients were enrolled at the same dose level. Dose escalation was only allowed if no 
more than 1 patient experienced a DLT.
If in study I, more than 1 out of 6 patients had a DLT, the cohort was expanded to 9 pa-
tients. If no more than 3 out of 9 patients experienced DLT, this dose was the maximum 
tolerated dose (MTD) and the dose used in the preceding cohort was the recommended 
phase II dose. If in study II more than 1 of the 6 patients had DLT, this dose was the MTD 
and the dose used in the preceding cohort the recommended phase II dose. In case of 
grade IV toxicity (except alopecia, nausea and vomiting), the recommended dose was 
defined as one dose level below the level at which the grade 4 toxicity occurred. To 
proceed to the next cohort, 6 weeks (Study I) or 2 weeks (Study II) must have elapsed 
after the last radiation fraction of the last patient. 
Efficacy and tolerability assessments
Baseline assessments included physical examination, complete blood count, electro-
cardiogram (ECG) < 2 weeks before the start of treatment and chest-upper abdomen 
computed tomography (CT), CT or MRI brain, TRT planning CT and a PET scan within 4 
weeks before treatment. The lung function test included a forced expiratory volume in 
one second (FEV1) and a diffusion capacity (DLCO) within 4 weeks before start of the 
treatment. Routine blood tests for blood chemistry and haematological toxicity were 
performed before each chemotherapy administration. Toxicity was graded according to 
the National Cancer Institute Common Toxicity Criteria version 3 (NCI-CTC) and assessed 
on day 1, 8, 15 and 21 of each cycle by physical examination, direct questioning and 
appropriate hematological and biochemical values. Post treatment follow-up included 
a chest-upper abdomen CT at 1, 3, 6, 9 and 12 months, lung function tests at 3 and 12 
months, NCI-CTC toxicity scoring and RTOG toxicity scoring at 1, 3, 6, 9 and 12 months, 
and an ECG at 1, 3, 6, 9 and 12 months. Tumor response was assessed according to 
RECIST criteria (23).
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Statistical and analytical plan
Patients who received at least cycle 1 and 2 (concomitant chemo-radiotherapy) were 
included in the primary outcome analysis, i.e the MTD of cisplatin and pemetrexed with 
concurrent radiotherapy. All patients who received at least one 1 dose of pemetrexed or 
cisplatin were evaluated for safety analysis and tumour response assessment. This safety 
analysis included serious adverse events (SAES) related to study treatment, discontinua-
tion, listings of CTCAE 3 toxicities and RTOG acute and late toxicities. 
RESULTS
Study I was prematurely terminated because of poor accrual and study II because of the 
inferior activity of pemetrexed in SCLC based on the interim results of the GALES trial in 
SCLC-ED (24).
In study I, between April 2006 and January 2008, 3 males and 1 female were enrolled. 
Median age was 59 years (range 54-64); 3 had ECOG performance status (PS) 1, 1 PS 
0; 3 had stage IIIA, 1 stage IIIB; 1 squamous cell carcinoma, 1 adenocarcinoma and 2 
undifferentiated carcinomas were diagnosed.
In study II, between March 2007 and December 2007, 6 males and 3 females have been 
included with a median age of 70 years (range 50-80); 2 had PS 0, 7 PS 1.
In study I, 4 patients completed cohort 1 without DLT. All patients received 3 cycles of 
chemotherapy without dose reductions. In none of the patients radiation therapy was 
interrupted because of adverse events (AE). In one patient a non-study related SAE oc-
curred 2 days after the end of the radiotherapy. He died of intracranial haemorrhage (at 
that time, the thrombocyte count was normal) as a result of a car accident This study 
participant was replaced in this cohort. Treatment-related grade 3 and 4 toxicities are 
summarized in Table 3. No febrile neutropenia or toxic deaths were observed. Acute 
and late pulmonary and esophageal toxicities are summarized in Table 4. In one patient 
grade 2 late pulmonary toxicity was diagnosed.
Two patients achieved a partial response, 1 patient had a complete response. One 
patient died with progressive disease at 21 months, the other patients are still alive at 
3 years.
In study II, 9 patients were included in the safety analysis and 5 in the tumour response 
evaluation. Four of the 9 patients completed treatment. Three patients in cohort 2 
discontinued treatment due to an AE; 1 because of renal failure after the first course of 
chemotherapy, 1 because of femoral artery occlusion and 1 because of grade 3 peripheral 
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sensory neuropathy. Two patients received only 1 cycle of chemotherapy because 
of premature closure of the trial. In total, 3 patients were replaced as they were not 
evaluable for DLT. None of the patients in cohort 1 or 2 experienced DLT. In one patient, 
dose reductions for pemetrexed and cisplatin were required because of dehydration at 
cycle 2. In one patient the cisplatin dose was reduced at cycle 4 because of decrease in 
renal function. Treatment-related grade 3 and 4 toxicities are summarized in Table 3. 
No febrile neutropenia or toxic deaths were observed. Acute and late pulmonary and 
esophageal toxicities are summarized in Table 4. One patient in cohort 1 experienced a 
grade 3 acute esophageal toxicity, this patient was able to complete radiation therapy 
without delay. One patient in cohort 2 developed grade 2 late pulmonary toxicity.
Table 3. Treatment-related grade 3 and 4 toxicities after cisplatin and pemetrexed with concurrent radiotherapy in study I and II 
according to the National Cancer Institute Common Toxicity Criteria version 3 and RTOG toxicity scoring
Study I (NSCLC) 
Cohort No DLT Hematological toxicity Non-hematological toxicity
1 4 no 1: G3 leucopenia 1: G3 hyperglycemia
Study II (LD-SCLC)
Cohort No DLT Hematological toxicity Non-hematological toxicity
1 3 no 1: G3 anemia, G3 thrombocytopenia 
1: G3 thrombocytopenia, G3 neutropenia 
1: G3 lymphopenia 
1: G3 anorexia, G3 fatigue
1: G3 esophageal toxicity
2 6 no 2: G3 lymphopenia,
1: G3 neutropenia
1: G3 anorexia, G3 renal toxicity
1: G3 fatigue, G3 anorexia,
     G3 femoral artery occlusion
1: G3 peripheral sensory neuropathy
Definitions of abbreviations G3= grade3; DLT= dose limiting toxicity; NSCLC= non-small cell lung cancer; SCLC=small cell lung cancer
Table 4. Pulmonary and esophageal toxicity after treatment with cisplatin-pemetrexed and concurrent radiotherapy in study I and II, 
according to RTOG toxicity scoring
Study I (NSCLC)                             Pulmonary toxicity                                                             Esophageal toxicity
1 4 no Acute: /
Late: 1 G2
Acute: 1 G1
Late: /
Study II (LD-SCLC)
Cohort No DLT  Pulmonary toxicity  Esophageal toxicity
1 3 no Acute: 2 G1, 1 G2 
Late : 2 G1 
Acute: 3 G2, 1 G3
Late : 1 G2
2 6 no Acute: 1 G1
Late: 1 G2
Acute: 2 G1
Late: /
Definitions of abbreviations G= grade; DLT= dose limiting toxicity; NSCLC= non-small cell lung cancer; SCLC=small cell lung cancer
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Four patients achieved a partial response, 1 patient progressed after 2 and 4 cycles of 
chemo-radiotherapy. 
Of the 4 patients who completed treatment, 1 patient died 6 months, one 14 months 
and one 11.5 months after the start of treatment, all of them because of disease progres-
sion. One patient is still alive. 
dISCUSSION
Because these two phase I trials were terminated prematurely and prior to the occur-
rence of DLT’s, we are unable to establish the MTD of cisplatin and pemetrexed with 
concurrent radiotherapy in locally advanced NSCLC and LS- SCLC. However, these two 
studies provide additional data on the toxicity of this new combination and are impor-
tant for future trials. 
From our data we may conclude that systemic doses of pemetrexed and cisplatin up to 
500 mg/m2 and 75 mg/m2, respectively, can safely be combined with radiotherapy up 
to 50 Gy in 25 fractions. Overall the toxicity profile is favourable. Hematological toxici-
ties were mild and no dose reductions for haematological toxicity were needed. Similar 
results were presented at ASCO 2008 by Brade et al (25) and Gadgeel et al (26). They 
concluded that full dose of pemetexed and cisplatin with full dose of RT is well tolerated 
in stage III NSCLC. In our study, grade 3 and 4 acute or late pulmonary toxicities have not 
been observed. Although one patient experienced a grade 3 acute esophageal toxicity, 
this patient was able to complete radiation therapy. Because 2 out of 13 patients (15%) 
developed late grade 2 pulmonary toxicity, close follow-up for late pulmonary toxicity is 
recommended, especially in studies with higher radiation dosages. 
Pemetrexed is the first 3rd generation cytotoxic which can be administered at full 
dose with concurrent chemoradiotherapy. Choy et al. demonstrated recently that a 
gemcitabine-carboplatin combination concurrent with thoracic radiotherapy is well 
tolerated with a MTD of gemcitabine of 450 mg/m2 and carboplatin area under the 
curve (AUC) of 2 with thoracic radiation to 63 Gy. These dosages of gemcitabine and 
carboplatin are far below systemic effective dose levels (27). Recently, a phase III study 
in non-squamous unresectable locally advanced stage III NSCLC has started with full 
dose pemetrexed 500 mg/m2, cisplatin 75 mg/m2 and radiotherapy 66 Gy in 33 fractions 
followed by consolidation pemetrexed. 
Unfortunately, pemetrexed proved to be inactive in SCLC. Jalal et al. evaluated single-
agent activity of pemetrexed in relapsed SCLC and reported disappointing response 
rates (28). The interim analysis of the GALES trial, a phase III trial comparing carboplatin 
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with etoposide versus carboplatin with pemetrexed, showed that the pemetrexed arm 
was unable to meet the predefined endpoint of noninferiority. Overall response rates 
were also inferior for the pemetrexed arm (24.9% versus 40.5%, p<0.001) (24). Recent ev-
idence suggests that tumors associated with a high expression of thymidylate synthase 
(TS) may be resistant to the effects of pemetrexed; recently it is shown that TS expression 
is high in SCLC, explaining the minimal activity of pemetrexed in SCLC (29,30).
In conclusion, the combination of full doses of cisplatin (75-80 mg/m2 ) and pemetrexed 
500 mg/m2 with concurrent radiotherapy up to 50 Gy (25 x 2 Gy) is well tolerated. 
Pemetrexed is the first 3rd generation cytotoxic found to be tolerable at full dose with 
concurrent radiotherapy. Further studies in locally advanced NSCLC are warranted. 
Veerle BW 2.indd   55 19-11-09   15:56
Chapter 3
56
REFERENCES
 1. Aupérin A, Le Péchoux C, Pignon JP, C. Koning, B. Jeremic, G. Clamon, et al. Concomitant radio-
chemotherapy based on platin compounds in patients with locally advanced non-small cell lung 
cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006;17:473-
483.
 2. Machtay M, Hsu C, Komaki R, Sause W, Swann R, Langer C, et al. Effect of overall treatment time on 
outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: 
Analysis of the radiation therapy oncology group (RTOG) experience. Int J Radiat Oncol Biol Phys 
2005;63:667-671.
 3. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined che-
motherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. 
Cancer 1995;76:593-601.
 4. Schild SE, Wong WW, Vora SA, Halyard M, Northfelt D, Kogut H, et al. The long-term results of a 
pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally 
advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2005;62:1432-1437.
 5. West H, Albain KS. Current standards and ongoing controversies in the management of locally 
advanced non-small cell lung cancer. Semin Oncol 2005;32(3):284-292.
 6. Kim YS, Yoon SM, Choi EK, Yi BY, Kim JH, Ahn SD, et al. Phase II study of radiotherapy with three- 
dimensional conformal boost concurrent with paclitaxel and cisplatin for stage IIIB non-small-cell 
lung cancer. Int J Radiat Oncol Biol Phys 2005;62: 76-81.
 7. Cohen EE, Vokes EE. Induction chemotherapy and radiotherapy in locally advanced non-small cell 
lung cancer. Hematol Oncol Clin North Am 2004;18: 81-90.
 8. Warde Pe et al. Does thoracic irradiation improve survival and local control in limited-stage small-
cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10(6):890-899.
 9. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL ,et al. A meta-analysis of 
thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327(23):1618-1624.
 10. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of 
concurrent verus sequential thoracic radiothreapy in combination with cisplatin and etoposide 
for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. 
J Clin Oncol 2002;20:3054-3060.
 11. Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingstone RB, Komaki R, Wagner H, et al. Twice-daily 
compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concur-
rently with cisplatin and etoposide. N Engl J Med 1999;340 (4):265-271.
 12. Turrisi AT 3rd. Limited-disease small-cell lung cancer research: sense and nonsense. Int J Radiat 
Oncol Biol Phys 2004;59(4):925-927.
 13. Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, et al. Importance of timing for thoracic 
radiotherapy in the combined modality treatment of limited-stage small-cell lung cancer. The 
National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993;11(2):336-344.
 14. Shih C, Chen VJ, Gossett LS, Gates SB, Mackellar WC, Habeck LL, et al. LY231514, a pyrrolo (2,3-
d) pyrimidine-based antifolate that inhibits multiple folate- requiring enzymes. Cancer Res 
1997;57:1116-1123.
 15. Adjei AA. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 
2003;3:145-156.
Veerle BW 2.indd   56 19-11-09   15:56
57
Cisplatin/pemetrexed with concurrent radiotherapy
 16. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, Von Pawel J, et al. Randomized phase 
II trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously 
treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
 17. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study 
of pemetrexed in combination with cisplatin versus cipslatin alone in patients with malignant 
pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
 18.  Scagliotti GV, Parikh P, von Pawel J, Biesma B, Van Steenkiste J, Manegold C, et al. Phase III study 
comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive 
patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-
51.
 19. Bischof M, Weber KJ, Blatter J, Wannenmacher M, Latz D, et al. Interaction of pemetrexed (Al-
imta, multi-targeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys. 2002 Apr 
1;52(5):1381-8.
 20. Seiwert TY, Connell P, Mauer AM, Hoffmann PC, George CM, Szeto L, et al. Phase I study of peme-
trexed, carboplatin and concurrent radiotherapy in patients with locally advanced or metastatic 
non-small cell lung or esophageal cancer. Clin Cancer Res 2007; 13(2):515-522. 
 21. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin- versus carbo-
platin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an 
individual patient data meta-analysis. J Natl Cancer Inst 2007;99(11): 847-850.
 22. International Commission on Radiation Units and Measurements.1993.ICRU Report 50: Prescrib-
ing, recording and reporting photon beam therapy. Report 50. Oxford (UK): University of Oxford 
Press.
 23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines 
to evaluate response to treatment in solid tumors. European Organization for Research and 
Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of 
Canada. J Natl Cancer Inst 2000;92 (3):205-216.
 24. Socinski MA , Smit E.F, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin (PC) versus 
etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small 
cell lung cancer (ED-SCLC): interim results. 2008 ASCO Meeting.
 25. Brade A, Bezjak A, MacRae, et al. A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radia-
tion (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC) J Clin Oncol 26:2008 (20 
suppl; abstr 7550).
 26. Gadgeel S.M., Ruckdeschel J.C., Wozniak A, et al. Pemetrexed and cisplatin with concurrent tho-
racic radiation therapy (TRT) followed by docetaxel in stage III non-small-cell lung cancer (NSCLC) 
patients. J Clin Oncol 26:2008 (20 suppl; abstr 7569).
 27. Choy H, Jain A, Moughan J, Curran W, Whipple G, Demas WF, et al. RTOG 0017: phase I trial of 
concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy (“Ping-
Pong Trial”) followed by adjuvant chemotherapy for patients with favorable prognosis inoperabel 
stage IIIA/B non-small cell lung cancer. J Thorac Oncol 2009;4: 80-86.
 28. Jalal S, Ansari R, Govindan R, Bhatia S, Bruetmen D, Fisher W, et al. Hoosier Oncology Group. 
Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II 
study. J Thorac Oncol 2009 Jan;4(1):93-96.
Veerle BW 2.indd   57 19-11-09   15:56
Chapter 4
58
 29.  Eismann U, Oberschmidt O, Ehnert M, et al. Thymidylate Synthase gene expression in solid 
tumors predicts for response to pemetrexed in vitro. J Clin Oncol 2006; ASCO Annual Meetings 
Proceedings; Vol 24, No 18S: 13058.
 30. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, et al. Thymidylate synthase expression in 
gastropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008;14:1059-1064.
Veerle BW 2.indd   58 19-11-09   15:56
CHA PTER 4
Lessons to learn from EORTC study 08981: A feasibility 
study of induction chemoradiotherapy followed by 
surgical resection for stage IIIB non-small cell lung cancer 
V. Surmonta,, R.J. van  Klaverena, C. Goorb, F. Schramelc, C. Manegoldd, C. Legrande, P. Van Schilf and 
J.P. Van Meerbeeckg
a. Department of Pulmonology, Erasmus MC-Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands
b. Department of Radiotherapy, AZ Middelheim, Antwerp, Belgium
c. Departme nt of Pulmonology, St Antonius  Hospital, Nieuwegein, The Netherlands
d. Departme nt of Medical Oncology, Thoraxklinik Rohrbach, Heidelberg, Germany
e. European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium
f. Departme nt of Thoracic and Vascular Surgery, University Hospital of Antwerp, Belgium
g. Departme nt of Pulmonology, University of Ghent, Belgium
Lung Cancer 2007;55:95-99.
Veerle BW 2.indd   59 19-11-09   15:56
Chapter 4
60
ABSTRACT
The present EORTC phase II feasibility study in stage IIIB (T4-N3) NSCLC was conducted 
to investigate whether an induction regimen with concurrent chemo-radiotherapy 
followed by surgery after restaging by re-mediastinoscopy and /or fluorodeoxyglucose-
positron emisson tomography (FDG-PET) was feasible in a multicenter setting. Unfor-
tunately, the study closed prematurely because of poor accrual. The combination of 
more stringent selection criteria, the incorrect prevailing view of Ethical Boards that a 
trimodality approach is too toxic, competing studies in the participating centers and the 
fact that patients with N3 disease could only be enrolled if a re-mediastinoscopy could 
be performed, underlie the low accrual. Although this study illustrate that the conduct 
of a tri-modality study in centers across Europe appeared to be difficult at that time, the 
number of centers with highly qualified and experienced specialists involved in this kind 
of multi-modality approaches is rapidly increasing. Future initiatives should, therefore, 
certainly be encouraged. Minimally invasive procedures such as EUS and EBUS should 
preferably be used for up-front mediastinal staging, mediastinoscopy with or without 
EUS should preferably reserved for restaging, and right-sided pneumonectomies should 
be avoided. Though evident, the feasibility to complete this kind of studies within a 
reasonable time period, is still a condition sine qua non.
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INTROdUCTION
The overall prognosis of locally advanced non-small cell lung cancer (NSCLC) stage 
IIIB (any T4 or N3) is poor, and primary surgery is rarely possible. Standard treatment 
for clearly unresectable disease is sequential or concurrent chemoradiotherapy with 
full dose chemotherapy (1). Several studies have demonstrated that locally advanced, 
potentially resectable and unresectable stage IIIA NSCLC may become operable after 
induction chemo- or chemo-radiotherapy (2,3). The strongest predictor of long-term 
survival after such an induction treatment appears to be the absence of residual tumor 
in the mediastinal lymph nodes at surgery, the so called down-staged patients (4-6).
Based on the promising results of induction therapy for stage IIIA (2, 7-9), the SWOG in-
vestigated if a tri-modality treatment was also feasible for stage IIIB NSCLC (study 8805) 
(2). A 3-year survival rate of about 25% was found, without survival difference between 
stage IIIA and IIIB. Again, the prognosis with persistent N2 or N3 disease after induc-
tion therapy was poor, with 5-year survival rates of about 15%. Although the induction 
treatment was different in subsequent trials (number of chemotherapy cycles, different 
drugs, standard or hyperfractionated radiotherapy), the resectability rate was similar at 
about 60%, with a pathologic complete remission rate of about 20% (10-14). It is evident 
now, that persistent N2 or N3 disease after induction treatment is a contra-indication 
for further surgery (3, 4, 15), and that only those who are downstaged benefit from 
induction therapy followed by resection. Despite these promising results, the potential 
role of a surgical resection following chemotherapy (with or without radiation) is still 
controversial. The series published so far are usually limited to single institutional expe-
riences and are listed in Table 1 (2, 16-18). Proper and reliable restaging after induction 
therapy is crucial in order to prove down-staging. Except for the study by Stamatis et al., 
restaging has been based on CT evaluation, known to be inappropriate for mediastinal 
staging and restaging with a low accuracy (19). Therefore, the Lung Cancer Group of the 
European Organisation for Research and Treatment of Cancer (EORTC) decided, to inves-
tigate by study 08981 the feasibility of a tri-modality approach of chemoradiotherapy 
followed by restaging, with the re-mediastinoscopy and resection in a multicenter set-
ting and this before the publication of the study by Stamatis et al. (16). 
EORTC 08981 study design, methods and results
The EORTC 08981 study was designed as a prospective, non-randomized phase II fea-
sibility study to determine the incidence of radically resected stage IIIB NSCLC follow-
ing induction chemoradiotherapy. The secondary end-points were the toxicity of the 
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induction regimen, the toxicity of the surgical procedure, the clinical response rate after 
the induction therapy and pathological response after surgery. Based on the Simon one 
sample two stage testing procedure (20), considering an unacceptable and an accept-
able success rate of respectively 40% and 60%, the total sample size was estimated to be 
62 eligible patients with an alpha error of 0.10 and a power of 0.95. In this multi-center 
study only patients with clinical stage IIIB NSCLC (any T4 or N3) could be enrolled. Im-
portant selection criterion for the participating centres was, however, that the thoracic 
surgeon was capable to perform a re-mediastinoscopy in case of N3 disease. If that 
particular expertise was not present, only patients with T4N0M0 NSCLC were enrolled. 
The T4 status had to be histologically confirmed. Patients with pleuritis carcinomatosis 
or N3 due to scalene or supraclavicular lymph node involvement were excluded. Induc-
tion chemotherapy treatment consisted of 3 cycles of cisplatin 80 mg/m2 on day one and 
etoposide 100 mg/m2 on day 1-3 intravenously. Involved field radiotherapy consisted of 
45 Gy in 1.8 Gy per fraction, for 5 days a week over a period of 5 weeks starting from day 
2 of chemotherapy cycle 2. Patients with T4 N0-1M0 disease without progression during 
induction therapy, proceeded directly to surgery without re-staging. If a FDG-PET facility 
was available, a PET scan was done at baseline. If initial PET positive mediastinal lymph 
nodes became PET negative at restaging, patients were allowed to proceed directly to 
thoracotomy without re-mediastinoscopy. When the PET scan remained positive, how-
ever, a re-mediastinoscopy had to be performed to exclude persistent N2/3 disease. If 
there was no PET facility available, patients with N2 or N3 disease without progression 
during induction therapy had to undergo a re-mediastinoscopy. 
Of the initial 10 European thoracic oncological centers expressing their interest in this 
trial, only 5 centers were eventually activated. Between May 2001 and August 2002, five 
male patients were enrolled in 2 centers. Median age was 67 years (range 60-74 years), 
all of them with WHO performance score 0 or 1. One patient progressed during induc-
tion treatment, and did not undergo restaging or surgery. One patient was restaged by 
endoesophageal ultrasound (EUS) instead of a re-mediastinoscopy. Grade 3/ 4 neutro-
penia or trombocytopenia occurred in 4 (80%) and 2 patients (40%), respectively. Half of 
them relapsed loco-regionally, the others on distant sites. Both patients who underwent 
a right-sided pneumonectomy developed a bronchopleural fistula. 
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dISCUSSION
Although it is evident that EORTC study 08981 is a negative study, several other investi-
gators have demonstrated that a tri-modality approach is feasible with acceptable toxic-
ity. Examples of this are the large Intergroup trial of North America, the German Lung 
Cancer Cooperative Group Study, the studies performed by the West German Cancer 
Center Consortium, the Italian and French tri-modality experiences and several phase-II 
studies performed in North America (11,16-18). 
The participating centers in EORTC study 08981 were large institutions, experienced 
in chemo-radiation, where multidisciplinary tumor board meetings take place weekly. 
Therefore, other reasons may underlie the discrepancy found with the studies published 
before. One of them is that we used more stringent selection criteria (Table 1). In our 
trial the T4 status had to be confirmed histologically and patients with supraclavicular 
lymph node involvement or lower lobe tumors with contralateral upper higher medias-
tinal lymph node involvement were excluded. In contrast, in the SWOG 8805 trial, 35% 
of the IIIB patients had N3 disease based on supraclavicular lymph node involvement. 
With the current available data, IIIB patients with supraclavicular lymph node involve-
ment should, to our opinion, not be enrolled in tri-modality protocols. Machtay et al. 
Table 1. Differences in the selection criteria and restaging methods in trimodality trials for stage III non-small cell lung cancer.
Stamatis (16) Grunewald (17) SWOG 8805 (2) INT 0139 
(18)
EORTC 08981
Number of patients 174 IIIB
218 IIIA
40 IIIB 51 IIIB
75 IIIA
429 IIIA 5 IIIB
Recruitment period 10 years 3 years 4 years 7 years 2 years
Participating institutes Single Single Multiple Multiple Multiple
Supraclavicular LN’s No Yes Yes No No
T4 esophagus, aorta, vertebrae
sattelite nodule
myocardium
malignant pleural/pericardial 
effusion
No
No
No
No
No
No
No
No
Yes
Not mentioned
Not mentioned
No
Not 
applicable
No
No
No
No
Lower lobe tumors with 
contralateral upper mediastinal 
LN’s 
Yes Yes Yes Not 
applicable
No
N2 and N3 confirmation method Histology Histology Histology Histology Histology
T4 confirmation method CT or MRI Histology Histology Not 
applicable
Histology
Restaging method Mediastinoscopy CT scan CT scan CT scan Mediastinoscopy
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reported a prolonged survival in a non-randomized study in patients with supraclavicu-
lar node metastases treated with chemoradiotherapy (21). On the contrary, Lee et al. 
demonstrated that patients with supraclavicular lymph node involvement treated with 
chemoradiotherapy had a median survival of only 12 months while it was 28 months 
for patients without supraclavicular lymph node involvement, which was statistically 
significant (22). 
A second major reason for the slow accrual is that our restaging method was different 
from those in the other studies (Table 1). CT evaluation is known to be inappropriate for 
the staging and restaging of the mediastinum (19) and only patients with cytological or 
histological confirmed downstaging (2,4) benefit from resection. Therefore, re-mediasti-
noscopy received a central role in the restaging of our patients. Even though two centers 
with surgeons experienced in performing re-mediastinoscopy participated, it appeared 
to be a major threshold for patient enrollement. Due to extensive fibrosis and difficult 
access, re-mediastinoscopy leads to more complications and often incomplete sampling 
of the mediastinum (23,24). Only few studies addressed the role of re-mediastinoscopy 
in the restaging of lung cancer (25-30). Although Van Schil et al. demonstrated that a 
re-mediastinoscopy has an accuracy of 85% and a negative predictive value of 75% (25), 
only a small number of patients had undergone radiotherapy, so that no final conclu-
sions can be drawn for the role of the re-mediastinoscopy after chemoradiotherapy 
(29). De Leyn et al. showed in a prospective trial that re-mediastinoscopy is technically 
feasible, but the sensitivity and negative predictive value are low due to fibrosis (30). 
Although mediastinoscopy is still regarded the gold standard for mediastinal staging, 
minimally invasive staging procedures such as EUS (31-37) and EBUS (36) are attractive 
alternatives, available in an increasing number of institutions. A combined approach 
of EUS- and EBUS-fine needle aspiration even allows the investigation of both sides of 
the mediastinum (36). This evolution might lead in an increasing number of institutions 
to a shift in the sequence of mediastinal staging procedures. Upfront staging could be 
done by minimally invasive procedures such as EUS and EBUS, while surgical proce-
dures could be reserved for playing a role in restaging after induction therapy (29). In 
this way, a technically more difficult re-mediastinoscopy is avoided. FDG-PET has not 
yet proven to be enough accurate in mediastinal restaging. Initial promising data for 
the assessment of downstaging of mediastinal lymph nodes could not be confirmed 
(37,38). Changes in the microenvironment of the tumor, such as altered perfusion after 
chemo- or chemoradiotherapy, may impair the presentation of FDG to the metastatic 
mediastinal node sites. Thus, PET-imaging is not performant enough to detect persistent 
N2/3 disease. Induction chemoradiotherapy results in a high percentage of false positive 
findings as a result of inflammatory reactions after radiotherapy. Therefore, restaging 
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should currently use invasive techniques, although FDG-PET may help to guide these 
procedures. Although the optimal restaging strategy is yet unknown, it should at least 
take place as soon as possible after the completion of the induction treatment to avoid 
long interruptions in the scheduled radiotherapy if no downstaging has been achieved.
Despite initial expression of interest in EORTC study 08981 by 10 large European can-
cer institutes, the Medical Ethical Boards of five institutes considered the tri-modality 
approach too controversial for this particular group of patients and did not gave their 
approval. On the other hand, in the centers that received Medical Ethical Board per-
mission, competing studies targeting the same patient group appeared to be ongoing 
afterwards. 
The prevailing view of many Medical Ethical Boards that a tri-modality approach for 
stage III NSCLC is inappropriate, is very debatable, given the fact that, for example, in 
superior sulcus tumors, a tri-modality approach is the standard of care. 
The recent results of the EORTC 08941 and the Intergroup study 0139 have shown 
however, that the extent of surgery determines the postoperative mortality and that 
in a sub group in which the resection was confined to a lobectomy there was a survival 
benefit. Although these two studies have not been designed to explore the effect of 
the extent of the resection, this subgroup analyses suggest that especially right-sided 
pneumonectomies should be avoided (5,12).
Although the number of participants in this trial is low and no final conclusion can be 
drawn, the results of the five included patients are disappointing with a high rate of 
pneumonectomies, major complications after a right-sided pneumonectomy and poor 
overall survival. 
In conclusion, although this study illustrates that the con duct of a tri-modality study 
across Europe appeared to be difficult in the 1990s, the number of centers with highly 
qualified and experienced specialists involved in this kind of multi-modality approaches 
has rapidly increased since then. Future initiatives should, therefore, certainly be 
encour aged. Therefore it is very important to ensure full com mitment of all investiga-
tors involved in tri-modality treat ment. Minimally invasive procedures such as EUS and 
EBUS should preferably be used for up-front mediastinal stag ing, mediastinoscopy with 
or without EUS should preferably be reserved for restaging, and especially right-sided 
pneu monectomies should be avoided. Though evident, the feasi bility to complete the 
study within a reasonable time period is still a condition sine qua non. 
Veerle BW 2.indd   65 19-11-09   15:56
Chapter 4
66
ACkNOwLEdgEMENTS
This publication was supported by grants number  2U10 CA11488-28 
through 2U10CA11488-36 from the National Cancer Institute (Bethesda, Maryland, USA). 
Its contents are solely the responsibility of the authors and do not necessarily represent 
the official views of the National Cancer Institute. This research project was supported by 
the Koningin Wilhelmina Fund (The Netherlands).
Conflict of Interest Statement
None declared
Veerle BW 2.indd   66 19-11-09   15:56
67
EORTC 08981
REFERENCES
 1. Rowell NP, O’ Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane 
Database Syst. Rev. 2004 Oct 18; (4) CD002140. Review.
 2. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT 3rd, Weick JK et al. Concurrent cisplatin/etopo-
side plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung 
cancer: mature results of Southwest oncology group phase II study 8805. J Clin Oncol 1995; 13: 
1880-1892.
 3. Choi NC, Carey RW, Daly W, Mathisen D, Wain J, Wright C et al. Potential impact on survival of 
improved tumor downstaging and resection rate by preoperative twice-daily radiation and 
concurrent chemotherapy in stage IIIA non-small cell lung cancer. J Clin Oncol 1997; 15: 712-722.
 4. Betticher D.C, Hsu Schmitz SF, Totsch M, Hansen E, Joss C, von Briel C et al. Mediastinal lymph 
node clearance after docetaxel-cisplatin chemotherapy is prognostic of survival in patients with 
IIIA pN2 NSCLC : a muli-center phase II trial. J Clin Oncol 2003; 21: 1752-1759.
 5. Van Meerbeeck J, Kramer G, Van Schil P, Legrand C, Smit EF, Schramel FM et al. A randomized 
trial of radical surgery versus thoracic radiotherapy in patients with stage IIIA-N2 NSCLC after re-
sponse to induction chemotherapy ( EORTC 08941). J Clin Oncol 2005; 23 no. 16S:1095s (abstract 
7015).
 6. Bueno R, Richards WG, Swanson SJ, Jaklitsch MT, Lukanich JM, Mentzer SJ et al. Nodal stage after 
inducton therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg. 2000 
Dec; 70 (6): 1826-31.
 7. Roth JA, Fosella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS et al. A randomized trial comparing 
perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small 
cell lung cancer. J Nat Cancer Inst 1994; 86: 673-680.
 8. Roth JA, Atkinson EN, Fosella F, Komaki R, Bernadette Ryan M, Putman Jr JB et al. Long-term 
follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and 
surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 
21: 1-6.
 9. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A et al. A randomized trail compar-
ing perioperative chemotherapy plus surgery with surgery alone in patients with non-small-cell 
lung cancer. N Engl J Med 1994; 330: 153-158.
 10. Rusch VW, Albain KS, Crowley JJ. Neoadjuvant therapy: a novel and effective treatment for stage 
IIIB non-small cell lung cancer. Ann Thorac Surg 1994; 58: 290-295.
 11. Rice TW, Adelstein DJ, Koka A. Accelerated induction therapy and resection for poor prognosis 
stage III non-small cell lung cancer. Ann Thorac Surg 1995; 60: 586-592.
 12. Rice TW, Adelstein DJ, Ciezki JP, Becker ME, Rybicki LA, Farver CF et al. Short-course induction 
chemoradiotherapy with paclitaxel for stage III non-small cell lung cancer. Ann Thorac Surg 1998; 
66: 1909-1914.
 13. Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H et al. Preoperative chemo-
therapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated 
radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: mature results 
of a phase II trial. J Clin Oncol 1998; 16: 622-634.
 14. Thomas M, Rube C, Semik M, von Eiff M, Freitag L, Macha HN et al. Impact of preoperative bi-
modality induction including twice-daily radiation on tumor regression and survival in stage III 
non-small cell lung cancer. J Clin Oncol 1999; 17: 1185-1193.
Veerle BW 2.indd   67 19-11-09   15:56
Chapter 4
68
 15. Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MJ, Green MR. Results of CALGB 8935: a multi-
institutional phase II trimodality trial for stage IIIA (N2) non-small cell lung cancer. J Thorac 
Cardiovasc Surg 1995; 109: 473-485.
 16. Stamatis G, Eberhard W, Pöttgen C. Surgery after multimodality treatment for non-small-cell lung 
cancer. Lung Cancer 2004; 45 Suppl 2: S107-S112. 
 17. Grunenwald D, Andre F, Le Péchoux C, Girard P, Lamer C, Laplanche A et al. Benefit of surgery after 
chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc 
Surg 2001; 122: 796-802.
 18. Albain KS, Swann RS, Rusch VR, Turrisi AT, Sheperd FA, Smith CJ et al. Phase III study of concurrent 
chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA 
(pN2) non-small cell lung cancer: outcomes update of North American Intergroup 0139 (RTOG 
9309). J Clin Oncol 2005; 23 no. 16S: 624S (abstract 7014).
 19. Mateu-Navarro M, Rami-Porta R, Bastus-Piulats R, Cirera-Nogueras L, Gonzalez-Pont G. Remedias-
tinoscopy after induction chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2000; 70: 
391-395.
 20. Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental 
treatments and a control in clinical trials. Biometrics 1989; 45: 537-547.
 21. Machtay M, Seiferheld W, Komaki R, Cox JD, Sause WT, Beyhardt RW. Is prolonged survival 
possible for patients with supraclavicular nodes metastases in NSCLC treated with chemoradio-
therapy: analysis of the radiation therapy oncology group experience. Int J Radiat Oncol Biol Phys 
1999;44:847-853.
 22. Lee DH, Han JY, Cho KH, Pyo HR, Kim HY, Yoon SJ et al. Phase II study of induction chemotherapy 
with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etopo-
side and cisplatin in patients with stage III NSCLC. Int J Rad Oncol Biol Phys 2005; 63: 1037-1044.
 23. Cesario A, Margaritora S, Trodella L, Valente S, Corbo GM, Macis G et al. Incidental surgical findings 
of a phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with unresect-
able non-small cell lung cancer. Lung Cancer 2002; 37: 207-212.
 24. Trodella L, Granone P, Valente S, Turriziani A, Macis G, Corbo GM et al. Phase I trial of weekly 
gemcitabine and concurrent radiotherapy in patients with inoperable non small cell lung cancer. 
J Clin Oncol 2002; 20: 804-810.
 25. Van Schil P, van der Schoot J, Poniewierski J, Pauwels M, Carp L, Germonpre P et al. Remediastinos-
copy after neoadjuvant therapy for non small cell lung cancer. Lung Cancer 2002; 37: 281-285.
 26. Cesario A, Margaritora S, Porziella V, Granone P. Intrathoracic staging in non small cell lung cancer: 
re-do mediastinoscopy revisited. Lung Cancer 2003; 40: 227-228.
 27. Pauwels M, Van Schil P, De Backer W, Van den Brande F, Eyskens E. Repeat mediastinoscopy in the 
staging of lung cancer. Eur J Cardiothorac Surg 1998 ;14 : 271-273.
 28. Meersschaut D, Vermassen F, Brutel de la Riviere A, Knaepen PJ, Van den Bosch JM, Vanderschueren 
R. Repeat mediastinoscopy in the assessment of new and recurrent lung neoplasm. Ann Thorac 
Surg 1992; 53: 120-122.
 29. Olsen PS, Stentoft P, Ellefsen B, Petterson G. Re-mediastinoscopy in the assessment of resect-
ability of lung cancer. Eur J Cardio Thorac Surg 1997; 11: 661-663.
 30. De Leyn P, Stroobants S, Vansteenkiste J. Prospective study of accuracy of redo videomediasti-
noscopy and PET-CT in detecting residual mediastinal disease after induction chemotherapy for 
NSCLC. Lung Cancer 2005; 49 Suppl 2: S3 (Pr2)
 31. Annema JJ, Veselic M, Versteeg MI, Willems LN, Rabe KF. Mediastinal restaging: EUS-FNA offers a 
new perspective. Lung Cancer 2003; 42: 311-318.
Veerle BW 2.indd   68 19-11-09   15:56
69
EORTC 08981
 32. Junker K. Histopathologic evaluation of mediastinal lymph nodes in lung cancer. Lung Cancer 
2004; 45 Suppl 2:S79-83.
 33. Caddy G, Conron M, Wright G, Desmond P, Hart D, Chen RY. The accuracy of EUS-FNA in assessing 
mediastinal lymphadenopathy and staging patients with NSCLC. Eur Respir J 2005 ; 25 :410-415.
 34. Eloubeidi MA, Tamhane A, Chen VK, Cerfolio RJ. Endoscopic ultrasound- guided fine-needle 
aspiration in patients with non-small cell lung cancer and prior negative mediastinoscopy. Ann 
Thorac Surg 2005; 80: 1231-1239.
 35. Larsen SS, Vilmann P, Krasnik M, Dirksen A, Clementsen P, Maltbaek N et al. Endoscopic ultrasound 
guided biopsy versus mediastinoscopy for analysis of paratracheal and subcarinal lymph nodes 
in lung cancer staging. Lung Cancer 2005; 48(1): 85-92.
 36. Vilmann P, Krasnik M, Larsen SS, Jacobsen GK, Clementsen P. Transesophageal endoscopic 
ultrasound guided fine-needle aspiration (EUS-FNA) and endobronchial ultrasound guided 
transbronchial needle aspiration (EBUS-TBNA) biopsy: a combined approach in the evaluation of 
mediastinal lesions. Endoscopy 2005; 37: 833-839.
 37. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic 
and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004; 5: 531-540.
 38. Detterbeck F, Vansteenkiste J, Morris DE, Dooms CA, Khandani AH, Socinski MA. Emerging ap-
plications of positron emission tomography imaging in the management of patients with lung 
cancer. Chest 2004; 126: 1656-1666.
 39. Wright CD, Mathisen DJ. Sulcus superior tumors. Curr Treat Options Oncol 2001; 2(1): 43-49.
 40. Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small-cell lung cancer. J 
Clin Oncol 2005; 23 (14): 3257-69.
 41. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D et al. Induction chemoradiation 
and surgical resection for non-small cell lung carcinomas of the sulcus superior: initial results of 
SWOG Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg 2001; 121 (3): 472-483.
Veerle BW 2.indd   69 19-11-09   15:56
Veerle BW 2.indd   70 19-11-09   15:56
CHAP TER 5
Stage IIIA-N2 NSCLC: a review of its treatment approaches 
and future developments.
J.P. van Meerbeeck and V.F.M. Surmont
Department of Respiratory Medicine & Thoracic Oncology, University Hospital, De Pintelaan 185, 9000 Ghent (Belgium)
Lung Cancer 2009; 65: 257-267.
Veerle BW 2.indd   71 19-11-09   15:56
Chapter 5
72
ABSTRACT
Few issues are as controversial in non-smal cell lung cancer as the management of 
patients with stage IIIA-N2 non-small cell lung cancer. This manuscript reviews the 
reasons of and the biases inherent to this controversy and discusses the different treat-
ment approaches with emphasis on survival, as evidenced by meta-analyses and large 
randomized clinical trials. Prospects on novel treatment modalities and future research 
opportunities are presented.
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INTROdUCTION
Non-small-cell lung cancer (NSCLC) represents 80% of all lung cancers, and approxi-
mately 15% of these are at presentation diagnosed with stage IIIA [1]. The definition of 
stage IIIA has changed with the successive editions of the UICC staging classification, 
since it was first coined (Table 1) [2]. According to the 6th edition, stage IIIA includes pa-
tients with either malignant involvement of one or several ipsilateral mediastinal lymph 
node(s) or T3N1 tumours [1]. In the new proposed classification, T4 tumours without 
mediastinal lymph node invasion (N0-1) will be added to this stage [3]. 
Ruckdeschel et al. [4] and André et al. [5] have proposed to subclassify stage IIIA accord-
ing to the extent of mediastinal lymph node involvement, as the latter has an inverse 
correlation with survival. This classification has been the basis for the recent ACCP-
guideline [6] and is presented in Table 2 in a slightly adapted version.
A first subgroup of stage IIIA patients consists of tumours with locoregional extension 
without mediastinal lymph node involvement (IIIA-0). Due to the novel definitions of 
T3 and T4 and the inclusion of T4N0-1 tumours in stage IIIA in the new proposed clas-
sification, it is likely that this subgroup will numerically increase in the future from the 
present day one third fraction. The treatment of this subgroup is not the focus of the 
present review.
Table 1: definition of stage IIIA according to successive editions of the UICC TNM-staging classification of lung cancer
UICC edition 5 6 7 (proposed)
Reference [2] [1] [3]
T and N categories included in IIIA T3N0-1 
T1-3 N2
T3N1
T1-3 N2
T3N1
T1-3 N2
T4N0-1
Table 2: subclassification of stage IIIA , adapted from [4-6]
Subcategory Definition Frequency
IIIA-0 T3N1 or T4N0-1 without N2 involvement 6% of NSCLC at presentation, 32% of stage 
IIIA [1]
IIIA-1 Incidental nodal metastases found on final 
pathology examination of the resection specimen
Up to 14% of thoracotomies [9,10]
IIIA-2 Nodal (single station) metastases recognized 
intraoperatively
IIIA-3 Nodal metastases (single or multiple station) 
recognized by prethoracotomy staging 
(mediastinoscopy, other nodal biopsy, or PET scan)
10% of NSCLC at presentation, 67% of clinical 
and pathological stage IIIA
Veerle BW 2.indd   73 19-11-09   15:56
Chapter 5
74
A second subgroup contains patients with so-called unexpected N2-involvement in the 
pathology specimen (IIIA-1) or at thoracotomy (IIIA2), found in 14-24% of patients [7, 8]. 
The introduction of more accurate preoperative staging techniques has resulted in con-
flicting data on the rate of unsuspected IIIA-1- involvement. Gonzalez et al. report a 8% 
false negative mediastinal lymphnode staging with systematic PET-scan and selective 
mediastinoscopy in 90 cM0 operable patients, which compares with their 6% false nega-
tive rate using routine mediastinoscopy approach in a similar prior cohort of patients 
[9]. Cerfolio et al. however still found 14% unsuspected microscopic N2 (IIIA-1) in their 
consecutive series of NSCLC, considered N2 negative after integrated PET-Ct scan [10]. 
The same authors picked up 16 of 22 cases with microscopic N2-disease using routine 
mediastinoscopy and endoscopic transesophageal ultrasound with fine needle aspira-
tion (EUS-FNA) in 153 patients with clinically N2-negative mediastinum after integrated 
PET-Ct scan [11]. 
The largest subgroup of stage IIIA consists of patients with clinical ipsilateral lymph 
node invasion at presentation, either demonstrated by non-invasive imaging or (mini-
mally) invasive techniques (IIIA-3) or ‘bulky’ at imaging (IIIA-4). Patients from the IIIA-3 
subgroup are variously regarded ‘resectable’ or ‘marginally resectable’, depending on the 
number and location of the lymph node(s) involved, whereas patients from the IIIA-4 
subcategory are considered ‘primary unresectable’ [12]. Table 3 summarizes the survival 
data of several registries and large data sets of these patients. 
Table 3: Outcome of resected stage IIIA-N2 patients according to several registries
Source UICC 5 data 
set
UICC 6 data 
set
JJC-LCR data set German registry Mayo 
Clinic
UICC 7 data 
set
Reference 2 1 13 14 15 3
Period 1975-1988 1975-1988 1999 1996-2005 1997-2003 1990-2000
Clinical (C) or 
pathological (P)
C P C P C P P C C P
N of pts with N2 (% 
of all pts in series)
NA NA 471 
(9)
344 
(18)
1628 ² 
(13)
1862 ² 
(15)
431³ 
(21)
714 4 (13) 2832 5 
(12)
4441 5 
(16)
Median survival (m) 12* 18* 12* 18* 36* 34* 24* 16.4 24* 24*
1 y (%) 50* 60* 50 64 62 71 69
2 y (%) 17* 45* 26 40 60* 60* 50* 38 50* 45*
3y (%) 19 32 26
4 y (%) 12* 35* 15 26 44* 40* 32* 15 35* 29*
5 y (%) 10* 30* 13 23 38 33 30 8 31 22
UICC: Union Internationale Contre Le Cancer; JJC-LCR: Japanese Joint Committee-Lung Cancer Registry.
NA: not available; *: data extrapolated from Kaplan Meier curves; ²: includes an unspecified number of T3N1; ³: includes 9 cases of T4N2; 
4: includes 43 cases of T3N1 and 18 of TXNXM0; 5: includes 134 cases of cT4N2 and 217 of pT4N2; all c patients were operated upon.
All percentages are rounded to the next unit
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The observed variation in outcome reflects the stage-specific shift in survival by improv-
ing staging techniques and changing staging classifications and adds to the caution 
when using historical series in comparisons. 
It is assumed that the fraction of IIIA-3 patients will remain unchanged in the near future: 
whereas on the one hand, the advent of FDG-PET/Ct-scan and endoscopic ultrasound 
techniques will upstage about 10% of stage III patients to either N3 or M1 [16], the same 
techniques will on the other hand upstage a number of lower stage patients to IIIA-3 
[11]. When looking across the UICC datasets of 1997 and 2007 [1, 3], the fraction of clini-
cal N2 patients has hence increased from 9 to 12%. 
METHOdS
This article reviews the treatment approach for stage IIIA-N2 NSCLC, with emphasis put 
on evidence obtained by randomized trials, systematic reviews, pooled analyses, meta-
analyses and guidelines. This evidence was obtained as follows:
(i) a PubMed search using the key words as mentioned in the abstract, applying sepa-
rately the instruments’ default limits [Meta-Analysis], [Practice Guideline], [Random-
ized Controlled Trial] and [Review]
(ii) a manual search of recent guidelines [ESMO, ACCP, NICE, NCCN] and their cross-
references, published between 2005 and 2008
(iii) a manual search of congres proceedings of ASCO, WCLC, ESMO since 2005.
(iv) a search of www.clinicaltrials.gov using the key words as mentioned in the abstract 
and cross referencing with (i) and (iii).
(v) Data were whenever possible recalculated for IIIA-N2 patients and the latest source 
used whenever double reports of the same series were retrieved.
Single modality surgery 
Two studies have examined the survival of 79 patients following complete resection 
who were positive at mediastinoscopy [17]. The studies showed a 5-year survival of 
between 9% and 18%. It is less than the outcome of N2 patients with negative medi-
astinoscopy but involves few patients. A systematic review of 5 studies (735 patients 
with radiologically identified N2-disease prior to resection) found a variable 5-year 
survival ranging from 8-31% (weighted average 23%) [17]. However, three of the studies 
included adjuvant radiotherapy with or without chemotherapy. Failure was in more than 
half of the cases due to distant relapses, originating from occult micrometastatic disease 
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missed at clinical staging. From series that have reported on prognostic subgroups of 
pN2, the only conclusion that can realistically drawn is that multistation nodal disease 
has a somewhat worse prognosis than single station involvement, but the site of a single 
metastatic nodal station probably has no significant effect [reviewed in 6]. This analysis 
was confirmed by the IASLC-staging committee database wherein three nodal groups 
were found to have significantly different survival rates: patients who had pN1 single-
zone disease, those who had either multiple pN1 or single pN2 zone metastases, and 
those who had multiple pN2 lymph node zones involved [18]. 
Postoperative chemo- and radiotherapy
The poor survival rates with surgery has led to efforts at adding non-surgical (chemo- 
and/or radio-) therapy with hopes to improve long term survival by reducing the 
distant relapses. Several randomized trials have shown an improved survival with 
cisplatin-based postoperative chemotherapy. This evidence has been pooled in a recent 
meta-analysis in which the subgroup of pIIIA patients (mostly but not exclusively pN2) 
appear to have a 17-20% reduction in the risk of death (Table 4), improving their 5 year 
survival rate with 13-15% [19,20]. The benefit of overall survival was however, smaller in 
an individual patient data meta-analysis of randomized trials addressing the benefit of 
adjuvant chemotherapy on surgery [21], but included an improved local recurrence free 
interval and persisted when postoperative radiotherapy (PORT) was added to surgery 
[22]. 
Although PORT was shown to have a significant detrimental effect on overall survival 
in stage pI-II, the pooled data in pN2 patients show no clear difference but a small re-
duction in local recurrence [23]. Results from a subgroup analysis of a randomized trial 
addressing adjuvant chemotherapy [24] and from a retrospective epidemiological study 
[25] suggest benefit of PORT on overall outcome in stage IIIA .This issue is currently 
being prospectively studied in the LUNG-ART trial [26]. 
Post-induction surgery
Parallel to the abovementioned adjuvant therapies, the same non-surgical approaches 
were added preoperatively in order not only to reduce the distant relapse rate, but aim-
ing at a possible parenchyma-sparing resection and better compliance to chemotherapy. 
The medical literature is replete with phase 2 series reporting the outcome of patients 
with stage IIIA NSCLC treated with this neoadjuvant approach [6]. A systematic review 
reported tumour response to preoperative (primary) chemotherapy from six prospective 
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phase II trials in patients with stage IIIA or IIIB NSCLC [27]. The review reported a non-
weighted average effect size for radiological response rate of 64%, a disease progression 
of 4% and for histological complete response of 24% of patients. Survival is improved as 
compared with historical controls and is influenced by patient age, complete resection, 
pathologic stage, nodal downstaging and extent of resection, but not by the type of 
induction regimen, chemo-or chemoradiotherapy [28-30]. 
Most if not all series have administered 2 to 3 cycles of a platinum combination, as these 
regimens were consistedly used in advanced NSCLC and associated with the highest 
response rates. The latter are typically higher in stage IIIA, with figures varying from 
50-70%. Although no formal randomized comparison between different neoadjuvant 
regimens in stage IIIA-N2 has been conducted, the available non-randomized evidence 
shows that 3-drug combinations are not superior to 2-drug ones, and that combinations 
of platinum and third generation drugs are equivalent and more active than combina-
tions with second generation drugs [31]. For fear of toxic interaction, series with con-
comitant chemoradiotherapy have mostly used second generation combinations, e.g. 
cisplatin with either etoposide or a vinca alkaloid.
Three randomized trials have compared chemotherapy and chemoradiotherapy as 
induction regimen in stage III NSCLC [32-34]; 1 more is ongoing and 1 has been prema-
turely closed due to a lack of accrual (Table 5) [35-37]. Taken together, these trials suggest 
that induction chemoradiotherapy results in better rates of resectability, pathological 
downstaging and pathological complete remissions than chemotherapy alone, without 
significantly affecting overall or progression-free survival survival. Two small random-
ized trials have compared surgery preceded by either neoadjuvant chemotherapy or 
radiotherapy [38,39]. Their results are inconclusive and difficult to interprete due to a 
small sample size, per protocol analysis and the variable use of perioperative chemo- 
and radiotherapy across treatment arms. 
Twelve randomized trials have compared neoadjuvant chemotherapy followed by 
surgery versus surgery alone in patients with stage IIIA NSCLC with variable numbers 
of N2-involvement [reviewed in 6]. A number of these trials have not yet been pub-
lished as full papers. Table 4 summarizes the available evidence as pooled analyses of 
survival data of these trials [20, 40, 41]. It can be concluded that a significant benefit in 
favour of neoadjuvant chemotherapy is present ranging at 5 years from 6-14%, albeit 
weakened by confounding factors as the inhomogeneity of the patients included, the 
inadequate sample size and the variable addition of postoperative treatments. The use 
of chemotherapy prior to surgery has raised concern that surgical complications may 
be increased. A series of 335 patients (259 surgery alone, 76 chemotherapy followed 
by surgery) was studied out of 380 consecutive patients undergoing lobectomy or 
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larger resection [42]. The use of preoperative chemotherapy did not significantly affect 
morbidity or mortality overall, based on clinical stage, postoperative stage, or extent of 
resection. No significant differences in overall or subset mortality or morbidity including 
pneumonia, acute respiratory distress syndrome, reintubation, tracheostomy, wound 
complication or length of hospitalization were seen. In another series, 470 patients treat-
ed with induction chemotherapy and surgery from 1993 through 1999 were reviewed 
[43]. Univariate and multivariate methods for logistic regression model were used to 
identify predictors of adverse events. Overall, a surgical mortality rate of 4% was found, 
which compared favourably to other primary surgery studies. Total morbidity and major 
complication rates were 38% and 27%, similar to previous primary surgery studies. The 
authors concluded that overall morbidity rates were not significantly affected by the 
use of induction therapy. They reported an operative mortality rate of 24% for patients 
undergoing right pneumonectomy following induction therapy. This number was 
higher than previous mortality rates seen in trials where patients did not have induction 
therapy. The authors recommended that right pneumonectomy after induction therapy 
can be performed very selectively and only when no alternative resection is possible. 
Neoadjuvant carboplatin and paclitaxel increased the perioperative severe complica-
tions in a cohort of 34 patients compared with a similar cohort of 67 patients operated 
Table 5: randomized trials comparing induction chemotherapy and chemoradiation in stage III NSCLC
Reference N Treatment Complete 
resection rate 
(%)
Rate of pathological downstaging 
(pD) and complete remission 
(pCR) (%)
Progression free 
(PFS); overall 
survival (OS)
Fleck [32] 48 P-5FU + RT ->S- 
PORT
52 NA PFS at 3y: 40%
48 MVP->S->PE 31 NA PFS at 3y: 21%
Sauvaget [33]
44
MVP->S 55 pD +pCR: 50 Median OS: 19 m
MVP->P-5FU -> S 66 pD +pCR: 58 Median OS: 18.5 m
GLCCG [34]
260 PE ->S ->PORT 32% pD: 11; pCR: 7 Median PFS: 9.5 m
Median OS: 17.6 m
264 PE->CV+HFRT ->S 37% pD: 17; pCR: 22 Median PFS: 10 m
Median OS: 15.7m
RTOG 0412 [35] NA Carbo-paclit -> S Trial stopped due to low accrual
Carbo-paclit +RT 
->S
National Cancer 
Center, Korea [36]
NA PE->S Ongoing
PE + RT -> S
SAKK 18/00 [37] NA PD -> S Ongoing 
PD -> RT ->S
Abbreviations: S: Surgery; RTOG: Radiation Therapy Oncology Group; SAKK: Swiss Anti Cancer Coalition; CTRT: concomitant 
chemoradiation; PORT: postoperative radiotherapy; PE: cisplatin-etoposide; CV: carboplatin-vindesine; RT: radiotherapy; HFRT: 
hyperfractionated radiotherapy; PD: cisplatin-docetaxel; 5FU: 5-fluorouracil; MVP: mitomycin C-vindesin-cisplatin; NA: not available
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by the same surgeons [44]. The most common complication was the failure to respond 
to antibiotics given for pneumonia. Investigators in France reviewed 114 patients who 
underwent thoracotomy following induction chemotherapy [45]. In this series, there 
was only 1 death following pneumonectomy in 55 patients. 
Overall morbidity rate was 29%, similar to other surgical series. The authors concluded 
that preoperative chemotherapy did not increase postoperative morbidity and mortality. 
A German cooperative group compared preoperative chemotherapy and concomitant 
chemoradiation and observed a doubling of the mortality rate (4.5 versus 9.2%) with the 
latter [34]. Another French group reported a 30-day mortality of 6.7% in a series of 60 
patients undergoing pneumonectomy after induction chemotherapy [46]. A Canadian 
group reported a 27% overall mortality after 27 pneumonectomies and even a 50% for 
complex pneumonectomies. Causes of death were adult respiratory distress syndrome 
and postoperative hemorrhage [47].
Although the abovementioned series give conflicting results, most experts agree that 
after induction treatment, a pneumonectomy should be avoided, and that the use of 
concomitant chemoradiotherapy further increases the operative mortality, even in 
experienced centers. 
Based on the observed improvement, neoadjuvant chemotherapy followed by surgery 
quickly became the new standard of care for clinical stage IIIA NSCLC and prospective 
series and studies in homogenous N2-subgroups confirmed the earlier results with even 
better outcome, albeit selection and stage migration biases cannot be excluded and the 
results look less favourable when analysed on an intention- to- treat basis than on per-
protocol basis [48-50]. Whether chemotherapy should hence precede or follow resec-
tion is likely to require a large randomized trial. Taking into account the heterogeneity 
of trials and the limited intertrial comparability between neoadjuvant and adjuvant 
populations, both induction and adjuvant chemotherapy seem to result in a benefit 
of the same magnitude in stage IIIA-N2 patients and such a trial will probably show 
equivalence of the approaches [20].
(Post-induction ) radiotherapy and chemoradiotherapy 
A full review of this topic is beyond the scoop of this manuscript. The interested reader is 
referred to a number of recent in-depth reviews [6,51]. The issue is further blurred by the 
lack of discrimination between stages IIIA and B in the studies reported. The following 
landmark findings are however evidence-based by meta-analyses (Table 6):
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1. Adding platinum-containing chemotherapy either at systemic doses preceding or at 
low radiosensitizing dose concomitant with chest radiotherapy in good performance 
patients significantly improves the outcome as compared to single modality chest radio-
therapy with traditional dose and fractionation schedules (1.8-2.0 Gray (Gy) per fraction 
per day to 60 to 70 Gy in 6-7 weeks), which yields in poor survival rates and patterns 
of failure which are both locoregional and distant [52,53]. Although the evidence was 
already observed in a previous meta-analysis, the latter did not specifically analyse for 
stage IIIA and for the sequence in which both modalities were administered [54].
2. Concomitant chemoradiotherapy at systemic doses results in superior outcome as se-
quential chemoradiotherapy, at the cost of a moderately increased toxic morbidity and 
is considered the present standard of care in selected patients [55]. Five year survival 
rates of 15% in a mixed population of selected stage III patients seem hence achievable 
and are comparable to unmatched series using a surgical approach.
3. In all meta-analyses, the effect was observed to be independent of patient and tumour 
characteristics, substage (IIIA vs. IIIB) and time period in which the trials were conducted.
Definitive-dose thoracic radiotherapy should be no less than the biologic equivalent of 60 
Gy, in 1.8-Gy to 2.0-Gy fractions to the planning target volume (PTV) [56]. Ideally, this requires 
3-dimensional (3D) conformal radiotherapy, a technique characterized by beam outlines 
that match the shape of the PTV. Mapping of the PTV is improved when using information 
from FDG-PET/CT-scan and-whenever available- from the (minimally) invasive mediastinal 
staging techniques, to match the closest possible the actual ‘involved field’ (IF). PTV-tailored 
fields allow the administration of higher total radiation doses which have been associated 
with improved local control and better survival in retrospective series without concomitant 
Table 6: Individual patient meta-analyses of outcome of stage IIIA patients treated with chemoradiotherapy
Comparison Reference Arms N pts with IIIA Hazard ratio
95% CI
Radiotherapy versus 
radiotherapy combined with 
platinum-based chemotherapy
Rolland et al
[52]
Radiotherapy 449
0.91 
(0.79-1.05)
Platinum-based concomitant 
chemoradiotherapy
548
Radiotherapy versus sequential 
chemoradiotherapy
Rolland et al 
[52]
Radiotherapy 723
0.87
(0.78-0.97)
Sequential 
chemoradiotherapy
741
Radiotherapy versus combined 
chemoradiotherapy at 
sensitizing dose
Aupérin et al
[53]
Radiotherapy 490
0.81
(0.71-0.92)
Concomitant 
chemoradiotherapy
592
Sequential versus concomitant 
approach at systemic doses of 
chemotherapy
Aupérin et al
[55]
Sequential 
chemoradiotherapy
190
0.72
(0.58-0.90)Concomitant 
chemoradiotherapy
188
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chemoradiotherapy [57]. However, due to the lack of randomized data the relationship be-
tween radiation dose, tumor volume and survival is still debated [58]. The field of (thoracic) 
radiotherapy is rapidly moving with dose-localization techniques aiming at irradiating the 
tumour with near surgical precision and at higher dosages, reducing the frequency of the 
radiation associated pneumonitis and esophagitis [59]. It is hence expected that local control 
of the tumour will further improve in the near future with less morbidity. Distant failure pat-
tern will have to be addressed by more and better systemic therapy, either using cytotoxic 
or biological agents. However, adding more chemotherapy before or after a concomitant 
chemoradiotherapy regimen has not been associated with improved survival [60-62]. 
One small randomized trial has compared radiotherapy and neoadjuvant chemotherapy 
followed by surgery [64]. The trial was stopped prematurely and did not show any dif-
ference in outcome.
Neoadjuvant chemo(radio-) therapy followed by either radiotherapy or 
surgery
Adding a systemic treatment to either locoregional modalities-surgery or thoracic radio-
therapy- was hence associated with an improved outcome in uncontrolled trials. With 
opinions differing with regard to the standard approach, investigators embarked on 
strategies comparing which local treatment modality is most effective. In a systematic 
review from 2006, 2 randomized trials were mentioned [65]. In one study, the inclusion 
criteria included the demonstration of pathological N2 disease [66] but the TNM status 
of participants was not well described in the other study [67]. These trials were diverse 
in terms of the interventions and populations and therefore not suitable for pooled 
analysis. In none of the studies was the surgical treatment arm found to be significantly 
superior to the nonsurgical group in terms of overall survival. A pooled analysis of the 
two studies comparing chemotherapy followed by surgery with chemotherapy followed 
by radiotherapy found a significant statistical heterogeneity between these studies, so a 
pooled analysis was not performed [65]. In one study there were two treatment related 
deaths in the chemotherapy/surgery group and one in the chemotherapy/ radiotherapy 
group [66]. Treatment related deaths were not described in the other trial [67]. Taylor 
et al. observed an equivalent outcome in patients randomized to either concurrent 
chemoradiation or induction chemotherapy followed by resection [68]. However, pa-
tients undergoing induction C/S often needed postoperative RT to achieve local control 
equivalent to that achieved with concurrent CRT.
The European Organization for Research and Treatment of Cancer (EORTC) performed 
a large multicenter randomized trial to compare surgery with radiotherapy in patients 
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with stage IIIA-N2 NSCLC who showed response to induction chemotherapy [69]. There 
was no significant difference in median survival (17.5 months in the radiotherapy 
arm versus 16.4 months in the surgery arm), 5-year overall survival (14% versus 16%) 
or progression-free survival (Table 7). Patients randomized to radiotherapy tended to 
relapse more frequently in the chest, whereas those randomized to surgery had more 
distant metastases. In a posthoc unplanned univariate subgroup analysis of the surgical 
arm, 5-year survival was longer if a radical resection was performed, nodal downstag-
ing was present or if a lobectomy was performed. The authors concluded that, after a 
radiologic response to induction chemotherapy, surgery is not superior to radiotherapy, 
which remained the preferred treatment in view of its lower morbidity and mortality.
US investigators conducted the Intergroup (IG) trial 0139, wherein patients with T1-3 
tissue proven N2M0 NSCLC and Performance Status of 0-1 were randomized between 
induction chemoradiotherapy followed by either surgery or consolidation radiotherapy 
to 61 Gy. PORT was optional in case of incomplete resection. Both arms received con-
Table 7: Randomized trials in stage IIIA-N2 NSCLC comparing surgery and radiotherapy as locoregional modalities after induction 
chemo(radio)-therapy
Study (reference)
EORTC 08941 [69] Intergroup 0139 [70]
Treatment arm Induction 
chemotherapy + 
surgery
Induction 
chemotherapy + 
radiotherapy
Induction 
chemoradiotherapy + 
surgery
Chemoradiotherapy
Number of patients with 
IIIA-N2
167 166 202 194
Chemotherapy regimen Platinum based - Cisplatin-etoposide -
Radiotherapy total dose 
(Gray)
- 60 45 61
Rate of pneumonectomy/
(bi-)lobectomy/ exploratory 
thoracotomy (%)
47/ 38/ 14 - 27/ 49/ 4 -
R0 resection rate(%) 50 - 71 -
Treatment related mortality 
rate (%)
4 <1 8 2
Pathological nodal 
downstaging rate (%)
41 (pN0-1) - 38 (pN0) -
Pathological complete 
respons rate (%)
5 - 15 -
Median PFS (months) 9.0 11.3 12.8 10.5
Locoregional failure rate (%) 32 55 10 22
Median OS (months) with 
95% CI
16.4 (13.3-19.0) 17.5 (15.8-23.2) 23 22.2
5 y SR (%) with 95% CI 15.7 (10-22) 14 (9-20) 27.2 20.3
PFS: progression free survival; OS: overall survival; R0: microscopically radical resection; 
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solidation chemotherapy with two cycles of cisplatin/etoposide. The results of this trial 
are only available as abstract [70]: progression-free survival was significantly better in 
the surgery group but overall survival did not differ, mainly because of the postop-
erative mortality (Table 7). Longer follow-up confirms the significantly improvement 
in progression-free survival but not in overall survival, when surgery follows induction 
chemoradiation. Three factors were found in multivariate analysis to be associated with 
improved outcome: lobectomy, pathological downstaging and completeness of resec-
tion. An unplanned exploratory analysis showed a significant better survival for patients 
who underwent lobectomy compared to matched irradiated patients. 
An ongoing Danish trial compares consolidation radiotherapy versus surgery with post-
operative radiotherapy, both following induction chemotherapy in stage IIIA-N2 NSCLC 
[71]. This trial started its accrual in 1998 and was expected to have its last patient en-
rolled in January 2008. Mature results are not to be expected before 2010 at the earliest.
dISCUSSION
Comparing the results of EORTC 08941 and IG 0139 , the following conclusions can be 
drawn:
1. Although both trials claim to target a population of patients with stage IIIA-N2, 
they are composed of other subgroups of patients: the EORTC study results are 
more representative of the IIIA-4 subgroup, while the Intergroup trial reflects IIIA-3 
patients. This might already explain the observed absolute differences in outcome 
between both trials.
2. Both trial show equipoise in overall survival between surgery and thoracic radio-
therapy. Although this does not mean that surgery is not feasible or inferior to radio-
therapy, the results do not justify a presumption of efficacy of thoracic surgery, nor a 
defeatism against radiotherapy. In both trials, the operative morbidity and mortality 
is higher than with radiotherapy in both trials, suggesting that a preference is to be 
given to the safest approach, regardless of the III-A subgroup studied.
3. The rate of pathological nodal downstaging is low, confirming the low accuracy of 
radiological response assessment (see further) and a low activity of the induction 
regimens used. The rate of complete pathological remission with neoadjuvant che-
motherapy is lower than with chemoradiotherapy, confirming the results of other 
aforementioned series [30-32]. 
4. In both trials local control with surgery is better than with radiotherapy, as the 
locoregional relaps rate in the EORTC study was higher with radiotherapy and 
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progression-free survival was better in the Intergroup trial. Although this observa-
tion can be credited to the surgical resection only, it cannot be excluded that the 
administration of PORT in the EORTC trial and an imbalance in the consolidation 
chemotherapy in the IG-trial are responsible for this finding, as both modalities have 
been shown to reduce local control [21, 23].
5. Exploratory subgroup analyses of both trials show an improved outcome in patients 
who are downstaged, and/or in whom a complete resection can be obtained with 
a lobectomy, as compared to either operated patients without these features, or 
compared to matched irradiated patients. 
Arguments in favour of restricting surgery to certain predictive categories are of a cir-
cular kind, as these factors are derived from a multivariable analysis and are then used 
to categorize the same data. Similar to the procedure in prognostic genomic signatures 
first isolated by hierarchical clustering in a test set, the predictive validity of these factors 
should be proven by applying them to a new series, independent from the one from 
which they were derived. There is a flaw in the promulgation of those factors to select 
patients who are most likely to benefit from radical surgery, in that they were all defined 
postoperatively. Completeness of resection can only be defined post hoc, lymph node 
status is revised as part of pathological staging, and surgeons are not likely to be certain 
before the operation that a pneumonectomy will definitely not be necessary for an indi-
vidual patient with stage III, even in one showing radiological evidence of response. This 
fact is illustrated by the rates of pneumonectomy averaging 25% in some of the best 
surgical series [48-50]. If physicians are to have a set of predictive criteria upon which to 
select or counsel their patients, these criteria must be available before surgery and be 
validated before they can be used. 
Paulson defines surgical salvage as the difference between the 5-year survival and 
the operative mortality rate and considers surgery futile when this figure approaches 
zero [72]. In the IKA PLUS study [73], the primary outcome measure was the number 
of futile thoracotomies, defined as the presence after resection of either benign lung 
lesion; pathologically proven mediastinal lymph-node involvement (stage IIIA–N2) 
other than minimal N2-disease; stage IIIB disease; explorative thoracotomy for any other 
reason; or of recurrence or death within one year after randomisation. Similarly to these 
definitions, one might define a thoracotomy in stage III NSCLC as futile whenever the 
difference between the 5 year survival rate and the sum of (i) persisting pN2/3 rate (ii) 
exploratory thoracotomy and (iii) the rate of recurrence or death from any cause within 
1 year, approaches zero. In the absence of data, one might speculate about the futility of 
surgery in both abovementioned randomized trials.
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Areas of uncertainty and further research
The optimal treatment of patients presenting with stage IIIA-N2 disease is a moving tar-
get, as clinicians are constantly challenged with improvements in staging and therapy, 
resulting in evolving patterns of approach. This reflects in a number of areas of ongoing 
or planned research.
The vast majority of IIIA-N2 patients will have their mediastinal lymph node involvement 
clinically suspected and demonstrated. Crucial to patient selection will be a thorough-
full mediastinal staging, in order to exclude those patients with false positive or negative 
imaging studies. Minimally invasive techniques using fine needle aspiration via echo-
endoscopic guidance through either esophagus (EUS) or bronchus (EBUS) allow access 
to mediastinal and hilar lymph nodes under conscious sedation. Both are considered 
complementary and are likely to supersede the more invasive surgical mediastinal pro-
cedures [74, 75]. An ongoing randomized trial is investigating this issue [76].
These techniques will result in an increase of the number of so-called ‘minimal N2’ 
patients, who would previously proceed to immediate surgery. These patients are more 
likely to be defined as ‘resectable’ by some but data from patients with head and neck 
cancer show that post-chemoradiotherapy nodal control rate is better with small volume 
lymph node disease as compared to a large volume one [77]. Although comparable data 
are lacking in NSCLC, their extrapolation might make modern concomitant chemoradio-
therapy an attractive alternative to study in these patients.
Our present systemic induction treatment is still poor. Ongoing Korean and Swiss tri-
als compare the optimal intensity of induction treatment [36,37]. It is unclear whether 
new cytotoxic drugs will result in an improved outcome, as most third generation drug 
containing induction combinations seem to have a similar activity in locally advanced 
disease. Many’s expectations are turned towards an incremental effect of adding a tar-
geted biological agents to the standard induction treatment, either during or following 
radiotherapy. The latter approach was not successfull in a trial conducted by SWOG, 
wherein patients with stage III were treated with consolidation docetaxel after chemora-
diotherapy and then randomized between gefitinib, a small molecule oral inhibitor of the 
Epidermal Growth Factor Receptor (EGFR) and placebo. A detrimental effect of gefitinib 
was observed [81]. Early data on the concomitant use of chemoradiotherapy and cetux-
imab and bevacizumab are promising [82,83] and need randomized confirmation [91]. 
As mentioned earlier, consolidation chemotherapy after chemoradiotherapy was also 
shown not to improve outcome and is currently not advocated [62]. 
As only downstaged patients seem to benefit from multimodality treatment, medias-
tinal restaging by both imaging and endoscopic techniques will increasingly become 
of interest. The correlation between Ct-response and pathological downstaging in the 
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mediastinum has been shown to be low and even patients with stable disease can have 
pathological complete responses [81]. Opinions differ whether PET-Ct scan is currently 
enough accurate to confidently predict mediastinal downstaging. Whereas several au-
thors have shown that a decrease in glucose uptake in the primary tumour –as measured 
by SUVmax- is predictive for survival and pathological response in the primary tumour, 
the sensitivity, specificity and accuracy of PET-Ct in predicting mediastinal downstaging 
in patients with proven N2 involvement was lower than in initial staging [82-84]. De Leyn 
et al. prospectively demonstrated that integrated PET-Ct scan was significantly more 
accurate for the restaging of the mediastinal lymph nodes than either Ct scan, PET-CT 
scan or remediastinoscopy but reached still only 83% [85]. This compares poorly with 
the first reports on the use of EBUS or EUS for mediastinal restaging after induction 
therapy [86-87]. It is expected that the minimally invasive EBUS and EUS will change the 
spectrum of restaging of the mediastinum in the near future [88]. 
In order to address the question which locoregional therapy is to be preferred after 
mediastinal downstaging, a trial would be required randomizing patients with clinical 
substage IIIA 3 and perhaps 4 after adequately proven downstaging by induction therapy, 
between resection and radiotherapy. The current heterogeneity of the (re-)staging pro-
cedures and the large required sample size are two important hurdles for such a study. 
Local recurrence remains an important challenge, certainly with chemoradiotherapy. 
One way to circumvent this is by escalating the total dose of irradiation given. Whether 
this is feasible will be explored by an upcoming US Intergroup trial, in which stage III pa-
tients will be randomized between a conventional regimen of 63 Gy versus an conformal 
regimen of 74 Gy, both given along concomitant and consolidation chemotherapy [89]. 
Improvements in dose localization techniques such as Involved Field Radiotherapy 
(IFRT), Intensity Modulated Radiotherapy (IMRT), four dimensional radiotherapy (4D-RT), 
Image Guided Radiotherapy (IGRT), breathing-adapted radiation therapy, particle beam 
therapy or a combination of these will come of age and become standard, allowing high 
dose irradiation with near-surgical precision, in patients with low burden N2-involvement 
with sparing of normal lung tissue and other radiosensitive organs (myelum, esophagus, 
heart, liver, kidneys). IFRT has been shown to result in a low incidence of ‘out of field’ 
nodal failures. In a randomized trial comparing IFRT and elective nodal irradiation, 
comparable tumour control, reduced incidence of radiation pneumonitis and a superior 
3 year survival were observed [90]. In a non-controlled series of patients treated with 
chemoradiation, IMRT resulted in significantly lower levels of severe radiopneumonitis 
and esophagitis compared with 3D-conventional radiotherapy [91, 92]. Clinical, dosi-
metric, and patient selection factors may have influenced the observed rate of radiation 
pneumonitis. The target volume can further be reduced by including only the FDG-PET 
Veerle BW 2.indd   87 19-11-09   15:56
Chapter 5
88
avid volume. The early experience with IFRT using this so-called FDG-PET/Ct painting 
technique has been reported to result in low isolated nodal failure rates [93]. Others 
have not confirmed these preliminary data [94]. Data are still scarce regarding the use 
of respiratory gating in locally advanced NSCLC. The three-dimensional displacement of 
a nodal mass exceeded 10 mm in one series [95]. In a retrospective series, respiration-
gated radiotherapy by 4D-RT reduced the risk of pulmonary toxicity in middle and lower 
lobe tumours [96]. Early results suggest that proton beam therapy permitted higher total 
doses with concomitant chemotherapy, yet were associated with reduced esophageal 
reactions compared with 3-dimensional conformal photon therapy [97].
guidelines
Several societies have issued guidelines with regard to the treatment of stage IIIA3-4 
NSCLC [6, 56, 98-100]. However, some of these guidelines do not specifically address the 
issue of N2-disease in its various subcategories. 
A recommendation for the routine use of adjuvant cisplatin-based chemotherapy in 
case of pN2 (IIIA1 and 2) is unanimously given by most oncological societies. In patients 
with completely resected stage IIIA NSCLC, PORT is controversial and not recommended 
for routine use by US and Canadian oncological societies because of the lack of prospec-
tive, randomized clinical trial data evaluating its efficacy [98]. 
The British National Collaborating Centre for Acute Care guidance recommends che-
motherapy and radical radiotherapy as first choice for eligible patients with stage IIIA, 
surgery with or without PORT or adjuvant chemotherapy as suitable for some patients 
and does not recommend preoperative chemotherapy except within a clinical trial [99]. 
This guidance does however not specifically address the issue of N2- disease.
The ESMO recommends preoperative cisplatin-based combination chemotherapy in 
patients with stage IIIA N2 disease [100]. For restaging, a CT scan of the chest and upper 
abdomen should be performed and minimally invasive techniques providing mediasti-
nal cytohistological diagnosis may be considered. Surgery is considered questionable 
in those patients with persistent N2 disease after chemotherapy. This guidance does 
however not specifically address the role of definitive chemoradiation and is vague with 
regard to the evidence provided and its weighting.
The American College of Chest Physicians (ACCP) provides the most thoroughly docu-
mented, updated and evidence-based guidelines with regard to the treatment of stage 
IIIA NSCLC [6]. The ACCP recommends that in NSCLC patients with stage IIIA-N2 disease 
identified preoperatively, induction therapy followed by surgery is not recommended 
except as part of a clinical trial. Furthermore, although the use of any induction chemo-
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therapy followed by surgery in stage IIIA lung cancer appears feasible, published data 
do not support this treatment as the standard of care in the community.
The US National Comprehensive Cancer Network (NCCN) practice guidelines in Oncology 
allocate a category 1 evidence to definite concomitant chemoradiation for patients with 
clinical T1-3N2 NSCLC and a category 2B evidence to surgery in case of non-progression after 
an induction with either chemotherapy or chemoradiation for clinical T1-2N2 NSCLC [101].
Taken together, these guidelines suggest a limited role for immediate surgery in patients 
with stage IIIA that is preoperatively documented, recommend a combined approach 
with a systemic induction treatment combined or followed by a locoregional interven-
tion with definite radiotherapy or resection, the latter in highly selected cases.
Recommendations 
Concomitant chemoradiation is increasingly becoming the standard of care in clinical 
stage IIIA3-4 in selected patients with a good risk profile: low co-morbidity, good perfor-
mance and pulmonary function and adequately staged as described earlier. In the absence 
of any comparative data, a combination of cisplatin and etoposide, both at systemic doses 
as used in IG 0139, is considered appropriate. Conventional daily 1.8-2.0 Gy fractionation 
remains the standard after 2 randomized trials show no significant benefit for hyperfrac-
tionation [60-61]. Total dose can be escalated from the present 60-63 Gy till 66-70 Gy with 
an acceptable increase in radiation esophagitis and pneumonitis, provided the volume 
of healthy lung and the relative esophageal volume receiving more than 20 Gy (V20max) 
remains acceptable (<35%) and/or the mean lung dose is inferior to 20 Gy [90,91]. 
For those patients with stage IIIA3-4 not qualifying for adequate concomitant chemo-
radiation as described above, a sequential approach with either post-induction surgery 
or radiotherapy might be indicated. Post-induction surgery should be performed by an 
experienced team and avoid pneumonectomy. Post-induction radiotherapy should aim at 
the same total dose and fractionation as described earlier, whenever necessary restricting 
the irradiated volume to the post-chemotherapy involved field by excluding downstaged 
mediastinal nodes with appropriate imaging or endoscopic techniques. In both instances, 
the post-induction treatment should preferably not be delayed beyond 30-40 days after 
the last cycle of induction chemotherapy to avoid accelerated repopulation [102].
Figure 1 shows the treatment algorithm presently followed at the author’s institution for 
the routine care of patients with stage IIIA -3, 4 NSCLC.
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CONCLUSIONS
More than 20 years have elapsed since the term stage IIIA was fi rst coined by Mountain in 
1986. Radically resected incidental pIIIA-1/2 should be followed by adjuvant chemother-
apy, whenever appropriate. Surgical resection after induction treatment for cIIIA-3/4 can 
be radical but whether this approach is superior to modern thoracic radiotherapy remains 
unproven. Patients should be given a balanced view of both treatment options, taking 
into account the availability of local expertise and resources and treatment complications.
This gradual shift of treatment has been made possible by the collaboration of many inves-
tigators and patients and has known the growth pains of the oncological specialty, con-
tinuously balancing between improving techniques and the need to constantly validate 
their promising results in endpoints relevant for the patient: survival and his/her quality 
of life. The way ahead looks promising, albeit not less diffi  cult, with a plethora of novel 
techniques and drugs waiting to be tested before being implemented. We ought it to our 
patients to guide them through these challenges with dedication and professionalism.
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ABSTRACT
Purpose : Carboplatin area under the curve (AUC) 5 ml/min d1 with gemcitabine 1250 
mg/m2 d1, 8 is a widely used regimen in advanced NSCLC. Grade 3-4 thrombocytopenia 
and neutropenia is frequent.
The aim of this study is to investigate, whether toxicity of gemcitabine/carboplatin could 
be reduced by administering carboplatin on day 8 instead of day 1 without decrease in 
response rate. (RR)
Methods: Patients received gemcitabine 1250 mg/m² on days 1 and 8, carboplatin AUC 5 
on day 1 (arm A) or day 8 (arm B). Drugs were administered over a 21-day cycle. Toxicity 
and RR were evaluated weekly and every second cycle, respectively. 
Results: 71 patients were enrolled. We found 79 % (95% confidence interval (CI) 61-
91%) grade 3-4 toxicity (neutropenia and thrombocytopenia) in arm A and 50% (95% 
CI 32-68%) in arm B; 66% grade 3-4 thrombocytopenia in arm A and 26% in arm B. We 
observed 30% grade 4 hematological toxicity in arm A and 3% in arm B. RR was similar 
in both arms. 
Conclusions: Although the study was prematurely closed , we believe that the current 
data remain of interest. The schedule with carboplatin on day 8 is associated with less 
grade 3-4 neutropenia and thrombocytopenia with comparable dose intensity.
Veerle BW 2.indd   100 19-11-09   15:56
101
Two schedules of the 21-day regimen of carboplatin/gemcitabine
INTROdUCTION
Lung cancer is the leading cause of cancer-related deaths in many countries. Ap-
proximately 40% of patients with non-small cell lung cancer (NSCLC) have metastatic 
disease at the time of diagnosis. The primary role of chemotherapy in patients with 
advanced NSCLC is palliative and safeguarding patients’ quality of life (QOL) is an im-
portant issue. So, for the choice of treatment, side-effects have to be taken into account. 
Platinum-based chemotherapy remains the standard palliative chemotherapy regimen 
in metastatic non-small cell lung cancer [1]. In an attempt to avoid cisplatin-induced 
toxicities, carboplatin was substituted to cisplatin as its administration results in less 
severe neurotoxicity, nephrotoxicity, nausea and vomiting [2]. In patients with advanced 
NSCLC, carboplatin-based chemotherapy has been extensively investigated [3-10]. In 
a recent meta-analysis carboplatin-based chemotherapy regimens were considered 
equivalent to cisplatin-based chemotherapy regimens in patients with advanced NSCLC 
[11]. The combination of a platinum and gemcitabine is among the current standard 
regimens in Europe for the treatment of advanced NSCLC [12]. In comparative studies 
the gemcitabine/carboplatin combination had a similar outcome as the gemcitabine/
cisplatin combination in terms of overall response rate, median time to progression, 
response duration and survival [6,13]. Non-hematological toxicity was however lower in 
the gemcitabine/carboplatin treated patients.
The dose limiting toxicity in the gemcitabine/carboplatin chemotherapy regimen is 
haematological [14,15] In the currently-used 3-weekly dose regimen in which gem-
citabine and carboplatin are both administered on day 1 and gemcitabine again on day 
8, thombocytopenia grade 3-4 was found in more than 40% of cases, neutropenia grade 
3-4 in 20% [16]. 
The hypothesis of the present study was that the administration of carboplatin on day 
8 instead of day 1 would result in less hematological toxicity of the gemcitabine/carbo-
platin combination without compromising the activity of the gemcitabine/carboplatin 
combination.
METHOdS
Patient selection 
Patients with histologically or cytologically proven stage IV or IIIB NSCLC with malignant 
pleural effusion and/or supraclavicular lymph nodes were eligible. Other selection 
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criteria were: measurable disease according to the RECIST criteria [17]; age older than18 
years; WHO performance status less than 2; adequate bone marrow reserve (hemoglo-
bine > 6.0 mmol/l or 9.66 g/dl; absolute neutrophil count ≥ 1.5 x 109 /L, platelet count 
≥ 100 x 109/L) and a calculated creatinin clearance rate of at least 50 ml/min. Exclusion 
criteria were weight loss of more than 10% of body weight in the month prior to reg-
istration, the presence of other malignancies (previous or present), except adequately 
treated in situ carcinoma of the cervix or basal cell carcinoma of the skin and a previous 
malignancy more than 5-years ago without evidence of recurrence. No prior therapy 
for NSCLC was allowed. Patients were registered and randomized at the Unit Trials and 
Statistics of the Erasmus Medical Center Rotterdam, prior to start of treatment and after 
verification of the eligibility criteria. The study was approved by the ethical committee 
of the Erasmus MC and all participating hospitals. Patients were included after written 
informed consent.
Treatment Plan
Patients in arm A were treated with gemcitabine (1250 mg/m2 days 1,8) and carboplatin 
(AUC 5 ml/min day 1). Patients in arm B were treated with gemcitabine (1250 mg/m2 
days 1,8) and carboplatin (AUC 5 ml/min day 8). Both drugs were administered as a 21-
day cycle, on an outpatient basis. Treatment was given until progression of the disease 
with a maximum of 4 courses, or unless unacceptable toxicity occurred or the patient 
refused further treatment. Patients with a complete response after 4 cycles could receive 
2 additional cycles to a maximum of 6. Tumor response was assessed after every second 
cycle. Post-study therapy was permitted at the discretion of the investigator. The dose 
of gemcitabine was reduced to 1000 mg/m2 and the dose of carboplatin to AUC 4 in 
subsequent cycles if the nadir of the absolute neutrophile count (ANC) was < 0.5 X 109/L 
and/or the nadir of the platelets was < 50 X 109/L or in case of febrile neutropenia or 
severe bleeding (grade 4). If on day 21 the white blood count (WBC) was < 3 X 109/L, ANC 
< 1.5 X 109/L and the platelets < 100 X 109/L, treatment was delayed until these criteria 
were met. In case of more than two weeks of delay, the patient went off-treatment. In 
case the platelets were ≤ 50 X 109/L and/or the WBC ≤ 1 X 109/L and/or the ANC ≤ 0.5 
X 109/L on day 8 no carboplatin or gemcitabine was given. In all other cases no dose 
reduction for carboplatin on day 8 was allowed. Dose adjustments for gemcitabine on 
day 8 are summarised in Table 1. 
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Efficacy and tolerability assessments
Study assessments including physical examination, complete blood count and elec-
trocardiogram had to be performed within 2 weeks before the start of treatment, 
chest-upper abdomen computed tomography scan (CT), bone scan or PET-scan within 
3 weeks before the start of treatment. Routine blood tests for blood chemistry and 
haematological toxicity were performed before each chemotherapy administration. Re-
sponse assessments by CT were performed after every two cycles using RECIST criteria.
Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria 
version 2 (NCI-CTC) and assessed on day 1, 8, 15 and 21 of each cycle by physical ex-
amination, direct questioning and appropriate hematological and biochemical values. 
Hematological toxicity rate is defined as the rate of any grade 3-4 thrombocytopenia 
and/or neutropenia during chemotherapy.
Study design, statistical considerations and analysis
The study was an open multicenter randomized phase II trial. Eligible patients were ran-
domized in a 1:1 fashion by computer list. All participants were stratified by institution, 
disease stage, WHO performance status, gender and age. A Bryant and Day design was 
used to simultaneously assess response rate and hematological toxicity as co-primary 
endpoints [18]. Secondary endpoints were overall survival and 1-year survival. 
Based on predefined expectations that arm A (carbo/gem day 1) is associated with a 
grade 3-4 toxicity (thrombopenia and neutropenia) in 30% of cases with a response rate 
of 45% and that arm B (carbo/gem day 8) is associated with 15% grade 3-4 toxicity and a 
respons rate of 45%, we designed the study as follows. Considering P0 = 30% (unaccept-
able response rate) and P1 = 50% (acceptable response rate) and T0 = 30% (unacceptable 
toxicity rate) and T1 = 15% (acceptable toxicity rate), with an alpha of 0.10 and a power of 
90%, the sample size was estimated to be 67 patients in each arm. A first stage analysis 
was planned after the inclusion of the first 54 patients (2x 27). For both arms the follow-
ing rule was applied: if 8 or less patients showed a response and/or 8 or more patients 
Table 1 Per Protocol Dose adjustments Gemcitabine day 8
Gemcitabine dose level WBC (x109/L) ANC (x109/L) Platelets (x109/L)
100% ≥ 2 ≥ 1 ≥ 100
75% ≥ 1 ≤ 2 ≥ 0.5 ≤ 1 50-99
0% ≤ 1 ≤ 0.5 ≤ 50
Abbreviations:
WBC: white blood count
ANC: absolute neutrophile count
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developed grade 3-4 thrombocytopenia and/or neutropenia, closure of the arm was 
necessary. Patients who did not receive any treatment, were excluded from the toxicity 
analysis and patients for whom response was not assessed due to early death or early 
discontinuation were excluded from the activity analysis.
Response and toxicity rates, including 95% confidence intervals, were reported. Survival 
was estimated according to Kaplan Meier.
RESULTS
Patients and disease characteristics
A total of 71 patients (34 in arm A and 37 in arm B) were enrolled in the study between 
April 2004 and March 2006, before the planned first stage analysis. 71 patients were 
included in our study instead of 54 because not all patients were evaluable for response 
and results of the first stage analysis were not immediately available. 
As the previous described stopping rule was achieved for both arms, the investigators 
decided to close the study accrual prematurely. 
Two of the patients were ineligible (one because of WHO 2 at baseline and one patient 
with a simultaneous oesophageal carcinoma). 
Patient and disease characteristics at baseline for the 69 eligible patients were well bal-
anced between both arms and are summarized in Table 2.
Table 2. Patient and disease characteristics
overall Arm A Arm B
Number of patients 69 34 35
Gender
male 
female
52 (75%)
17 (25%)
25
9
27
8
Age
median
range
61
39-77
61
41-77
61
39-74
ECOG Performance
0
1
11 (16%)
58 (84%)
6
28
5
30
Stage of disease
IIIB
 IV
13 (19%)
56 (81%)
6
28
7
28
Histology
squamous
adenocarcinoma
other
14 (20%)
33 (48%)
22 (32%)
8
17
9
6
16
13
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dose administration and intensity
The total and median number of cycles administered were well balanced between the 
treatment groups (117 and 4 cycles in arm A, versus 113 and 4 cycles in arm B). Median 
dose intensity for gemcitabine in arm A is 708 mg/m2/week (range 189-847) and in arm 
B 804 mg/m2/week (range 314-849). Relative Dose Intensity is 85% in arm A, 96% in arm 
B. The median total carboplatin dose in arm A is 1830 mg versus 2090 mg in arm B. The 
main reason for dose adjustments was hematological toxicity. Gemcitabine day 1 dose 
reductions occurred in 9% of cycles in arm A and in 3% in arm B. For gemcitabine day 
8, dose adjustments occurred in 11% of cycles in arm A and in 5% in arm B. Carboplatin 
doses were reduced in 9% of cycles in arm A and in only 1% in arm B.
Toxicity
Four patients were excluded from the toxicity analysis as they received no chemotherapy.
The frequency of the toxicity check was weekly and balanced between the two arms, 
with in arm A 7% missing values for ANC and/or platelets compared to 6% in arm B.
The most frequently observed toxicities were neutropenia and thrombocytopenia. 
There were no treatment-related deaths on either arm. Table 3 shows the grade 3-4 
toxicity (neutropenia and thrombocytopenia) in arm A: 79% (95% confidence intervals 
(CI) 61-91%) and in arm B: 50% (95% CI 32-68%) Grade 3-4 thrombocytopenia occurred 
in 66% of patients in arm A and in 26% in arm B. Platelet transfusions were required in 
Table 3. Hematological toxicities and Response
Toxicity Arm A (n=33) Arm B (n= 34)
platelets/ANC gr 3-4 26 (79%) 17 (50%)
platelets/ ANC gr 4 10 (30%) 1 (3%)
platelets gr 3-4 22 (67%) 9 (26%)
ANC gr 3-4 18 (55%) 12 (35%)
ANC gr 4 10 (30%) 1 (3%)
Platelets gr 4 1 (3%)  0 (0%)
Response
CR
PR
SD
PD
 
0
6
21
3
1
5
19
9
Overall RR (%) 20% 18%
Abbreviations:
CR: complete response
PR: partial response
SD: stable disease
PD: progressive disease
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14% of patients in arm A and in 0% in arm B. Only one patient (arm A) developed febrile 
neutropenia.
The observed differences between arm A and B are even more pronounced when only 
grade 4 hematological toxicity is analysed. (see Table 3). 
Grade 4 non-hematological toxicity was mild: only one patient (arm A) developed grade 
4 skin-rash. Among grade 3 non-hematological toxicities the most frequent were leth-
argy (4 patients: 2 arm A, 2 arm B), elevated transaminases (2 patients, 1 arm A, 1 arm 
B), febrile neutropenia (1 patient, arm A), constipation (1 patient, arm B), dehydration (1 
patient, arm B) and diarrhea (1 patient, arm B). 
Response and outcome
Five out of 69 patients were considered unassessable for response evaluation as they 
did not receive at least 2 cycles of therapy: 1 patient died before the first response 
evaluation (due to pneumonia) and in 4 patients early discontinuation was necessary (2 
patient’s withdrawal, 1 patient’s best interest, 1 patient grade 3 liver toxicity and grade 4 
skin rash). In the remaining 64 patients we observed 1 complete response and 11 partial 
responses; 40 patients remained stable and 12 progressed under treatment, either 
radiologically and/or clinically.
In arm A an overall response rate of 20% ( 95% CI 7.7-38.6%) was seen, 18.2% (95% CI 
7-35.5%) in arm B.
The median survival time for all patients was 7.3 months, with a 1-year survival rate of 
28%. Median survival for arm A was 9.4 months, for arm B 6.8 months . 
dISCUSSION
With carboplatin-gemcitabine being widely used as a standard regimen in advanced 
NSCLC, we wanted to investigate whether administration of carboplatin on day 8 in-
stead of day 1 could reduce its haematological toxicity without a loss of activity. Based 
on the early stopping rule, the study was prematurely closed as response rates in both 
arms were lower and toxicities higher than expected in the statistical design. Accord-
ing to earlier data showing response rates varying between 20-40%, we set the lower 
threshold of activity for this phase II trial below which a regimen would not be of interest 
for further study, at 30%. Although the patients’ demographics seem quite similar to 
these of other studies, the standard arm in the present study did not reach the expected 
threshold response rate and its overall survival is also lower than reported probably due 
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to a high percentage of patients (81%) with stage IV disease. Compared to other trials, 
grade 3-4 hematological toxicity in the present study is high. This probably reflects the 
weekly sampling instead of sampling at retreatment or at clinical toxicities only. Another 
reason for the premature closure could be that the cut-off value for acceptable/unac-
ceptable response and toxicity in the standard arm was too optimistic. 
Although the study was prematurely closed, data obtained for the two treatment groups 
are interesting. Response rates were found to be similar but we observed a considerably 
lower rate of hematological toxicity by administering carboplatin on day 8 instead of 
day 1 with preservation of the dose intensity. 
Gemcitabine/cisplatin combination is one of the most widely used regimens in Europe 
for first-line treatment in patients with advanced NSCLC. Problems with cisplatin ad-
ministration in this palliative setting include a significant non-hematologic toxicity and 
the need for in hospital hydration. Carboplatin constitutes a reasonable alternative to 
cisplatin in this combination as it is easier to use in outpatient setting and is associated 
with fewer non-hematological side-effects. 
Since several studies demonstrated that a carboplatin-based two drug combination is 
effective with a favourable safety profile and is well tolerated, gemcitabine and carbo-
platin is a widely used combination for the treatment of advanced non-small-cell lung 
cancer [13, 19,20]. In the advised 3-weekly schedule with gemcitabine (1250 mg/m2) 
and carboplatin (AUC 5), both administered on day 1, the treatment is well tolerated, 
but clinicians frequently have to deal with grade 3-4 neutropenia and especially grade 
3-4 thrombocytopenia. Even though severe bleeding problems are infrequently seen, 
physicians feel uncomfortable especially about this thrombocytopenia because it neces-
sitates more attention, repeated platelets count controls, dose reductions and platelets 
transfusions [21] In the present study, the high incidence of grade 3-4 thombocytopenia 
in arm A led to frequent platelet transfusions. 
The Norwegian Lung Cancer Study Group, recently report a grade 3 thrombocytopenia 
of 25% and grade 4 thrombocytopenia of 19% in the carboplatin day 1-gemcitabine regi-
men resulting in more frequent transfusions and higher costs [22]. The high frequency of 
thrombocytopenia in the gemcitabine/carboplatin treatment is thought to be due to a 
synergistic thrombocytopenic effect of both agents. Gemcitabine single agent therapy 
was studied earlier in advanced non-small cell lung cancer and was associated with a 
low frequency of thrombocytopenia of 2% [23]. In advanced non-small cell lung cancer, 
carboplatin has been studied as single agent and is known to have a thrombocytopenic 
effect, but carboplatin has been studied as single agent and is known to have a throm-
bocytopenic effect in other malignancies also in other malignancies. Furthermore, as 
this dose limiting toxicity is less frequently found in gemcitabine combinations with 
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cisplatin, it can be postulated that this toxicity is increased by the association of carbo-
platin to gemcitabine. The high incidence of thrombocytopenia on day 15 in arm A can 
be explained by the fact that gemcitabine on day 8 is administered at the time platelets 
are already lowering. On day 8, the thrombocyte count in most patients is - although 
lower than on day 1,- still high enough to administer the planned dose of gemcitabine. 
In arm B gemcitabine is given as single agent on day 1 which will have a minor effect 
on platelets on day 8, the day when carboplatin is administered. The same reasoning 
applies for the incidence of neutropenia. Similar effects are reported for the cisplatin/
gemcitabine regimen [24,25,26]. In a randomized phase III study comparing two dif-
ferent schedules of administration of cisplatin in combination with gemcitabine, the 
regimen with cisplatin on day 15 was associated with significant less thrombocytopenia 
compared to the arm with cisplatin on day 2 [24]. The difference in toxicity in our study 
cannot be explained by a difference in missing data of ANC and platelets in the two 
arms. 
In a randomized phase II study, gemcitabine (1100 mg/m2 days 1,8) and carboplatin 
(AUC 5, day 8) every 4 weeks was compared to gemcitabine (1000mg/m2 days 1,8) and 
carboplatin (AUC 5, day 1) every 3 weeks [27]. The treatment with carboplatin on day 8 
showed a more favourable toxicity profile. Although the 28-day regimen appeared to be 
associated with less preferable outcomes (response rate and median time to progres-
sion), differences between treatment groups were not statistically significant. Median 
progression-free survival and response rates were 3.8 months and 22.9%, respectively, 
with the 28-day regimen, and 4.9 months and 40.4%, respectively, with the 21-day 
regimen. Differences in progression-free survival, response rate and overall survival 
were not statistically significant. We believe that the reported decrease in response is 
due to an asymmetry in rescheduling: 4 weeks in the carboplatin-day 8 regimen vs 3 
in the carboplatin day 1 regimen. In contrast with this study we report no difference in 
response rate when both regimens are rescheduled every 3 weeks.
A limitation of our study is that the sample size is too small to reasonably consider any 
comparisons between the two arms in terms of survival. In the Ricci study, patients 
treated in the arm with cisplatin on day 15 experienced a significantly more prolonged 
progression free survival and overall survival [24]. 
CONCLUSION
In conclusion, this study was designed to investigate the possibility of lowering toxic-
ity of the standard chemotherapy regimen carboplatin- gemcitabine in patients with 
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advanced NSCLC. Although the study was prematurely stopped, we believe that the 
current data remain of interest. With comparable dose intensity, the schedule with 
carboplatin day 8 is associated with less grade 3-4 neutropenia and thrombocytopenia.
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ABSTRACT
Background: The rationale of sequential chemotherapy is to maintain dose intensity and 
to preclude cumulative toxicity by increasing drug diversity. 
Purpose: to investigate the toxicity and efficacy of the sequential single agent regimen 
of gemcitabine followed by paclitaxel in first line stage IIIB/ IV non-small cell lung cancer 
(NSCLC) patients with good performance status (PS).
Patients and methods: In this non-randomized phase II trial gemcitabine 1250 mg/m2 
was administered on day 1 and 8 of course 1 and 2; Paclitaxel 150 mg/m2 on day 1 and 8 
of course 3 and 4. Primary endpoint was response rate (RR), secondary endpoints toxic-
ity and time to progression (TTP). 
Results: Of the 21 patients (median age 56, range 38-80 years; 62 % males, 38 % females) 
10% (2/21) had stage IIIB, 90% (19/21) stage IV, 15% PS 0, 85% PS 1. No dose reduc-
tions were needed. Of the 20 evaluable patients 20% had a partial response, 30% stable 
disease, 50% progressive disease. Median TTP was 12 weeks (range 6-52 weeks), median 
overall survival (OS) 8 months (range 1-27 months) and the 1-year survival was 33%. One 
patient had grade 3 hematological toxicity, 2 patients a grade 3 peripheral neuropathy. 
Conclusions: the sequential administration of single agent gemcitabine followed by 
paclitaxel in first line treatment of advanced NSCLC had a favourable toxicity profile, a 
median TTP and OS comparable with other sequential trials reported and might, there-
fore, be a treatment option for NSCLC patients with high ERCC1 expression.
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INTROdUCTION
Even with the use of novel chemotherapeutic agents, the prognosis of patients with 
advanced NSCLC remains poor. Platinum based chemotherapy combined with either 
gemcitabine, vinorelbine, paclitaxel or docetaxel is currently the mainstay in the 
treatment of advanced NSCLC (1-5). Standard therapy for advanced NSCLC results in 
response rates of 20 to 40%, a median survival between 8-10 months and 1-year survival 
rates between 30-50% (1-3). 
Chemotherapy may lead to the selection of chemo-resistant tumor clones. Frequent 
exposure to different cytotoxic agents with brief intervals may inhibit tumor re-growth 
and limit the emergence of drug resistant cell lines (6,7). Sequential chemotherapy 
administration offers the possibility to increase drug diversity while maintaining dose 
intensity, potentially leading to less dose reductions, an optimal dose intensity and 
prolonged treatment duration and disease control (6,7). 
In order to investigate the validity of this approach, we decided to conduct a non-
randomized phase II study, to investigate the toxicity and efficacy in terms of time to 
progression and response rate of a sequential single agent regimen consisting of gem-
citabine followed by paclitaxel in the first line treatment of patients with stage IIIB/ IV 
NSCLC.
PATIENTS ANd METHOdS
In this multi-center trial patients with stage IIIB (malignant pleural effusion or N3 due 
to supraclavicular lymph node involvement) and stage IV have been enrolled between 
2003-2006. The study was approved by the ethical committees of the Erasmus MC and 4 
other hospitals. Patients were included after written informed consent. Other selection 
criteria were: measurable disease according to the RECIST criteria (8), age over 18 years, 
WHO performance status less than 2, adequate bone marrow reserve (absolute neutro-
phil count ≥ 2.0 x 109 /L, platelet count ≥ 100 x 109/L), adequate hepatic function (total 
bilirubin ≤ 1.5 x upper normal limit, ASAT and ALAT ≤ 3.0 x upper normal limit, alkaline 
phosphatase ≤ 2.5 x upper normal limit, total billirubin 1.5 - 2.5 x upper normal limit and 
ASAT or ALAT 3-5 x upper normal limit in case of liver metastases).
Exclusion criteria were prior treatment with chemotherapy and the presence of other 
malignancies (previous or present), except adequately treated in situ carcinoma of the 
cervix or basal cell carcinoma of the skin and a previous malignancy more than 5-years 
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ago without evidence of recurrence (except for malignant melanoma, hypernephroma 
or breast cancer).
Treatment 
Gemcitabine 1250 mg/m2 was administered intravenously on day 1 and 8 of course 1 
and 2 as a 30-minutes infusion. Paclitaxel 150 mg/m2 was administered intravenously 
on day 1 and 8 of course 3 and 4 as a 3-hours infusion. One course was defined as two 
weekly doses of chemotherapy followed by one week of rest and one cycle as 2 courses 
of gemcitabine followed by 2 courses of paclitaxel (Fig. 1). At least 1 cycle was adminis-
tered unless patient refusal or excessive toxicity precluded further therapy. If there was 
no PD after 1 cycle the same treatment schedule could be repeated up to a maximum 
of 2 cycles. If PD was observed at the end of the first or second cycle, further treatment 
was according to local policy.
Efficacy and tolerability assessments
Study assessments included physical examination, complete blood count, electrocardiogram, 
tumor measurements (chest X-ray and chest-upper abdomen computed tomography 
scan), within 4 weeks before start of the treatment. Routine blood test for blood chemistry 
and haematological toxicity were performed before each chemotherapy administration. 
Response evaluation by CT took place after every 2 courses by RECIST criteria (8). Toxicity 
was graded according to the National Cancer Institute Common Toxicity Criteria version 3 
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Figure 1. Treatm schedule  
 
 
 
 
Course 1      Course 2 
 
Day1  Day 8  Day 15 Day 22  Day 29 Day 36 
 
 
Gemcitabine Gemcitabine Rest  Gemcitabine Gemcitabine Rest 
                      =1 cycle 
 
 
Course 3     Course 4 
 
Day 43 Day 50 Day 57 Day 64 Day 72 Day 80 
 
 
Paclitaxel Paclitaxel Rest  Paclitaxel Paclitaxel Rest 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Treatment schedule  
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(NCI-CTC) and was assessed every 3 weeks by physical examination, direct questioning and 
haematological and biochemical parameters.
Statistical considerations
It was hypothesized that if the sequential regimen had an efficacy lower than 25%, it 
was unlikely to be of interest and would not result in further investigation. According to 
Fleming’s single stage procedure P0 was set at 0.20. The response percentage that would 
certainly warrant further investigation (P1) was set at 0.40. With a power of 0.93 and an 
a of 0.06 this implies that 35 patients had to be enrolled. For the power calculation the 
best response during the first cycle has been used. P values < 0.05 were considered 
significant.
RESULTS
Twenty-one patients have been enrolled in this trial over a 3-years period due to com-
peting trials in the participating centres. Median age was 56 years (range 38-80 years), 
62 % (13/21) was male, 38 % (8/21) female, 10% (2/21) had stage IIIB, 90% (19/21) stage 
IV, 15 % (2/21) ECOG performance status 0, 85% (18/21) ECOG 1. Ten (47.5%) patients 
had an adenocarcinoma, 3 (14.5%) squamous cell carcinoma and 8 (38%) had large cell 
carcinoma. (Table 1)
Tabel 1 Patient characteristics 
Number of patients 21
Gender
male 
female
13 (62%)
 8 (38%)
Age
median
range
59
38-80
ECOG Performance
0
1
 2 (10%)
19 (90%)
Stage of disease
IIIB
 IV
 2 (10%)
19 (90%)
Histology
squamous
adenocarcinoma
large cell
 3 (14.5%)
 10 (47.5%)
 8 (38%)
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One non-evaluable patient died one week after the first gemcitabine dose administra-
tion due to a cerebral vascular accident. At that time the platelet count was normal. Of 
the 20 evaluable patients 20% (4/20) achieved a partial response (PR), 30% (6/20) stable 
disease (SD) and 50% (10/20) progressive disease (PD). (Table 2) Five patients (25%) 
progressed after 2 courses of gemcitabine, all of them had an adenocarcinoma. Median 
time to progression (TTP) was 12 weeks (range 6-52 weeks), the median overall survival 
(OS) 8 months (range 1-27 months) and the 1-year survival rate 33%. Toxicity was mild: 
only one patient developed grade 3 hematological toxicity, in two others there was 
grade 3 peripheral neuropathy occurring at the second cycle. There were no treatment-
related deaths. No dose reductions were needed.
dISCUSSION
In this non-randomized phase II study, the sequential administration of single agent 
gemcitabine followed by paclitaxel in the first line treatment of advanced NSCLC had a 
favourable toxicity profile, a median TTP and OS comparable with other sequential trials 
reported in the literature (Table 3) (9-20).
When we designed our study (2002-2003) Vansteenkiste et al. reported that treatment 
of patients with symptomatic advanced NSCLC with single agent gemcitabine, resulted 
in a superior clinical-benefit response rate compared to cisplatin-based combination 
chemotherapy. Gemcitabine was equally effective in controlling ‘disease-specific’ symp-
toms, but superior in controlling ‘constitutional’ symptoms (21). Therefore, single 
agent gemcitabine in first line treatment of stage IIIB/IV NSCLC was at that time a valid 
therapeutic choice and we decided to investigate the sequential administration of two 
single agent non-cross resistant chemotherapeutic drugs, gemcitabine and paclitaxel. 
In the present study, paclitaxel was selected as sequential agent because taxanes do 
not require the presence of an intact p53 pathway for apoptosis induction in contrast to 
DNA-damaging agents like gemcitabine (22). The dose of paclitaxel of 150 mg/m2 was 
based on the results of phase I and II trials (23-25). Akerley et. al reported on a phase I 
trial of weekly paclitaxel administered over 3 hours for 6 consecutive weeks followed by 
2 weeks of rest. From this study the recommended phase II dose was 175mg/m2/week 
Tabel 2 Results of the 20 evaluable patients
Response Number of patients
PR  4
SD  6
PD 10
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Table 3. Overview of the sequential studies reported in the literature  (Continu on next page)
Study Phase N= Regimen RR 
(%)
PD
(%)
MS 
(m)
1year OS 
(%)
PFS 
(m)
Major grade 3-4 
toxicity
(%)
doublet→ 
doublet
Gebbia (9) III 400 G + IFO (2)→CDDP + VNR (2)
versus
CDDP + VNR (2)→G + IFO (2)
versus
CDDP + VNR (up to 6 cycles)
versus
CDDP + G (up to 6 cycles)
19
32
44a
34
59
33
25
37
NR
NR
9
8.2
NR
NR
24
20
3.1a
5
4.1
4
Neutropenia 
57/67/26/21
Thrombo 
32/35/17b/41
Vomiting 
13/15/21/23
Asthenia 
29/35/35c/50
doublet 
→ SA
Edelman (10) III 204 CBDCA + G (3)→PTX(3)
versus
CDDP + VNR (3)→DOC(3)
21
28
29
22
9
9
34
36
4
4
Neutropenia 47a/70
Anemia 19/14
Thrombocytopenia 
37/2a
Fatigue 7a/18
Emesis 5a/24
Toxic deaths 3/3
Clark (11) II 18 CDDP (2) + VNR(2)→DOC (4) 31 44 9.5 44 NR Leukopenia 45d
Emesis 26d
Toxic deaths 3
Grossi (12) II 51 CDDP + PTX (2)→VNR( 2)
→G (2)
43 25 14 53 6.8 Neutropenia 41
Toxic deaths 1
Kubota (13) III 401 CBDCA + PTX (up to 6)
versus
VNR + G (3)→DOC (3)
36a
23
10
16
13.8
13.1
55.5
55.6
6
5.9
Neutropenia 54/30a
Neuropathia 21/2a
Toxic deaths 0/2
SA → 
doublet or 
triplet 
Feliu (14)
Rixe (15)
II
II
52
32
PTX (6)→CDDP + GEM + VNR 
(up to 6)
DOC (4)→CDDP + VDS (4)
56
17
31
27
NR
11
56
47
9
4.4
Neutropenia 20
Neuropathy 12
Emesis 10
Neutropenia (gr 
4) 71
Febrile neutropenia 
14
Neuropathy 24
SA→SA
Present study II 21 G →PTX 20% 50 8 33 3 Neutropenia 4
Neuropathy 9
Manegold
(16)
II-III 338 G +DOC (6)
versus
G (3) “DOC (3)
33a
22
NR
NR
7.3
7.4
27
25
6.3a
 4.9
Neutropenia 36/27
Infection 17/13
Dyspnoe 21/20
Asthenia 12/11
Martoni (17) II 52 G(3)→VNR (until PD) 23 23 10 42 6 Neutropenia 22e
Constipation 3e
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(23). In the subsequent phase II trial this dose-dense regimen led to a high proportion 
of grade 3-4 neutropenia and grade 2-3 peripheral neuropathy (32%) (24). Therefore, 
in the CALGB study 9713, weekly paclitaxel at a reduced dose of 150 mg/m2/week for 6 
consecutive weeks was used followed by 2 weeks of rest. They demonstrated that this 
dose-dense regimen could be administered safely (25).
Because 50% of the participants in our trial had disease progression and because disease 
progression occurred already after 2 courses of single agent gemcitabine, we decide to 
close our study prematurely. At that time, it had also become evident from the literature 
that single agent gemcitabine in first line treatment of stage IIIB/IV NSCLC was inferior 
compared to platinum-based doublets (26,27). 
Even though our study has been closed prematurely, our data add to our current 
understanding on the treatment of NSCLC because they contribute to the concept of 
maintenance therapy with non-cross resistant drugs. In a recent randomized phase III 
trial of maintenance pemetrexed plus best supportive care versus placebo plus best 
supportive care, PFS was 4 months in the pemetrexed arm versus 2 months in the 
placebo arm with an hazard ratio (HR) of 0.6 (p< 0.00001) and the OS was 13.4 months 
versus 10.6 months, respectively (HR 0.79, p=0.012) (28). The phase III trial of immediate 
versus delayed docetaxel after first line chemotherapy in advanced NSCLC showed also 
a superior progression free survival (statistically significant) and greater median overall 
survival (not statistically significant) for the arm with immediate docetaxel (29). These 
trials support the rationale of using a non-cross-resistant third generation agents before 
Study Phase N= Regimen RR 
(%)
PD
(%)
MS 
(m)
1year OS 
(%)
PFS 
(m)
Major grade 3-4 
toxicity
(%)
Poon (18) II 23 G (3) → CDDP (4) 21 52 14.6 63 3.3 Neutropenia 13
Anemia 13
Hirsch (19) II 42 VNR (2) → G 38 36 8 29 3.5 No grade 3-4 tox.
Tibaldi (20) II 56 G (3)→ DOC (3) 16 43 8 34 4.8 Neutropenia 5.4
Thrombopenia 3.6
Mucositis 3.6
Diarrhea 3.6
Asthenia 9
a: statistically significant
b: difference in thrombocytopenia incidence between CT arms was statistically significant (p=0.0001)
c: asthenia more frequent in the GC arm than VC arm (50% vs 35%, p=0.015)
d: toxicity evaluated per cycle
e: worst toxicity per step
Abbreviations: G: gemcitabine, IFO: ifosfamide; CDDP: cisplatin; VNR: vinorelbine; CBDCA: carboplatin; PTX: paclitaxel; DOC: docetaxel; 
RR: response rate; MS: median survival; MPFS: median progression- free survival; NR: not reported; OS: overall survival; PD: progressive 
disease; SA: single agent
NR: not reported
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disease progression has occurred. We also believe that a single agent non-platinum 
approach could be of value in ERCC1 positive patients, especially in the perspective of 
individualized treatment. Patients with completely resected NSCLC and ERCC1-negative 
tumors appeared to benefit from adjuvant cisplatin-based chemotherapy, whereas 
patients with ERCC1-positive tumors did not (30). A prospective trial of 366 patients, in 
which patients with low ERCC1 were selected for platinum-based therapy (docetaxel, 
cisplatin), while those with high ERCC1 expression were directed to alternate non-
platinum therapy (docetaxel, gemcitabine), demonstrated a significantly higher overall 
response rate in the genotypic arm compared to the non-selected control arm (31). 
The response rate in the low ERCC1 group receiving platinum chemotherapy was 53%, 
but the RR in the high ERCC1 non-platinum arm was 47%, compared to 39% for the 
non-selected group receiving platinum therapy. A prospective phase II feasibility trial in 
which patient’s therapy was selected based on ERCC1 expression showed that the low 
ERCC1 group treated with gemcitabine/carboplatin and the high ERCC1 group treated 
with gemcitabine/docetaxel had a similar median survival of 13 months and response 
rates of 44% (32). 
Our data also confirm that gemcitabine is less active in adenocarcinoma’s than in squa-
mous cell carcinoma’s (1) because all patients in our trial who progressed after 2 courses 
of gemcitabine had an adencocarcinoma.
In conclusion, although this non-randomized phase II study failed to meet the primary 
efficacy endpoint, the sequential administration of single agent gemcitabine followed 
by paclitaxel in first line treatment of advanced NSCLC had a favourable toxicity profile, 
a median TTP and OS comparable with other sequential trials reported in the literature 
and might, therefore, be a treatment option for NSCLC patients with high ERCC1 expres-
sion.
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ABSTRACT
Background: Oral treatment regimens with few side-effects are appealing in the 2nd or 3rd 
line treatment of non-small cell lung cancer (NSCLC) patients. 
Purpose: The aim was to investigate the efficacy and toxicity of the oral combination 
etoposide, Uracil-Tegafur (UFT) and leucovorin in 2nd or 3rd line in Caucasian patients 
with advanced NSCLC.
Methods: Etoposide 50 m g/m2, UFT 250 mg/m2 and leucovorin 90 mg (fixed dose) were 
dosed in 3 gifts approximately 8 hours apart for 14 days followed by one week rest every 
3 weeks until progressive disease (PD). Primary endpoint was response rate (RR), second-
ary endpoints toxicity and time to progression (TTP). 
Results: The median number of cycles was 3.5 (95%CI 2-5); 9 patients received ≥ 6 cycles, 
4 >10 cycles. The median dose intensities for etoposide and UFT were 223 mg/m2/week 
(95% CI 213-232) and 1092 mg/m2/week (95% CI 1032-1167), the relative dose intensities 
92% and 90 %, respectively. Grade 3/4 neutropenia was observed in 12% (4/32), grade 
3/4 thrombocytopenia in 15 % (5/32), without febrile neutropenia. Non-hematological 
toxicity grade 3 included hepatic toxicity (6%), lethargy (15%), diarrhea (3% ) and nausea 
(3%). One patient developed grade 4 arterial ischemia. Fourteen percent (95% CI 4-33%) 
(4/28) had a confirmed partial response , 57 % (95% CI 44-81%) (16/28) stable disease 
and 28% (95% CI 19-56%) (8/28) progressive disease. The median TTP was 3 months 
(95% CI 1.3-4.4), the median overall survival 6.7 months (95% CI 4.0-9.3). 
Conclusion: The combination of UFT, etoposide and leucovorin is active in 2nd or 3rd line 
therapy of Caucasian NSCLC patients and because of its favourable toxicity profile this 
treatment warrants further investigation.
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INTROdUCTION
Lung cancer is world-wide the leading cause of cancer-related deaths. Approximately 
40% of all patients with non-small cell lung cancer (NSCLC) have metastatic disease at 
the time of diagnosis. Platinum-based chemotherapy remains the standard of care for 
the first line therapy of patients with metastatic NSCLC and good performance status. 
Since several years 2nd and even 3rd line therapy has become part of our therapeutic 
arsenal (1-4). Several agents including docetaxel, pemetrexed and the epidermal growth 
factor receptor-tyrosine kinase inhibitor (EGFR-TKI) erlotinib are available for 2nd line 
treatment, but it is yet unknown what the preferred drug or drug combination is for 
this setting (5-9). A direct comparison between pemetrexed and docetaxel in a non-
inferiority randomized phase III study showed similar activity but less toxicity for the 
pemetrexed arm (7).
Oral agents with few side effects are appealing in 2nd or 3rd line setting when patients 
are usually in a less favourable condition. The combination of the oral agents Tegafur 
and Uracil (UFT) appeared to be effective in adjuvant setting in Asian NSCLC popula-
tions (10,11) with few side effects even after prolonged administration. Tegafur is the 
pro-drug of 5-Fluor Uracil (5-FU) and Uracil inhibits the rate-limiting catabolic enzyme 
for 5-FU, dihydropyrimidine dehydrogenase. Leucovorin enhances the cytotoxicity of 
5FU by one of its metabolites 5,10-methylenetetrahydrofolate. The FdUMP/thymidylate 
synthase complex that forms after 5-FU administration depends on the presence of 
adequate concentrations of reduced folate (12,13). Leucovorin is a derivative of tetrahy-
drofolic acid, the reduced form of folic acid, which increases intracellular concentration 
of reduced folates, thus stabilizing the FdUMP/ thymidylate synthase complex (13).
The efficacy of single agent UFT in advanced NSCLC appeared to be modest, with response 
rates of only 9% (14). In 1st line treatment of advanced NSCLC doublets have proven to 
be more effective in terms of response rate and overall survival than single agents (15). 
A recent meta-analysis showed that in 2nd line both platinum and non-platinum based 
doublets significantly increased the response rate compared with single agents, but 
without improvement in overall survival and with an increase in toxicity (16). In contrast, 
Smit et al. recently reported that the combination of carboplatin and pemetrexed was 
superior with regard of time to progression (TTP) compared with pemetrexed alone 
in 2nd line without increase in toxicity (17). UFT with cisplatin, but without leucovorin, 
has been investigated in 1st line Japanese NSCLC patients, with response rates ranging 
from 28-47% and acceptable toxicity (18,19). However, the same combination led to low 
response rates and high toxicity in Caucasians, which precluded further studies (20). 
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Despite the fact that etoposide has well known activity in NSCLC (21,22), there are no 
reports on the single-agent activity of oral etoposide in refractory NSCLC except one ret-
rospective study which showed no activity (23). In vitro data show synergism between 
UFT and etoposide in mouse Lewis lung carcinoma cell lines (24). Despite the fact oral 
etoposide is known to have variable absorption and hence disposition, and the lack of 
pharmacokinetic data on the interaction of oral etoposide with UFT, the combination of 
oral UFT and etoposide was well tolerated and appeared to be active in first line gastric 
cancer (25) and in pre-treated breast cancer and head and neck tumors (26-27). 
Purpose of our study was to investigate the efficacy and toxicity of the non-cross resis-
tant oral drug combination UFT, etoposide and leucovorin in 2nd or 3rd line in Caucasian 
patients with advanced NSCLC.
METHOdS
Selection criteria
Patients with histologically or cytologically proven stage IIIB with malignant pleural ef-
fusions and / or supraclavicular lymph nodes or stage IV NSCLC treated with at least one 
prior platinum-based 3rd generation drug combination have been selected. They had to 
have measurable disease (28), age >18 years, WHO performance status < 3, adequate 
bone marrow reserve (white blood count ≥ 3 x 109 /L, absolute neutrophil count ≥ 1.5 x 
109 /L, platelet count ≥ 100 x 109/L) and a calculated creatinin clearance rate of >50 ml/
min. Exclusion criteria were a recent (< 6 months) myocardial infarction, signs of cardiac 
failure or rhythm disturbances requiring medication, a history of another malignancy, 
except in situ carcinoma of the cervix or basal cell carcinoma of the skin and a previous 
malignancy more than 5-years ago without evidence of disease. Patients with symptom-
atic brain metastases were ineligible.
Evaluation and Treatment 
Baseline evaluation included a physical examination, complete blood count, electrocar-
diogram and a computed tomography (CT) of the chest and upper abdomen < 4 weeks 
before start of the treatment. Treatment consisted of oral etoposide 50 mg/m2 , oral 
Uracil-Tegafur 250 mg/m2 and oral leucovorin 90 mg (fixed dose) in 3 gifts approximately 
8 hours apart for 14 days followed by one week rest. Courses were repeated every 3 
weeks. All drugs had to be taken while fasting (no meal from one hour before until one 
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hour after taking the study medication). Three dosing groups were defined according 
to body surface area (< 1.6 m2, 1.60-1.8 m2 and > 1.8 m2). Tumor response evaluation 
took place after every 2 courses according to the RECIST criteria. (28) Evaluable were 
those who received at least 2 chemotherapy courses. Treatment was stopped in case 
of severe toxicity, disease progression or when it was considered in the best interest of 
the patient. Haematological and non-hematological toxicity was assessed before start 
of each cycle. Toxicity was graded according to the National Cancer Institute Common 
Toxicity Criteria (NCI-CTC) version 3.
Statistics
This is a non-randomized open label phase II study. The minimum response rate below 
which treatment is considered of no interest is set at 5%. Responses rates of 20% or 
higher are clearly of interest and should be detected with a power of 80 %. The hy-
pothesis that the response rate is at most 5% should be rejected with a type I error of 
5% (alpha = 0.05) According to the 2-phase Simon design (29) 10 patients are needed 
for the first part of the trial. If one response is observed, the UFT-etoposide-leucovorin 
combination is of potential interest and another 19 patients could be enrolled. If at the 
end of the trial 3 or fewer responses are observed, a minimum response rate of 20% can 
be rejected. Overall survival and TTP were estimated according to the log rank test and 
plotted according to Kaplan- Meier (30). 
RESULTS
Patients 
Over a 18-months period 35 Caucasian patients from 2 institutions have been enrolled 
in 2005-2006. In the first part of the trial 15 patients instead of 10 because 1 patient was 
ineligible (symptomatic brain metastases) and 4 were excluded from interim-analysis 
because of protocol violations (n=2) or because they received < 2 cycles of chemother-
apy (one patient experienced extreme fatigue and another died after a non-study drug 
related myocardial infarction). In the 2nd part of the trial 20 patients have been enrolled, 
2 patients were not evaluable for response. The characteristics of the 34 eligible patients 
are summarized in Table 1. 53% (18/34) of patients received 2nd line and 47% (16/34) 3rd 
line therapy.
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dose intensity and toxicity 
The median number of cycles was 3 (range 0-34); 9 patients received ≥ 6 cycles, 4 of 
them even > 10 cycles. The median dose intensities for etoposide and UFT were 223 
mg/m2/week (95% CI 213-232) and 1092 mg/m2/week (95%CI 1032-1167) and the rela-
tive dose intensities 92% and 90 %, respectively. The most frequently observed grade 
¾ hematological toxicities were neutropenia in 12 % (4/32) and thrombocytopenia in 
15% (5/32), without febrile neutropenia (Table 2). Grade 3 non-hematological toxicity in-
cluded elevated transaminases in 6% (2/32), lethargy in 15% (5/32), diarrhea in 3% (1/32) 
and nausea in 3% (1/32). One patient developed treatment related grade 4 peripheral 
arterial ischemia. Admissions for adverse events occurred in 38 % (13/34) of which 26% 
was related to disease progression and 13% treatment related. 
Effect evaluation
28 patients were evaluable for response. Fourteen percent (95% CI 4-33%) (4/28) had a 
confirmed partial reponse , 57% (95%CI 44-81%) (16/28) stable disease and 28% (95% 
CI 19-56%) (8/28) progressive disease. The overall disease control rate was 71 % (20/28). 
The median TTP for all eligible patients was 3 months (95% CI 1.3-4.4) , for those treated 
in 2nd line 3.3 months (95% CI 1.4-5.2) and for 3rd line treatment 2 months (95% CI 0.8-4.4) 
(Fig 1). The median overall survival time was 6.7 months (95% CI 4.0-9.3) (Fig 2).
Tabel 1. Patient characteristics
N (%)
Eligible patients 34
Males
Females
19 (56)
15 (44)
ECOg Performance
0
1
2
 9 (27)
24 (71)
 1 (3)
Stage of disease
IIIB
 IV
11 (32)
23 (68)
Previous treatment
1
2
18 (53)
16 (47)
Treatment in first line:
Platinum-based doublet 
Non-platinum-based doublet
33 (97)
 1 (3)
Treatment in second line:
Single agent Taxanes (docetaxel, paclitaxel)
Platinum-based doublets
10 (62)
 6 (38)
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Costs
According to the Institution rates list 2007 of the Dutch Healthcare Authority (Tarieflijst 
Medisch Specialistische Behandeling Instellingen 2007 van de Nederlandse Zorgauto-
riteit) one 3-week cycle of UFT-etoposide-leucovorin costs 826 euros. In comparison, 
the costs for one 3-week cycle docetaxel, pemetrexed, erlotinb and topotecan are 1300, 
3200, 1528 and 1410 euros, respectively (Table 2).
dISCUSSION
This study shows that the combination of UFT, etoposide and leucovorin is active in 2nd or 
3rd line therapy of NSCLC patients with a favourable toxicity profile even after prolonged 
treatment and with relatively low costs in comparison with other 2nd line therapies.
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Fig 1.  Kaplan-Meier curve of the time to progression of non-small cell lung cancer patients after treatment with UFT-etoposide-
leucovorin in 2nd and 3rd line. 
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Fig 2.  Kaplan-Meier curve of the overall survival of non-small cell lung cancer patients after treatment with UFT-etoposide-leucovorin 
in 2nd and 3rd line.
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Although no formal comparisons can be made with historical series, they suggest that 
the response rate and TTP of our UFT-etoposide combination is comparable with those 
of the established 2nd line agents docetaxel, pemetrexed and erlotinib (Table 2). Median 
overall survival time seems to be lower than for pemetrexed and docetaxel, but compa-
rable with erlotinib which could be explained by the fact almost half of our patients was 
treated in 3rd line. A phase III trial comparing oral topotecan to intravenous docetaxel 
in patients with pretreated advanced NSCLC, demonstrated that also oral topotecan 
provides activity. The results in terms of ORR and TTP are comparable with our UFT-
etoposide trial. However hematological toxicity for oral topotecan is high; grade 3-4 
neutropenia in the oral topotecan arm was 50%, grade 3-4 anemia 26% and grade 3-4 
thrombopenia 26% (31).
With a similar range of efficacy, the toxicity of the UFT–etoposide combination is much 
lower than for the other 2nd line agents. Although costs have not been evaluated in our 
study, a cost estimation for UFT-etoposide seems lower than for the other 2nd line agents. 
Given the incurable nature of advanced NSCLC and the only limited survival advantage 
that can be achieved by 2nd or 3rd line treatment, treatment convenience and toxicity of 
the regimen are of great importance in the choice of treatment. Dubey et al. performed 
a survey of 464 lung cancer patients registered in the Alliance for Lung Cancer Advocacy 
Support and Education about their treatment preference and concerns about toxicity 
(32). In that survey 73% of the responders reported that they would choose a chemo-
therapy regimen because of its side-effect profile, assuming that outcome was equiva-
lent. Most important side effect were considered nausea and vomiting (48%), followed 
Table 2. Comparison of UFT-etoposide with the historical series of the registered 2nd line agents docetaxel, pemetrexed and erlotinib. 
Docetaxel Pemetrexed Erlotinib UFT-etoposide Oral Topotecan
Grade 3/4 neutropenia (%) 40.2 5.3 0 12.5 50
Grade 3/4 thrombopenia 
(%)
0.4 1.9 0 15.6 26
Febrile neutropenia (%) 12.7 1.9 0 0 26
Hospitalisation drug related 
AE (%)
10.5 6.4 NR 13 NR
Alopecia (any grade) (%) 37.7 6.4 0 57.1 20
Rash (grade 3/4) (%) 0.7 0.8 9 0 NR
Diarrhea (grade 3/4) (%) 2.5 0.4 6 3 4
Nausea (grade 3/4) (%) 1.8 2.6 3 3 4
ORR (%) 8.8 9.1 8.9 12.5 5 
TTP (median, months) 2.9 2.9 2.2 3 2.75
MS (months) 9.1 9.4 6.7 6.7 7
Costs for one cycle (euros) 1300 3200 1528 826 1410
Definition of abbreviations: AE: adverse event; ORR: objective response rate; TTP: time to progression; NR: not reported; MS: median 
overall survival. 
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by infection risk (20%) and fatigue (13%). Hair loss (9%) was of minor concern. Therefore, 
we believe that the UFT-etoposide combination deserves further investigation in 2nd or 
3rd line treatment in a randomized fashion. 
UFT activity might be correlated with thymidylate synthase (TS) expression. TS is an 
enzyme that plays an important role in DNA biosynthesis, catalyzing the methylation 
of fluorodeoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate 
(dTMP). It is the target enzyme for anti-metabolites such as 5-FU and UFT. Several 
studies clearly show a correlation between intra-tumoral TS mRNA expression and the 
response to 5-FU (33,34). TS protein expression levels appear to be negatively associ-
ated with prognosis in different tumor types due to a higher proliferative activity of the 
NSCLC cells (34,35). Miyoshi et al. showed that adjuvant treatment for stage I NSCLC 
patients with a TS negative expression led to a significant better survival compared to 
those who were TS positive (36). Ceppi et al. recently found higher TS levels in squamous 
cell and highly differentiated carcinomas (37). TS expression could, therefore, be used as 
a predictive marker for treatment of NSCLC patients with TS-inhibiting agents such as 
pemetrexed, UFT or 5-FU. 
Another mechanism involved in the activity of UFT could be the anti-angiogenetic prop-
erties of its metabolites gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone 
(GBL) (38,39). Therefore, a combination of UFT with other anti-angiogenetic agents like 
bevazucimab would be worth of investigation.
In conclusion, the combination of UFT, etoposide and leucovorin is active in 2nd or 3rd 
line therapy of Caucasian NSCLC patients and because of its favourable toxicity profile 
warrants further investigation.
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SUMMARy ANd CONCLUSIONS
Lung cancer is the leading cause of cancer mortality in the United States and Europe. 
Approximately 85% of the patients with lung cancer have non–small cell lung cancer 
(NSCLC), which can be classified into squamous, adeno, large cell and not otherwise 
specified (NOS) histologies. Two third of the patients have locally advanced or metastatic 
disease at the time of diagnosis.
Both for stage IIIA and IIIB disease, the advantages of a combined modality approach in-
cluding chemotherapy, radiation therapy with or without surgery are well documented 
for selected subsets of patients.
Although concurrent chemoradiotherapy is superior to sequential therapy, in a number 
of patients the sequential approach remains the treatment of choice. Approximately 
one third of our NSCLC patients have contraindications for cisplatin, such as inability 
to receive hyperhydration (cardiac dysfunction, renal failure) or pre-existing peripheral 
neuropathy or hearing loss. Patients with severe comorbidities are no good candidates 
for the concurrent chemoradiotherapy approach and for cisplatin-based chemotherapy.
In chapter 2 we discussed in a phase II study the toxicity and effectivity of the induction 
chemotherapy regimen of carboplatin and gemcitabine in 41 patients with stage IIIA and 
IIIB NSCLC. The induction treatment was active and well tolerated. In this phase II study 
an overall response rate of 51% was achieved and toxicity was mild. Thrombocytopenia 
grade 3 and 4 was present in 35% of cases, neutropenia grade 3 and 4 in 41%. There was 
no febrile neutropenia and non-hematological toxicity was mild. Relative dose intensity 
equaled 99% for carboplatin and 91% for gemcitabine. 89% of patients completed treat-
ment and underwent sequential radiotherapy. Although response rate was lower than in 
the induction regimens with cisplatin, gemcitabine and carboplatin administered accord-
ing to a 3-week schedule is an active and safe induction regimen and a reasonable alter-
native especially for patients in whom cisplatin-based chemotherapy is contraindicated.
For well selected patients with stage III unresectable NSCLC, concurrent chemoradio-
therapy is the treatment of choice (1-5).
In chapter 3 we present the results of 2 phase I trials with pemetrexed and cisplatin with 
concurrent thoracic radiotherapy. The first trial was performed in patients with unresect-
able stage III NSCLC with a good performance status, the second trial in patients with 
limited disease SCLC.
This is the first report on the acute and late toxicity of this new combined modality treat-
ment. Although both studies were prematurely closed without reaching the MTD, we 
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have demonstrated that the combination of full doses of cisplatin (75-80 mg/m2) and 
pemetrexed 500 mg/m2 with concurrent radiotherapy up to 50 Gy (25 x 2 Gy) is well 
tolerated. Hematological toxicity was mild, no febrile neutropenia or toxic deaths were 
observed. Grade 3 and 4 acute or late pulmonary toxicities have not been observed. 
Although one patient experienced a grade 3 acute esophageal toxicity, this patient was 
able to complete radiation therapy. In the stage III NSCLC study, two patients achieved 
a partial response, 1 patient had a complete response. One patient died with progres-
sive disease at 21 months (local failure), the other patients are still alive after 3 years of 
follow-up. Because in boths studies, 2 out of 13 patients (15%) developed late grade 2 
pulmonary toxicity, close follow-up for late pulmonary toxicity is recommended, espe-
cially in studies with higher radiation dosages. Currently, a randomized phase III study in 
unresectable non-squamous locally advanced stage III NSCLC with full dose pemetrexed 
500 mg/m2, cisplatin 75 mg/m2 and radiotherapy 66 Gy in 33 fractions followed by con-
solidation pemetrexed compared to cisplatin-etoposide with concurrent radiotherapy 
followed by consolidation chemotherapy is ungoing. (6)
Although this new combined modality treatment seems promising, this treatment 
appears to be suitable for highly selected patients. Our study in stage III NSCLC was 
conducted in 2 academic centers and only 4 patients have been enrolled in 18 months. 
Twelve patients have been registered, but appeared to be ineligible. Among these 
screening failures, 6 appeared to be stage IV NSCLC, 5 patients were ineligible because 
of V20 > 36% and 1 patient because of exceeding esophageal RT constraints. 
 Chapter 4 
Despite promising results, the role of a surgical resection after induction chemotherapy 
(with or without radiation) in stage IIIA and IIIB NSCLC remains controversial.
The EORTC 08981 study in stage IIIB (T4-N3) was conducted to investigate whether an 
induction regimen with concurrent chemoradiotherapy followed by surgery after restag-
ing by mediastinoscopy and/or FDG-PET was feasible in a multicenter setting. Unfortu-
nately the study closed prematurely and illustrates that the conduct of a tri-modality 
approach across Europe was difficult at that time. One of the reasons was that in case of 
N2 or N3, re-mediastinoscopy after induction treatment was mandatory and it appeared 
to be a major threshold for patient enrolment. At that time, minimally invasive staging 
procedures such as endoscopic esophageal ultrasound (EUS) and endoscopic bronchial 
ultrasound (EBUS) were not widely available. As these techniques are now available in 
most centers, it can be expected that these techniques will change the spectrum of re-
staging of the mediastinum in the near future (7,8). It is very unlikely that a scenario with 
two mediastinoscopies (at baseline and post-induction) will be the best one in future 
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multimodality treatment. Upfront staging with minimally invasive endoscopic tech-
niques has become very attractive; mediastinoscopy can then be performed in optimal 
conditions after induction treatment. Although the number of participants enrolled in 
our trial was low, the results are disappointing with a high rate of pneumonectomies and 
major complications after right-sided pneumonectomy. Subgroup analyses from both 
EORTC 08941 and the Intergroup Study 0139 (9,10) have shown an improved outcome in 
patients who are downstaged, and/or in whom a complete resection can be performed 
by lobectomy compared to matched irradiated patients. 
From EORTC 08981 we have learned that minimally invasive new staging and restaging 
techniques are warranted and that a right-sided pneumonectomy after induction treat-
ment should be avoided.
In general, in stage III-N2/3, the role of surgery compared with radical and adequate 
modern thoracic radiotherapy for local control after induction treatment is still a chal-
lenge. Further randomized controlled trials are needed to show superiority of neoad-
juvant treatment followed by surgical resection for patients with stage III-N2/3 NSCLC. 
Two large randomized controlled trials are ongoing in stage IIIA-N2 (11) and IIIA/B NSCLC 
(ESPATÜ,12). There is no consensus on the intensity of the induction therapy. In patients 
receiving induction chemoradiation, early toxicities (e.g. esophagitis and hematotoxic-
ity) are increased and in those undergoing surgery, postoperative mortality rate is higher 
especially when pneumonectomy is performed. Whether chemoradiation is superior to 
chemotherapy alone as induction therapy is currently investigated in a Swiss trial (13). 
In chapter 5 the treatment options for stage IIIA NSCLC are reviewed. Prospects on 
novel treatment modalities and future research opportunities are presented. Few issues 
are as controversial in NSCLC as the management of patients with stage IIIA-N2 NSCLC. 
The optimal treatment of patients presenting with stage IIIA-N2 disease is a moving tar-
get, as clinicians are constantly challenged with improvements in staging and changes 
in therapy, resulting in evolving patterns of approach. Incidental pIIIA-1/2 should be 
followed by adjuvant chemotherapy, whenever appropriate. Surgical resection after 
downstaging with induction treatment for cIIIA-3/4 can be radical and can result in 
long-term survival, but whether this approach is superior to modern radical thoracic 
radiotherapy remains unproven. In order to address this question a trial would be re-
quired randomising patients with clinical substage IIIA-3 and perhaps 4 after adequately 
proven downstaging by induction therapy between resection and radiotherapy. The 
current heterogeneity of the (re)staging procedures and the large required sample size 
are two important hurdles for such a study. Mediastinal restaging by both imaging and 
endoscopic techniques will increasingly become of interest. The minimally invasive 
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techniques, using fine needle aspiration via echo-endoscopic guidance through either 
esophagus (EUS) or bronchus (EBUS), are both considered complementary and are likely 
to be superior to the more invasive surgical mediastinal procedures (8). An ongoing 
randomized trial is investigating this issue (14). 
Improvements in dose localization techniques such as Involved Field Radiotherapy 
(IFRT), Intensity Modulated Radiotherapy (IMRT), four dimensional radiotherapy (4D-
RT), Image Guided Radiotherapy (IGRT), breathing-adapted radiation therapy (gating 
or tracking), particle beam therapy or a combination of these will become standard, 
allowing high dose irradiation with near-surgical precision. In summary, patients with 
locally advanced NSCLC encompass a heterogeneous group whose optimal manage-
ment approach is dependent on multiple factors and remains to be defined for some pa-
tients. A combined modality approach with chemoradiotherapy with a platinum-based 
regimen has become the preferred treatment for the majority of patients with stage III 
disease detected clinically. The role of surgery in patients with pre-operatively detected 
but non-bulky mediastinal lymph node involvement who respond to chemotherapy or 
chemoradiotherapy remains unclear, but seems reasonable in those patients with down-
staged nodal disease after induction therapy who do not require pneumonectomy. 
Adjuvant platinum-based chemotherapy should be offered to those patients found to 
have stage III disease at the time of surgery. 
A multidisciplinary approach to managing this diverse group of patients is recom-
mended. In daily practice, it is important that we provide our patients with a balanced 
view of the different treatment options, taking into account the treatment complications 
and the availability of local expertise and resources.
The majority of patients diagnosed with NSCLC will eventually be treated with chemo-
therapy for metastatic disease. The current standard for this group of patients with a 
good performance status is cis- or carboplatin in combination with a 3rd generation agent, 
including paclitaxel, gemcitabine, vinorelbine or docetaxel and more recently pemetrexed 
for patients with non-squamous histology (15-18). However, as pointed out in the intro-
duction, there is an ongoing debate about the choice of the platinum agent. Many North 
American physicians and Cooperative Groups prefer carboplatin-based therapies and also 
in Europe this regimen is frequently used. In chapter 6 we studied two schedules of a 
21-day regimen of carboplatin and gemcitabine in a randomized phase II study design. 
Although the study was prematurely stopped after first stage analysis, probably because of 
too optimistic predefined expectations, we believe that the current data remain of interest. 
The regimen in which carboplatin (AUC of 5) was administered on day 8 and gemcitabine 
1250 mg/m² on day 1 and 8 (Arm B) was associated with less grade 3 and 4 neutropenia 
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and thrombocytopenia compared with the standard regimen in which gemcitabine was 
administered on day 1 and 8 and carboplatin on day 1 ( Arm A). Seventy-nine percent 
(95% confidence interval (CI) 61-91%) grade 3-4 toxicity was observed (neutropenia and 
thrombocytopenia) in arm A and 50% (95% CI 32-68%) in arm B. Grade 3-4 thrombocy-
topenia occurred in 66% of cases in arm A and in 26% in arm B. The high incidence of 
grade 3-4 thombocytopenia in arm A led to frequent platelet transfusions. We observed 
30% grade 4 hematological toxicity in arm A and 3% in arm B. The two regimens had 
comparable dose intensity. The regimen with carboplatin administered on day 8 will 
lead to less frequent blood count controls, dose reductions and platelets transfusions, 
which is important for the daily patient care.
The optimal duration of platinum-based therapies has been an area of investigation as 
well. Four trials (19-20) showed that with a maximum of 4 courses of chemotherapy 
overall survival was equivalent to more than 4 courses with similar (21-23) or less toxic-
ity (20,21). Chemotherapy may lead to the selection of chemo-resistant tumour clones. 
Frequent exposure to different cytotoxic agents with brief intervals may inhibit tumor 
re-growth and limit the emergence of drug resistant cell lines (24,25). Sequential chemo-
therapy administration offers the possibility to increase drug diversity while maintaining 
dose intensity, potentially leading to less dose reductions, an optimal dose intensity and 
prolonged treatment duration and disease control (26,27). 
In chapter 7 we investigated the use of non-cross resistant sequential single agent che-
motherapy in first line advanced NSCLC patients, at a time the inferiority of single agents 
to platinum-based doublets was not proven. In this non-randomized phase II study the 
sequential administration of single agent gemcitabine followed by paclitaxel in the first 
line treatment of advanced NSCLC has a favourable toxicity profile, a median time to 
progression and overall survival comparable with other sequential trials reported in the 
literature. However, it has become now evident from the literature that single agent 
gemcitabine in first line treatment of good performance status patients with stage IIIB/
IV NSCLC is inferior compared to platinum-based doublets (27,28). Because of its favour-
able toxicity profile, our regimen with sequential single agents might be a viable option 
for elderly or poor performace status advanced NSCLC patients, as demonstrated in the 
study of Tibaldi et al (29). 
The results of the sequential study add to the existing knowledge on the treatment of 
NSCLC. First, the data contribute to the concept of maintenance chemotherapy with 
non-cross resistant drugs. Recent trials support the rationale of using non-cross-resis-
tant third generation agents before disease progression (26,27). Secondly, we strongly 
believe that our single agent non-platinum approach, might be of value in ERCC1 
Veerle BW 2.indd   143 19-11-09   15:56
Chapter 9
144
positive patients, especially if we move to a time of individualizing treatment (28). This 
hypothesis should be further tested in a clinical trial.
Our data confirm the results of recent trials, showing that gemcitabine is not as effective 
in adenocarcinoma as in squamous cell carcinoma (18). Recently, it has become clear 
that histology matters in the treatment of NSCLC and this is a big challenge especially 
for our pathologists. 
Second-line systemic therapy is chemotherapy administered once disease progression 
has been demonstrated after completion of first-line therapy. Approximately 40 to 50% 
of patients enrolled in first-line trials have subsequently received second-line therapy 
(19). There are currently three agents approved by the FDA for second-line therapy; two 
cytotoxic chemotherapy agents, docetaxel and pemetrexed, and the EGFR TKI, erlotinib 
(30-32). Currently many physicians base their choice for the second-line agent on per-
sonal and patient preferences, the presence of co-morbidity, the specific toxicity profiles 
associated with these agents and treatment convenience. Oral agents with few side ef-
fects are appealing in 2nd or 3rd line setting when patients are usually in a less favourable 
condition. In chapter 8, we have demonstrated that oral UFT-etoposide is active and 
well tolerated in second and third line Caucasian NSCLC patients with advanced disease. 
This is the first report on the efficacy of UFT-etoposide in Caucasian patients. With a 
similar range of efficacy, the toxicity of the UFT–etoposide combination is much lower 
than for the other 2nd line agents. Although costs have not been evaluated in our study, a 
cost estimate for UFT-etoposide appeared to be lower than for the other 2nd line agents. 
This is important given the high pressure on health care budgets today.
Thymidylate synthase is an enzyme that plays an important role in DNA biosynthesis and 
it is the target enzyme for anti-metabolites such as 5-FU and UFT. Recently it has been 
shown that TS levels are higher in squamous cell and highly differentiated carcinomas 
(33). TS expression could, therefore, be used as a predictive marker for the treatment of 
NSCLC patients with TS-inhibiting agents such as pemetrexed, UFT or 5-FU. Because of 
its low toxicity profile and low costs, UFT is also of special interest in the area of mainte-
nance chemotherapy. 
Today it has become clear that the crucial ‘flaw’ in the existing treatment paradigm for 
non-small cell lung cancer is the ‘one size fits all approach’. There is evidence now that 
we definitely have to change the “one size fits all approach” towards a personalized ap-
proach of treatment selection.
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As a consequence, in the area of new targeted therapies, we have to realize that even 
conventional chemotherapy is “targeted therapy”. The tools to begin appropriately 
“targeting” it are now available.
FUTURE PERSPECTIVES
Individualizing therapy for non-small cell lung cancer
In stage III NSCLC patients, integration of novel biological agents such as monoclonal 
antibodies and modern radiotherapy techniques as part of multimodality approach will 
further improve outcome. With the frequent occurrence of large tumour volumes and 
the central location in stage III NSCLC, high dose intensity may seem impractical. Several 
novel radiation techniques are likely to overcome this problem and to improve local 
control by delivery of higher radiation dose to smaller volumes, allowing for less toxicity. 
4D radiotherapy and dose painting offer the prospect for stage III NSCLC of using dose-
intensive schedules. Further implementation of these techniques needs well-designed 
clinical trials in appropriately selected patients.
Current practice for selection of therapy in patients with advanced stage NSCLC is largely 
empiric and based on patients characteristics such as age, performance status, weight loss.
In general, in our decision-making process, four dimensions are considered: evidence from 
the literature, individual patient characteristics (age, sex, performance status), patient pref-
erence (longer life versus quality of life) and physician experience and preference. Although 
this empiric process serves most patients well, in 2009 a paradigm shift has begun. Our 
decision-making process moves from empiric to an “integrated approach”. A variety of 
selection factors will make it possible to consider customizing therapy for the individual 
patient, by integrating clinical, histological and molecular factors. 
For the first time, randomized clinical trials in NSCLC suggest that histologic subtyping 
can also be used for chemotherapy selection (17) and recent advances in treatment 
of lung cancer require greater accuracy in the subclassification of non-small-cell lung 
cancer (NSCLC). Interobserver variability and the lack of specific, standardized assays 
limit the current abilities to adequately stratify patients for such treatments. MicroRNA 
biomarkers for the identification of i.e. squamous cell carcinoma and standardized as-
says are warranted.
The importance of histology subtype rises a diagnostic issue. In clinical practice and 
particularly in patients with metastatic disease, diagnosis is frequently performed by 
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fine-needle biopsy, which produces a general cytological NSCLC finding. However, 
based on the previous statement, an optimal treatment calls for a specific diagnosis. 
Treatment of “unspecified” tumours with some agents may expose patients to unneces-
sary risks or deny them potentially effective treatment. Therefore, should we still use 
invasive approaches to obtain a tumour sample tissue for a subtype of histological 
diagnosis? Recent data on, for example the thymidylate synthase enzyme, suggest that 
histology is a crude method of molecular selection. In the future, the possibility of ob-
taining a molecular characterization of circulating tumor cells could probably help avoid 
an invasive strategy for diagnosis. Eventually, we hope to find markers that substitute 
for the significance of histologic subtype. As in the field of breast cancer management, 
where therapy is dictated by estrogen receptor, progesterone receptor, and HER2/neu 
expression, we anticipate that molecular predictors of response will eventually supplant 
the role of histology when making clinical treatment decisions in patients with NSCLC. 
Technologies such as genomics, proteomics and biomarker development represent 
promising approaches with which to probe for predictive markers. Modern techniques 
have facilitated the identification of specific genetic factors that may play a role in dis-
ease progression and patient response to therapy, prompting research efforts to identify 
the clinical predictors of outcome for NSCLC. Recent evidence suggests that the applica-
tion of a pharmacogenomic approach has the potential to greatly improve survival in 
certain subpopulations of patients with NSCLC, which could profoundly influence the 
decision-making process used in evolving treatment strategies for this malignancy.
The future success of targeted therapies will need a coordinated, multidisciplinary team 
approach. Clinical trials that investigate the activity of novel agents and incorporate 
patient selection, based on clinical and molecular factors, are required.
Future challenges will include ensuring that molecular determinants are identified as 
novel chemotherapeutic agents are being developed, enabling rationale therapeutics. 
Clinical trials will then enrich patients with the molecular determinants, potentially 
increasing response rates and survival in a specific group of patients who express this 
molecular determinant. It is hoped that these patient-specific ‘individualized cocktails’ 
will substantially improve response rates and survival. Integrated decision-making, 
incorporating clinical, histologic and molecular factors is a future goal.
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SAMENVATTINg EN CONCLUSIES 
Longkanker is de belangrijkste oorzaak van kankersterfte zowel in Amerika als Europa. 
Ongeveer 85% van de longkanker patiënten hebben een niet-kleincellig longcarcinoom 
en twee derde presenteert zich met locaal gevorderde (stadium IIIA of IIIB) of gemeta-
staseerde ziekte (stadium IV).
Voor zowel stadium IIIA en IIIB niet-kleincellig longcarcinoom zijn de voordelen van een 
combinatie behandeling, bestaande uit chemotherapie, radiotherapie en/of chirurgie, 
voor goed geselecteerde patiënten, duidelijk aangetoond. 
Alhoewel chemotherapie toegediend gelijktijdig met bestraling leidt tot een betere 
overleving dan chemotherapie gevolgd door bestraling, blijft voor een grote groep 
patiënten de sequentiële behandeling de meest aangewezen behandeling. Ongeveer 
een derde van onze patiënten met niet-kleincellig longcarcinoom is niet geschikt voor 
een behandeling met cisplatine en dit omwille van cardiale problemen, nierfunctie-
stoornissen, neurologische- en gehoorsproblematiek. Ernstige comorbiditeit maakt een 
concomitante behandeling en toediening van cisplatine vaak onmogelijk.
In hoofdstuk 2 wordt een fase II studie besproken waarin het effect en de bijwerkingen 
van inductiechemotherapie met carboplatine en gemcitabine, bij 41 patiënten met 
stadium IIIA of IIIB niet-kleincellig longcarcinoom, wordt beschreven. We hebben aange-
toond dat het inductieschema werkzaam is en goed wordt verdragen. Het radiologisch 
responspercentage was 51% en de toxiciteit was vrij mild. In 35% van de patiënten werd 
een graad 3-4 thrombopenie vastgesteld en in 41% een graad 3-4 neutropenie. Febriele 
neutropenie werd niet gedocumenteerd en de niet-hematologische toxiciteit was laag. 
De relatieve dosisintensiteit voor carboplatine was 99%, voor gemcitabine 91%. 89% 
van de patiënten kon aansluitend worden behandeld met de geplande radiotherapie. 
De mediane overleving was 13 maanden, mediane tijd tot progressie 9 maanden.
Alhoewel de respons wat lager is dan in de inductiestudies met cisplatine, is de 
sequentiële behandeling met het drie wekelijks inductieschema met carboplatine en 
gemcitabine gevolgd door radiotherapie een goed alternatief, vooral voor patiënten die 
niet geschikt zijn voor cisplatine bevattende chemotherapie.
Voor een kleinere groep, goed geselecteerde patiënten met stadium III, is concomitante 
chemoradiotherapie de aangewezen behandeling.
In hoofdstuk 3 stellen we de resultaten voor van 2 fase I studies met pemetrexed, 
cisplatine met concurrent thoracale radiotherapie. De eerste studie werd uitgevoerd bij 
patiënten met goede performance status met niet-resectabel stadium III niet-kleincellig 
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longcarcinoom, de tweede studie bij patiënten met limited-disease kleincellig longcar-
cinoom.
Dit is het eerste manuscript waarin zowel acute als late toxiciteit van deze nieuwe 
combinatie behandeling worden beschreven. Alhoewel beide studies vroegtijdig zijn 
afgesloten zonder bereiken van de MTD, hebben we kunnen aantonen dat de volledige 
dosis van cisplatine (75-80 mg/m2) en pemetrexed 500 mg/m2 kan gecombineerd wor-
den met gelijktijdige thoracale radiotherapie tot een totale dosis van 50 Gy (25x2 Gy). 
Pemetrexed is het eerste, nieuwe derde generatie cytostaticum dat in volledige dosis 
kan gecombineerd worden met thoracale radiotherapie. Deze combinatie behandeling 
wordt goed verdragen. De hematologische toxiciteit was mild, er was geen febriele neu-
tropenie en er waren geen toxische doden. We hebben geen graad 3 of 4 acute of late 
long toxiciteit vastgesteld. Eén patient had een graad 3 acute slokdarmtoxiciteit, maar 
dit leidde niet tot onderbreken van de radiotherapie. Dosis limiterende toxiciteit werd 
niet vastgesteld. Van de 4 patiënten met stadium III niet-kleincellig longcarcinoom had 1 
patiënt een complete respons, 2 hadden een partiële respons, de vierde patiënt was niet 
evalueerbaar. Gezien in beide studies, 2 van de 13 patiënten (15%) graad 2 late pulmo-
nale toxiciteit ontwikkelden, is een nauwkeurige follow-up aan te raden, zeker in studies 
waar een hogere radiotherapie dosis wordt toegediend. Een gerandomiseerde phase III 
studie bij patiënten met niet-squamous stadium III niet-kleincellig longcarcinoom, met 
cisplatine 75 mg/m2 en pemetrexed 500 mg/m2 met concurrent radiotherapie 66 Gy in 
33 fracties gevolgd door consolidatie chemotherapie met pemetrexed, in vergelijking 
met cisplatine-etoposide met radiotherapie gevold door consolidatie chemotherapie 
naar keuze, is recent gestart in meerdere landen.
Alhoewel deze behandeling beloftevol lijkt, willen we toch benadrukken dat deze slechts 
voor een beperkte groep patiënten geschikt is. Onze fase I studie bij stadium III NSCLC 
werd uitgevoerd in 2 academische centra en slechts 4 patiënten werden geïncludeerd 
in een periode van 18 maanden. Twaalf patiënten werden geregistreerd maar bleken 
uiteindelijk niet geschikt voor inclusie; 6 omwille van stadium IV, 5 omwille van V20> 
36% en 1 omwille van een te verwachten slokdarmtoxiciteit die niet acceptabel was. 
Niet tegenstaande beloftevolle resultaten, blijft de rol van chirurgie na chemothera-
pie (met of zonder bestraling) bij stadium IIIA en IIIB niet-kleincellig longcarcinoom 
controversieel. In hoofdstuk 4 beschrijven we de EORTC 08981 studie. Deze studie bij 
patiënten met stadium IIIB (T4-N3) niet-kleincellig longcarcinoom werd uitgevoerd om 
te onderzoeken of inductie chemoradiotherapie gevolgd door chirurgie na restagering 
door middel van re-mediastinoscopie en/of FDG-PET, haalbaar was in een multicenter 
setting. Helaas moest de studie worden gesloten en bleek deze tri-modality behande-
Veerle BW 2.indd   152 19-11-09   15:56
153
Samenvatting, conclusies en toekomstige ontwikkelingen
ling op dat ogenblik moeilijk uitvoerbaar in Europa. Eén van de redenen was dat, in 
geval van N2 of N3, na de inductie behandeling een re-mediastinoscopie moest worden 
uitgevoerd, wat voor een aantal centra toch een belangrijke hinderpaal bleek. Minimaal 
invasieve stageringsprocedures zoals EBUS en EUS waren toen niet beschikbaar. Het is 
te verwachten dat met het de komst van EBUS en EUS het restageren van het medias-
tinum nu veel gemakkelijker wordt. Het is weinig waarschijnlijk dat een scenario met 
mediastinoscopie baseline en na inductie nog zal worden uitgevoerd in toekomstige 
multimodality behandelingen. Upfront stagering met minimaal invasieve endoscopi-
sche technieken is te verkiezen; de mediastinoscopie kan dan worden uitgevoerd in 
optimale omstandigheden na inductie therapie.
De resultaten van de patiënten in onze studie waren eerder ontgoochelend met veel 
pneumonectomieën en toch majeure complicaties na rechtszijdige pneumonectomie. 
Exploratieve subgroep analyses van zowel EORTC 08941 als de Amerikaanse Intergroup 
studie 0139, hebben aangetoond dat enkel patiënten met downstaging en complete 
resectie met lobectomie een gunstiger overleving hebben, vergeleken met bestraalde 
patiënten. 
Van EORTC 08981 hebben we geleerd dat nieuwe, minimaal invasieve stagerings en 
restagerings technieken nodig zijn en dat rechtzijdige pneumonectomie na inductie 
therapie moet vermeden worden.
De rol van chirurgie na inductie bij stadium III N2/N3 NSCLC blijft een punt van dis-
cussie. Gerandomiseerde, gecontrolleerde studies zijn nodig om de superioriteit van 
chirurgie na inductie tegenover radicale radiotherapie aan te tonen. Momenteel zijn 
twee dergelijke studies lopende in stadium IIA-N2 en IIIB niet-kleincellig longcarcinoom. 
Op dit moment is er nog geen consensus over de intensiteit van de inductie therapie. 
Of inductie chemoradiotherapie beter is dan inductie chemotherapie alleen, wordt nu 
onderzocht in een Zwitserse studie.
In hoofdstuk 5 wordt een overzicht gegeven van de verschillende behandel mogelijkhe-
den voor stadium IIIA niet-kleincellig longcarcinoom en de toekomstige ontwikkelingen 
worden besproken. De behandeling van patiënten met stadium IIIA-N2 niet-kleincellig 
longcarcinoom blijft een controversieel onderwerp. Bovendien is de optimale behande-
ling onderhevig aan verandering omdat we voortdurend te maken hebben met verbe-
tering in stageringsprocedures en veranderingen in therapieën. 
Patiënten met pIIIA-1/2 worden best behandeld met adjuvante chemotherapie zo mo-
gelijk. Chirurgische resectie na downstaging met inductiebehandeling voor patiënten 
met stadium cIIIA-3/4 kan radicaal zijn en resulteren in langdurige overleving. Of deze 
benadering beter is dan combined modality met moderne radiotherapie blijft de vraag. 
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Om deze vraag te beantwoorden zouden in een trial, patiënten met stadium IIIA-3/4 na 
adequate downstaging, moeten geradomiseerd worden tussen chirurgie en radiothe-
rapie. De heterogeniteit van de (re)stagering procedures en het groot aantal patiënten 
vereist voor dergelijke studie zijn een belemmerende factor.
Mediastinale (re)stagering door middel van nieuwere beeldvorming en minimaal inva-
sieve endoscopische technieken zoals EUS en EBUS wordt steeds belangrijker. EUS en 
EBUS zijn complementair en zullen waarschijnlijk de meer invasieve mediastinoscopie 
overbodig maken. Een gerandomiseerde studie die deze vraagstelling onderzoekt wordt 
momenteel geanalyseerd. Verbeteringen in dosis localisatie technieken zoals Involved 
Field Radiotherapy (IFRT), Intensity Modulated Radiotherapy (IMRT), vier dimensionele 
radiotherapie (4D-RT), Image Guided Radiotherapy (IGRT), radiotherapie aangepast 
aan de ademhaling (gating or tracking), partikel beam therapy of een combinatie van 
deze technieken, zullen standaard worden en zullen hoge dosis radiotherapie met bijna 
chirurgische precisie mogelijk maken.
Samenvattend, patiënten met locaal gevorderd niet-kleincellig longcarcinoom zijn een 
zeer heterogene groep en de optimale behandeling is afhankelijk van veel verschillende 
factoren en moet zeker voor een aantal patiënten nog gedefiniëerd worden. Een com-
binatie behandeling met chemotherapie en radicale radiotherapie is voor de meeste 
stadium III patiënten aangewezen. De rol van chirurgie bij patiënten met preoperatief 
vastgstelde N2,N3 klieren, die reageren op chemotherapie of chemoradiotherapie, blijft 
controversieel. Chirurgie lijkt een te verdedigen optie bij patiënten bij wie downstaging 
is bereikt en bij wie de resectie kan beperkt blijven tot een lobectomie. Accurate medi-
astinale restagering is derhalve zeer belangrijk.
De behandeling van stadium III patiënten kan zeker nog verbeterd worden en een 
multidisciplinaire benadering van deze patiënten is cruciaal. In onze dagelijkse praktijk 
is het heel belangrijk dat we onze patiënten een zo volledig mogelijk beeld geven van 
de verschillende mogelijkheden, rekening houdend met complicaties van de diverse 
behandelingen, de locale beschikbare expertise en voortschrijdende onderzoeksont-
wikkelingen. 
De meerderheid van onze longkanker patiënten zal vroeg of laat behandeld worden 
met chemotherapie voor gemetastaseerde ziekte.
De standaard behandeling voor deze patiënten met een goede performance status is 
cis-of carboplatine in combinatie met een derde generatie middel, paclitaxel, gemci-
tabine, vinorelbine of docetaxel en meer recent pemetrexed voor niet-squameuse his-
tologie. Nog steeds verschillen de meningen over het gebruik van cis- of carboplatine. 
In Noord-Amerika wordt heel veel carboplatine gebruikt en ook in Europa gaat steeds 
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meer de voorkeur uit naar carboplatine bij patiënten met gemetastaseerde ziekte. In 
hoofdstuk 6 vergelijken we in een gerandomiseerde fase II studie twee schema’s van 
de 21-dagen kuur carboplatine en gemcitabine. Alhoewel de studie vroegtijdig moest 
worden gesloten, zijn we van mening dat de data van deze studie interessant zijn. Het 
schema met carboplatine (AUC 5) toegediend op dag 8 en gemcitabine 1250 mg/m2 
op dag 1 en 8 (arm B) vertoont minder graad 3-4 thrombopenie en neutropenie in 
vergelijking met het standaard schema met carboplatine op dag 1 en gemcitabine op 
dag 1 en 8 (arm A). We vonden 79% graad 3-4 toxiciteit (thrombopenie en neutropenie) 
in arm A en 50% in arm B. Graad 3-4 thrombopenie werd vastgesteld in 66% in arm A en 
26% in arm B, graad 4 hematologische toxiciteit was 30% in arm A en 3% in arm B. De ef-
fectiviteit van beide schema’s lijkt vergelijkbaar. Het schema met carboplatine op dag 8 
kan in de dagelijkse praktijk zorgen voor minder bloedcontroles, minder dosisreducties 
en minder bloedplaatjes transfusies.
De optimale duur van platinum bevattende chemotherapie is reeds in verschillende 
studies onderzocht en er is aangetoond dat de overleving niet beter is wanneer meer 
dan 4 cycli chemotherapie worden gegeven. Meer dan 4 cycli platinum bevattende 
chemotherapie leidt tot meer toxiciteit en verminderde kwaliteit van leven.
Sequentiële chemotherapie is een benadering die het mogelijk maakt om verschillende 
drugs toe te dienen, dosis intensiteit te behouden en langduriger te behandelen met als 
gevolg langere ziektecontrole.
In hoofdstuk 7 onderzoeken we niet-cross resistente sequentiële single agent che-
motherapie als eerst lijns behandeling voor patiënten met gevorderd niet-kleincellig 
longcarcinoom. In deze niet-gerandomiseerde fase II studie hebben we aangetoond 
dat de sequentiële toediening van gemcitabine gevolgd door paclitaxel een behan-
deling is met een gunstig toxiciteitsprofiel en met een mediane tijd tot progressie en 
mediane overleving vergelijkbaar met de andere sequentiële studies uit de literatuur. 
Ondertussen is echter duidelijk geworden dat single agent gemcitabine als eerste lijn 
voor patiënten met goede performance status inferieur is aan een platinum gebaseerd 
doublet.
Ons schema met sequentieel single agents, gemcitabine en paclitaxel, zou wel kunnen 
gebruikt worden voor oudere patiënten of patiënten met minder goede conditie, zoals 
recent ook door andere auteurs is aangetoond. Het toedienen van sequentieel single 
agents past in het concept van maintenance chemotherapie met niet-cross resistente 
drugs. Zeer recente trials ondersteunen het gebruik van niet-cross resistente derde 
generatie drugs vóór het optreden van ziekteprogressie.
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We zijn van mening dat het sequentiële single agent non-platinum schema uit onze stu-
die waardevol zou kunnen zijn voor patiënten die ERCC1 positief zijn en derhalve geen 
baat hebben bij platinum bevattende chemotherapie. Deze hypothese zou moeten ge-
test worden in een klinische studie. Tot slot bevestigen onze resultaten de gegevens van 
recent onderzoek, waaruit blijkt dat gemcitabine minder actief is bij het niet-squameus 
carcinoom. Het wordt dus meer en meer duidelijk dat histologie van belang is bij de 
behandeling van het niet-kleincellig longcarcinoom en dat is een mooie uitdaging voor 
onze pathologen.
Tweede lijns chemotherapie is chemotherapie die toegediend wordt als ziekteprogressie 
wordt vastgsteld na het beëindigen van de eerste lijns behandeling. Momenteel zijn 3 
middelen geregistreerd voor 2e lijns behandeling van het niet-kleincellig longcarcinoom: 
docetaxel, pemetrexed en de EGFR TKI erlotinib. Voor behandeling in 2e of 3e lijn zijn 
orale middelen met weinig bijwerkingen te verkiezen, zeker omdat een aantal patiënten 
toch in een minder goede algmene toestand zijn. In hoofdstuk 8 hebben we in een 
fase II studie aangetoond dat oraal Uracil-Tegafur (UFT) met etoposide actief is en goed 
wordt verdragen in 2e en 3e lijn bij Caucasische patiënten met gevorderd niet-kleincellig 
longcarcinoom. Dit is het eerste artikel dat de effectiviteit van UFT-etoposide aantoont 
bij Caucasische patiënten. De effectiviteit in termen van tijd tot progressie en mediane 
overleving is vergelijkbaar met de andere 2e lijns middelen en de toxiciteit is beduidend 
minder. Een kostenschatting voor UFT-etoposide lijkt veel lager dan voor de andere 2e 
lijns middelen, wat van belang is gezien de enorme druk op de gezondheidsbudgetten.
Thymidylate synthase is een enzyme dat een rol speelt in de DNA biosynthese en een 
target enzyme voor anti-metabolieten zoals 5-FU, pemetrexed en UFT. TS expressie zou 
kunnen gebruikt worden als predictieve marker voor behandeling met middelen als 
pemetrexed, 5-FU en UFT.
Gezien zijn werking in 2e en 3e lijn, het gunstig bijwerkingsprofiel en lage kosten zou 
UFT-etoposide uitermate geschikt kunnen zijn voor maintenance behandeling na eerste 
lijns chemotherapie.
Het is nu duidelijk geworden dat de cruciale zwakte in de tot nu toe toegepaste behan-
delingen bij het niet-kleincellig longcarcinoom, de “one size fit all” benadering is.
Er is evidentie dat een geïndividualiseerde benadering en behandeling van de patiënt 
met een niet-kleincellig longcarcinoom nodig is.
In het tijdperk van de “targeted” therapieën moeten we ons realiseren dat conventionele 
chemotherapie eveneens “targeted” therapie is geworden en de middelen om adequaat 
te “targeten” zullen in de toekomst meer en meer beschikbaar zijn.
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TOEkOMSTIgE ONTwIkkELINgEN
Integratie van nieuwe biologicals, zoals monoclonale antibodies en moderne radiothe-
rapie technieken als onderdeel van multimodality behandeling, zal hopelijk de overle-
ving verbeteren van onze patiënten met stadium III NSCLC.
Er is momenteel veel beweging in het domein van de radiotherapie. Nieuwere radio-
therapie technieken zullen het mogelijk maken locale controle te verbeteren door 
toediening van hoge dosis radiotherapie op kleinere volumes met minder toxiciteit. 4D 
radiotherapie en “dose painting” met IMRT zullen toelaten bij stadium III NSCLC individu-
ele, dosis-intensieve schema’s toe te passen. Verdere implementatie van deze technieken 
zal mogelijk worden door goed opgezette studies bij goed geselecteerde patiënten.
Tot op heden gebeurde de keuze van therapie bij patiënten met gevorderd stadium 
longkanker vooral empirisch en gebaseerd op patiënten eigenschappen zoals leeftijd, 
gewicht en performance status. Verder baseren we ons op evidentie uit de literatuur, 
eigen voorkeur en ervaring. 
In 2009 is er toch een duidelijke verandering merkbaar. Onze benadering verschuift van 
een empirische naar een meer geïntegreerde approach. Het zal mogelijk worden een 
gepersonaliseerde behandeling te bieden, rekening houden met klinische, moleculaire 
en histologische factoren. Voor het eerst in de geschiedenis hebben gerandomiseerde 
studies bij het niet-kleincellig longcarcinoom aangetoond dat histologie kan gebruikt 
worden als selectie voor chemotherapie. Accurate subclassificatie van het niet-kleincellig 
longcarcinoom wordt daarom zeer belangrijk. Zogenaamde “unspecified tumours” hou-
den het risico in dat we patiënten onnodig blootstellen aan toxicteit van bepaalde the-
rapieën, terwijl we sommige patiënten goede behandelingen onthouden. De variabliteit 
tussen de waarnemers en het gebrek aan gestandardiseerde testen maakt accurate 
subclassificatie moeilijk; een bijkomend probleem is dat we vaak de diagnose van long-
kanker stellen op cytologie. Micro-RNA biomarkers die adenocarcinoom en spinocellulair 
carcinoom kunnen onderscheiden zijn daarom momenteel onderwerp van onderzoek.
Moleculaire karakterisatie van circulerende tumorcellen en identificatie van biomarkers 
zullen misschien het probleem van histologie subtype oplossen. Recente data betreffende 
bijvoorbeeld thymidylaat synthase tonen aan dat histologie eigenlijk een uiting is van 
moleculaire selectie.
Proteomics, genomics en de ontwikkeling van verschillende biomarkers zijn beloftevol. 
Het succesvol zijn van de targeted therapieën zal een gecoördineerde, multidisciplinaire 
aanpak vereisen. Studies die de activiteit van nieuwe middelen nagaan, gecombineerd 
met patiëntenselectie op basis van klinische en moleculaire factoren, zijn wenselijk. Ho-
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pelijk zullen deze “patiënt-specifieke geïndividualiseerde cocktails” dan ook resulteren 
in een betere overleving van onze longkanker patiënten.
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dANkwOORd
Velen hebben direct of indirect een bijdrage geleverd aan dit proefschrift. De enen met 
raad en daad, de anderen met de nodige afleiding. 
In de eerste plaats zijn we dank verschuldigd aan de patiënten die ondanks hun ziekte 
bereid zijn geweest aan de studies mee te werken. Zij hebben mij vooral geleerd dat 
humor, positiviteit en goede relaties met familie en vrienden belangrijk zijn in het leven.
Mijn promotor, Prof. Dr. H.C. Hoogsteden.
Henk, je bood me de gelegenheid om in Rotterdam te komen werken. Het Erasmus MC 
was voor mij eerst onbekend werkterrein, werd later een uitdaging en is uiteindelijk 
een zeer rijke ervaring geworden. Bedankt dat je mij de mogelijkheid hebt gegeven om 
binnen uw dienst Longziekten dit proefschrift te voltooien.
Mijn co-promotor, Dr. Rob van Klaveren.
Beste Rob, ik heb veel geleerd van je positief kritische beoordeling van de artikelen. Je 
inspirerende ideeën hebben veel bijgedragen aan dit werk. 
Als halve Belg zijnde, kon jij best begrijpen dat Belgen nu eenmaal anders zijn dan 
Nederlanders.
Mijn co-promotor, Dr. J. Aerts.
Beste Joachim, het is mooi te zien hoe jij privé-leven, klinisch werk en wetenschappe-
lijke activiteiten altijd vrolijk weet te combineren. Dank voor je dynamische begeleiding, 
doeltreffende aanmoedigingen en praktische inslag. Je optimisme werkt aanstekelijk.
De leden professoren van de kleine en grote promotiecommissie: Prof. P.C Levendag, 
Prof. K. Nackaerts, Prof. B.N Lambrecht, Prof. P. van Schil, Prof. J.P van Meerbeeck, Prof. 
E.F Smit en Prof. H.C de Koning, wil ik danken voor het plaatsnemen in de commissie en 
voor het kritisch doornemen van dit proefschrift.
Prof. Dr. J. van Meerbeeck. Beste Jan, door jou is mijn interesse in de thoracale oncologie 
aangewakkerd en ik heb ontzettend veel van je geleerd. Bedankt voor het vertrouwen 
dat je in mij stelde. Ik bewonder je gedrevenheid; steeds weer slaag je er in mensen warm 
te maken voor nieuwe wetenschappelijke projecten en onderzoeken. Je originaliteit en 
enthousiasme weten iedere keer weer te motiveren. Uw wetenschappelijke inbreng en 
suggesties maakten het mogelijk dit proefschrift te realiseren.
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Mijn collega’s van de afdeling Longziekten van het Erasmus MC wil ik bedanken voor 
de fijne samenwerking. Jullie hebben deze Belgische longarts warm ontvangen. In het 
begin was het wennen, maar na 5 jaar kon ik een glaasje melk en een broodje kroket wel 
smaken. Bedankt voor jullie geduld en collegialiteit.
Mijn collega’s artsen van het Erasmus MC, locatie Daniel den Hoed, wil ik graag vermel-
den in dit dankwoord.
De samenwerking met de interne oncologie heb ik steeds als plezierig ervaren. De 
motiverende discussies tijdens de patiëntenbesprekingen hebben mij veel bijgebracht. 
Maja, van jou heb ik veel geleerd over fase I; dank voor je constructieve en plezierige 
bijdrage aan onze fase I studie. 
Mijn collega’s van de afdeling radiotherapie wil ik bedanken voor de fijne samenwerking. 
Prof. P.C Levendag, dank voor het willen plaatsnemen in de promotiecommissie en voor 
de mogelijkheden die de dienst radiotherapie heeft geboden.
John, jouw humor en “stralend” optimisme zullen me altijd bijblijven.
Beste René en Emile, de allerbeste datamanagers, dank voor jullie precisie en bijdrage 
aan dit werk. Het was fijn met jullie samen te werken.
Beste Paul, dank voor het succesvol nemen van alle “statistische hindernissen”.
Beste Fanny, Ria, Anneke en Ginette, de onmisbare schakels van de poli. Dank voor jullie 
bewonderenswaardige patiëntenzorg. Ik waardeer jullie steeds warme interesse voor 
het Belgische thuisfront.
Beste Anne, ik heb geluk gehad met jou als uitstekende secretaresse. Bovendien had en 
heb ik nog steeds het voorrecht om ook buiten het werk op je beroep te kunnen doen. 
Telkens opnieuw weet je allerlei praktische problemen voor mij op te lossen. De afstand 
tussen Rotterdam en Gent heeft daar niks aan veranderd. Bedankt daarvoor. 
Beste Tatjana, je bent een echte “Topper”. 
Dank voor je professionele en uitstekende begeleiding van onze studie patiënten. Dank 
dat je paranimf wil zijn, maar bovenal dank voor je fijne vriendschap.
Beste Ellen en Frans, samen hebben we ons ingezet en gestreefd naar een optimale 
patiëntenzorg in de Daniel. Vaak waren er lastige hindernissen, maar mede dankzij jullie 
bleef het lukken.
Frans, ik ben blij dat je, ondanks je drukke agenda, de taak van paranimf opneemt.
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Beste Shelley, je maakte me wegwijs in Rotterdam en leerde me de mooie en leuke 
plekjes van Nederland kennen. Dank voor je goede raad, gastvrijheid en gezelligheid. 
Beste Prof. Dr. G. Joos. Beste Guy, dank voor de mogelijkheden die ik nu krijg binnen uw 
dienst Longziekten van het UZ Gent. Ik waardeer dat je mij de ruimte bood om de laatste 
hindernissen van dit boekje tot een goed einde te brengen. Ik wil u en mijn collega’s 
bedanken voor jullie geduld, vanaf nu ben ik voor de volle 100% inzetbaar.
Last but not least, het thuisfront:
André, dank voor je liefde, steun en begrip. Ik bewonder je geduld en relativeringsver-
mogen. Je inzet voor de kinderen is grandioos; mijn vele afwezigheden weet je altijd 
perfect op te vangen.
Lieve Laurence en Alexandre, jullie aanwezigheid en hartverwarmende glimlach zijn 
mijn mooiste cadeau.
Lieve ma en pa. Zonder jullie zou dit niet gelukt zijn. Jullie hebben mij een onbezorgde 
jeugd en alle kansen voor het leven gegeven. Altijd werd ik gesteund in de dingen die ik 
deed, ook al hadden jullie daar soms je eigen gedachten over. Ik ben blij dat we ook nu 
nog altijd kunnen rekenen op jullie raad en vooral daad. Ik draag dit boekje dan ook met 
veel liefde en respect aan jullie op. 
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Veerle Surmont is op 5 maart 1971 geboren te Izegem, België.
Zij volgde middelbaar onderwijs (Latijn-Wiskunde) aan het Bisschoppelijk Lyceum 
der Grauwe Zusters in Roeselare. In 1989 begon zij haar studies Geneeskunde aan de 
Katholieke Universiteit Leuven, waarna ze in 1996 het artsendiploma behaalde. Aan 
dezelfde universiteit volgde ze de opleiding interne geneeskunde (Prof. Dr. J. Févery) en 
aansluitend een opleiding tot longarts onder leiding van Prof Dr. M. Demedts. Zij volgde 
één jaar van haar opleiding longziekten in het Erasmus Medisch Centrum Rotterdam. Tij-
dens dat jaar was zij vooral werkzaam op de afdeling Thoracale Oncologie van de locatie 
Daniel den Hoed. In 2002 werd ze erkend als longarts. Hierna heeft ze vijf jaar gewerkt 
als staflid bij de dienst Longziekten (Prof. Dr. H.C. Hoogsteden) van het Erasmus Medisch 
Centrum Rotterdam, met als aandachtsgebied thoracale oncologie. Ze hield zich vooral 
bezig met klinische en poliklinische zorg, multidisciplinaire oncologische problematiek, 
klinische studies en patiëntgebonden wetenschappelijk onderzoek. In die periode zijn 
de studies beschreven in deze thesis tot stand gekomen.
Momenteel is de auteur werkzaam als staflid op de dienst Longziekten in het Universitair 
Ziekenhuis Gent, waar zij haar werkzaamheden in de thoracale oncologie verderzet. Zij 
is sinds maart 2009 secretaris van de EORTC Lung Group. 
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